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Summary 
 
A prospective randomised controlled clinical trial of treatment decisions informed by 
invasive functional testing of coronary artery disease severity compared with standard 
angiography-guided management was implemented in 350 patients with a recent non-ST 
elevation myocardial infarction (NSTEMI) admitted to 6 hospitals in the National Health 
Service. The main aims of this study were to examine the utility of both invasive fractional 
flow reserve (FFR) and non-invasive cardiac magnetic resonance imaging (MRI) amongst 
patients with a recent diagnosis of NSTEMI. In summary, the findings of this thesis are: (1) 
the use of FFR combined with intravenous adenosine was feasible and safe amongst patients 
with NSTEMI and has clinical utility; (2) there was discordance between the visual, 
angiographic estimation of lesion significance and FFR; (3). The use of FFR led to changes in 
treatment strategy and an increase in prescription of medical therapy in the short term 
compared with an angiographically guided strategy;  (4) in the incidence of major adverse 
cardiac events (MACE) at 12 months follow up was similar in the two groups. Cardiac MRI 
was used in a subset of patients enrolled in two hospitals in the West of Scotland. T1 and T2 
mapping methods were used to delineate territories of acute myocardial injury. T1 and T2 
mapping were superior when compared with conventional T2-weighted dark blood imaging 
for estimation of the ischaemic area-at-risk (AAR) with less artifact in NSTEMI. There was 
poor correlation between the angiographic AAR and MRI methods of AAR estimation in 
patients with NSTEMI. FFR had a high accuracy at predicting inducible perfusion defects 
demonstrated on stress perfusion MRI.  
This thesis describes the largest randomized trial published to date specifically looking at the 
clinical utility of FFR in the NSTEMI population. We have provided evidence of the 
diagnostic and clinical utility of FFR in this group of patients and provide evidence to inform 
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larger studies.  This thesis also describes the largest ever MRI cohort, including with 
myocardial stress perfusion assessments, specifically looking at the NSTEMI population. We 
have demonstrated the diagnostic accuracy of FFR to predict reversible ischaemia as 
referenced to a non-invasive gold standard with MRI. This thesis has also shown the futility 
of using dark blood oedema imaging amongst all comer NSTEMI patients when compared to 
novel T1 and T2 mapping methods. 
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Chapter 1 – Introduction and Literature Review 
 
1.1.1Epidemiology and Burden of Disease 
 Ischemic heart disease (IHD) is a condition characterized by inadequate oxygen 
delivery to the myocardium that is most commonly a consequence of coronary artery disease 
(1). It is a major cause of morbidity and mortality contributing approximately 30% to total 
worldwide deaths(2). It is estimated that 1,065,000 will have an acute coronary syndrome 
(ACS) annually (3). The deaths attributable to coronary and cardiovascular disease 
significantly out shadow deaths from cancer. The lifetime risk for developing coronary heart 
disease (CHD) after the age of 40 is 49% in men and 32% in women(3-5). Significant 
progress has been made in the management of CHD and ACS. Through these efforts, the 
mortality from myocardial infarction has significantly reduced and the management of 
patients with angina has improved (6, 7).  
 Ischaemic heart disease can manifest as stable angina or unstable clinical syndromes 
that include unstable angina, non-ST segment elevation myocardial infarction {NSTEMI and 
ST-segment elevation myocardial infarction {STEMI} with the two disease processes having 
distinct pathophysiological differences (Refer to Figure 1). NSTEMI shares similar 
pathophysiology to unstable angina but results in greater myocardial injury.  
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Figure 1: Pathophysiology and Clinical Presentations of Patients with Ischaemic Heart 
Disease. 
 
 Stable angina represents the more prevalent clinical manifestation of ischaemic heart 
disease with an estimated 20 000–40 000 individuals per million suffering from angina in 
European countries (1). Available data, from multiple studies suggest an annual incidence of 
uncomplicated angina pectoris of approximately 0.5% in western populations (8, 9). 
Estimates for annual mortality rates in patients with stable angina range from 0.9–1.4% per 
annum (10, 11), with an annual incidence of non-fatal MI between 0.5% and 2.6% (11, 12) in 
this group.  
 NSTEMI is the commonest form of acute myocardial infarction and a leading global 
cause of premature morbidity and mortality (6).  Recent studies have demonstrated a 
significant reduction in the incidence of STEMI over recent years whereas NSTEMI 
incidence has remained stable (6). Annual mortality rates from Europe have shown a non-
significant mortality difference between STEMI and NSTEMI being 9% and 11.6% 
respectively (13). However, recent data reported by investigators in the United States have 
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shown a significant mortality difference between the two groups.  McManus and colleagues 
demonstrated a 1-year mortality rate of 8.4 % in the STEMI cohort versus 18.7% in the 
NSTEMI group (4). The recent Acute Coronary Syndrome Prospective Audit (ACACIA) 
registry showed 1 year mortality of 8% for STEMI and 10.5% for NSTEMI (14). 
 
1.1.2 Pathophysiology of NSTEMI/UA 
 The pathogenesis of NSTEMI is thought to be due to a number of processes. Firstly, 
rupture or erosion of an unstable vulnerable atheromatous plaque with a superimposed non-
occlusive thrombus causing reduced myocardial perfusion, ischemia, and ultimately necrosis. 
Plaque instability is accelerated by inflammation of the arterial wall and by the expression of 
metalloproteinases present in T lymphocytes in the shoulder of the plaque; these enzymes are 
thought to attack the thin fibrous wall of the plaque (15).  
 The major components of coagulation that is, the platelets and the coagulation 
cascade, play critical roles in thrombus formation. Plaque rupture or erosion exposes platelets 
to subendothelial collagen initiating platelet adhesion to the damaged endothelium. This 
adhesion activates platelets leading to morphological changes. Multiple platelet agonists, 
such as adenosine diphosphate (ADP), thromboxane, and epinephrine, lead to a 
conformational change of the glycoprotein (GP) IIb/IIIa receptor on the platelets’ surface that 
binds them to fibrinogen, resulting in platelet aggregation and the formation of a “platelet 
plug.” Down-stream microembolization of platelet aggregates and plaque debris often causes 
distal myocardial necrosis. The exposure of tissue factor activates the coagulation cascade; its 
combination with factor V leads to the activation of coagulation factor X to form factor Xa, 
which in turn leads to the conversion of factor II (prothrombin) into factor IIa (thrombin); the 
latter is responsible for the conversion of fibrinogen to fibrin, which traps platelet aggregates, 
thereby forming a thrombus (16).  
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 The use of biochemical markers such as high-sensitivity C-reactive protein as well as 
intravascular imaging in the form of intravascular ultrasound and optical coherence 
tomography, have all confirmed the evidence of an inflammatory milieu evident in the 
coronary arteries of ACS patients with obstructive disease (17-20). In patients with 
obstructive disease without an overt inflammatory state enhanced sympathetic nervous 
system activation may cause changes in cardiovascular physiology that can result in plaque 
instability and subsequent ACS (21). 
 Coronary artery vasoconstriction, which may involve both the epicardial and 
microcirculation as occurs in adrenergic–mediated constriction, in cocaine abuse, and 
coronary syndrome X is also implicated in the pathogenesis of ACS. Moreover, NSTEMI can 
also occur as a result of an imbalance between myocardial oxygen supply and demand, 
secondary to increased oxygen demand as can occur in conditions such as tachyarrhythmias, 
fever, anaemia or sepsis with or without underlying coronary artery disease (22) 
These pathogenetic processes of NSTEMI are not mutually exclusive and one or more may 
be causal on an individual patient basis.  
 
1.1.3 Diagnosis of NSTEMI(23)  
History 
The clinical presentation of NSTEMI encompasses a wide variety of symptoms. 
Traditionally, several clinical presentations have been distinguished: 
• Prolonged (20 min) anginal pain at rest; 	   
• New onset (de novo) angina (Class II or III of the Classification of the Canadian 
Cardiovascular Society11);	  	   
• Recent destabilization of previously stable angina with at least Canadian 
Cardiovascular Society Class III angina characteristics (crescendo angina); 
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•  Post-MI angina. 
• However, it can also present in a more atypical fashion with increasing breathlessness 
and rarely syncope. 
ECG 
 The resting 12-lead ECG is the first-line diagnostic tool in the assessment of patients 
with suspected NSTEMI and it is recommended that it should be obtained within 10 min after 
first medical contact. The characteristic ECG abnormalities of NSTEMI are ST-segment 
depression or transient elevation and/or T wave changes (24). It should be appreciated that a 
completely normal ECG does not exclude the possibility of NSTEMI. In particular, ischaemia 
in the territory of the circumflex artery or isolated right ventricular ischaemia may not be 
associated with abnormalities on the 12-lead ECG (25). 
 
Biomarkers 
 Measurement of circulating cardiac troponin concentrations play a central role in 
establishing a diagnosis and stratifying risk and make it possible to distinguish between 
NSTEMI and unstable angina. In patients with MI, an initial rise in troponins occurs within 4 
hours of symptom onset and can remain elevated for up to 2 weeks. In NSTEMI minor 
troponin elevations usually resolve within 48-72 hours (23). An elevated troponin predicts 
short-term rates of myocardial infarction and death and also outcomes into the longer term. It 
is also widely used to guide management decisions and identify patients who may benefit 
from an early invasive strategy. However, troponin should not be used as a sole decision 
criterion for invasive management as certain high-risk troponin negative subgroups have an 
in-hospital mortality of 12.7% (26). The emergence of troponin tests with even higher 
sensitivity (i.e. detection of troponin concentration in nanograms / litre), is likely to 
compound the diagnosis and management of ACS patients even further. The incidence of 
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NSTEMI is likely to rise but the diagnostic concordance with hs-troponin elevations with 
plaque rupture, and the prognostic implications, are uncertain. 
1.1.4 Risk stratification in patients with NSTEMI  
 Current guidelines advocate that all patients with NSTEMI be risk stratified following 
diagnosis. This strategy enables the physician to decide on an immediate management 
strategy and also provide the patient with an idea about their future prognosis. Some patients 
with NSTEMI do not require risk stratification for obvious reasons e.g. cardiogenic shock 
and ongoing chest pain. However, most patients with NSTEMI will require risk stratification. 
The most commonly applied tools in use are the TIMI risk score and the GRACE risk score.  
The utility of such scores is in identifying patients who would benefit from an early invasive 
strategy of coronary angiography. For example, a GRACE score of >140 is an established 
cut-off for a patient being high risk and requiring early invasive therapy(27).  
 However, despite the use of clinical history, ECG, biomarkers and risk stratification 
tools, approximately 9-14% of patients with a NSTEMI who undergo angiography have no 
significant coronary stenosis (28-30).  When compared to patients with obstructive culprit 
disease, patients without significant disease have a much better short-term prognosis. Similar 
findings were reported in the CRUSADE registry whereby NSTEMI patients without 
significant coronary disease had a lower in-hospital death rate (30).  Therefore despite 
appropriate use of risk models to identify patients who may benefit from early intervention, 
clearly there is a need for improved methods of identification to complement current risk 
tools. 
 
1.1.5 Role of Non-Invasive Testing 
 Clinical guidelines do not recommend non-invasive stress testing in patients with 
recent NSTEMI because the reference diagnostic test is invasive coronary angiography, 
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which is also used to guide PCI. However, in situations of diagnostic uncertainty the use of 
non-invasive imaging can be helpful. Echocardiography is useful in assessing ventricular 
function, but regional dysfunction may be present in acute ischaemia as well as old infarction. 
Myocardial perfusion imaging at rest identifies one or more areas of hypoperfusion in almost 
all patients with NSTEMI, but as is the case with echocardiography cannot distinguish clearly 
between acute ischemia and old infarction (31) Computed tomographic coronary angiography 
is being used with increasing frequency in emergency departments, especially in patients 
deemed to be at low risk of having ACS (32). Its use in this manner is to exclude a severe 
coronary stenosis results in a high negative predictive value with the potential for earlier 
discharge from hospital but an increase in the rate of invasive coronary angiography (33). 
Cardiac MRI can simultaneously assess global and regional left ventricular function, 
perfusion, and myocardial viability (34) and will be discussed in greater detail later in this 
thesis.  
 
Summary 
 Thus despite clear diagnostic criteria and well validated methods for risk stratifying 
patients there remains a need for further methods to improve patient selection for an invasive 
approach in NSTEMI. 
 
1.2 MRI in NSTEMI 
 As has already been alluded to thus far, there are many issues regarding the diagnosis 
and risk stratification of patients with NSTEMI.  Risk stratification tools such as GRACE and 
the TIMI risk score allow for selection of higher risk patients to undergo an invasive strategy.  
However, even using these scores, many patients undergoing coronary angiography for 
NSTEMI have normal coronary arteries.  Therefore, new techniques that allow for improved 
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risk stratification and thus improved patient selection are needed. Novel cardiac MRI 
techniques may provide such a tool.  
 
1.2.2 The Ischaemic Area-at-Risk 
 The jeopardised region of acutely hypoperfused myocardium within a coronary 
distribution during coronary occlusion is defined as the area-at-risk (AAR) of infarction (35). 
Without prompt restoration of blood flow, myocardial necrosis within the perfusion territory 
will ensue as a ‘wavefront’ from the subendocardium to the subepicardium. Importantly, the 
wave of irreversible injury is preceded by reversible injury of the entire AAR (36). Treatment 
strategies such as revascularisation techniques and pharmacological therapies aim to salvage 
areas of acutely ischemic, but reversibly injured, myocardium. Thus non-invasive imaging 
methods that can delineate the jeopardised AAR and potentially salvageable myocardium are 
important in assessing the efficacy of such therapies and may potentially guide appropriate 
patient selection in some patients with ACS. For patients with myocardium at risk, early 
intervention is beneficial (37) however, for patients without myocardium at risk an invasive 
strategy confers no benefit.  
 Thus a diagnostic approach that identifies myocardium at risk within the 
heterogeneous NSTEMI population could facilitate timely coronary angiography and 
revascularisation and concentrate resource use. 
 Cardiac MRI (CMR) is a noninvasive technique for assessing heart structure and 
function without the need for ionizing radiation and is an increasingly utilized technique in 
the assessment of patients with ischaemic heart disease. The physics and technology of CMR 
enables the creation of a powerful magnetic field, often at either 1.5 or 3.0 Tesla that when 
applied, allows protons (hydrogen atoms) within the body to align either parallel or anti-
parallel to this field. This creates a net magnetic vector, allowing a radiofrequency (RF) pulse 
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to then be applied, which delivers energy to the protons and causing them to align in a 
different direction (transverse or perpendicular). On cessation of the RF pulse, the hydrogen 
atoms return back to their original (equilibrium) state, releasing energy and emitting a signal 
as they do so. This signal is then picked up and turned into an image (34). CMR technology 
has overcome many of the challenges with cardio-respiratory motion to provide clinically 
useful imaging scans. 
 The potential for CMR in the diagnosis and management of patients’ with NSTEMI is 
based upon the principle that acute myocardial injury is associated with multiple metabolic 
and structural changes leading to oedema in the affected perfusion bed, before the onset of 
irreversible injury. This higher water content in ischaemic territories is associated with higher 
T2 relaxation times (38) a contrast generating effect that can be used by CMR.  Extensive 
preclinical and human studies have established that T2 signal hyperintensity by cardiac 
magnetic resonance (CMR) indicates increased myocardial water content (35) T2 may 
increase within 30 min of ischaemia and remains elevated for 2 or more weeks following the 
initial ischaemic insult rendering it useful in the retrospective assessment of the AAR and for 
defining the culprit myocardial territory that is often challenging in NSTEMI patients due to 
the high incidence of multivessel disease (39). 
 Cardiac MRI characterises different tissues based on their specific nuclear magnetic 
properties, including T1 and T2. Simplistically, T1 relaxation time is the rate constant that 
describes how quickly protons realign with the main magnetic field back to their equilibrium 
state. T2 relaxation time is the rate constant that describes how long protons remain 
synchronous or “in phase” after being tipped perpendicular to the main magnetic field by a 
RF pulse (34).  
 As the heart is a moving organ images are acquired over several heartbeats, with 
breath-holding and ECG gating employed to allow synchronisation to the correct phase of the 
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cardiac cycle.  
 
1.2.2 Cardiac MRI: a “one-stop-shop” for a comprehensive assessment early after MI 
 Cardiac MRI has several applications in the acute phase of MI, including assessing 
myocardial function through cine imaging, detecting myocardial oedema (denoting the 
ischaemic AAR) and therefore allowing myocardial salvage to be calculated) through T2-
weighted (T2W) imaging and identifying irreversible myocardial injury through late 
gadolinium enhancement (LGE) imaging(34). 
 Moreover, several studies have shown that single-photon emission computed 
tomography (SPECT) and photon emission tomography (PET) may miss cases of sub-
endocardial necrosis due to the limited spatial resolution of these methods whereas these 
abnormalities may be detected by MRI which has higher spatial resolution (40-42). 
Therefore, cardiac MRI has higher diagnostic accuracy for myocardial necrosis and tissue 
viability than all other non-invasive imaging methods. 
 
1.2.3 T2 and T1 weighted imaging to assess myocardial oedema and area at risk (AAR)  
 T2-weighted (T2W) imaging identifies increased myocardial water content through 
increased signal intensity (35). Myocardial oedema is a natural consequence of acute 
myocardial infarction (AMI) and includes both irreversibly damaged and potentially 
salvageable myocardium, in the case of prompt reperfusion (43). Using the principles of T2W 
imaging, to detect myocardial oedema, AAR can be quantified. This method for identifying 
the AAR has been validated against AAR determined by histopathology as well as AAR 
obtained by angiographic measurements (44-46) 
 Even transient ischaemia can produce differences in the myocardial longitudinal (T1) 
and transverse (T2) relaxation times, and newer techniques have shown improved sensitivity 
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in identifying the culprit territory amongst patients with AMI (47, 48). Dark-blood fat-
suppressed (short tau inversion recovery, STIR) T2-weighted MRI methods (T2W STIR) are 
widely used for clinical and research purposes (37, 49)Following its development by 
Simonetti and colleagues dark blood STIR oedema imaging has enjoyed widespread use to 
assess for the presence of myocardial oedema (49).  Indeed several investigators have shown 
prognostic information using STIR imaging. For example, in a prospective study involving 
88 patients with NSTEMI, Raman and colleagues highlighted the potential for T2-STIR 
imaging in identifying oedematous myocardium and to distinguish patients requiring 
coronary revascularization from those that did not. 
  Moreover, the presence of oedema was associated with a higher hazard of a 
cardiovascular event or death within 6 months after NSTEMI (37). Yet, despite great 
theoretical promise, the clinical reality of using dark blood T2-STIR imaging has been far 
from optimal due to methodological problems inherent with the technique.  These include 
sensitivity of the sequence to artifacts from respiratory and cardiac motion, the variability in 
myocardial signal related to surface coil intensity inhomogeneity, and the subjectivity of 
image interpretation (50, 51). Thus, a more reliable method of assessing the T2 signal 
alteration may increase the clinical utility of T2 oedema imaging potentially leading to wider 
adoption.  
 Bright-blood T2-weighted MRI techniques have recently emerged as potential 
alternatives to dark-blood T2-weighted MRI. Kellman and colleagues developed a bright-
blood T2-prepared, single-shot steady-state free precession (T2-prepared SSFP) method, 
which involves surface coil intensity normalization; parallel imaging techniques, and motion-
corrected averaging (52). The group demonstrated improved diagnostic confidence in 
detecting acute from chronic AMI compared with dark blood imaging. Moreover, Aletras and 
colleagues developed another bright-blood T2-weighted method, ACUT2E (Acquisition for 
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Cardiac Unified T2 Oedema), which is a hybrid of turbo spin-echo (TSE) and SSFP(53). The 
TSE-SSFP method has higher signal-to-noise (SNR) and contrast-to-noise (CNR) ratio than 
T2-prepared SSFP. A non contrast, quantitative T2 mapping sequence using T2-SSFP has 
also been proposed and been shown to be more accurate than conventional T2 STIR at 
predicting AAR in animal and human models (45, 54). 
   Just as with T2, recent experimental studies have shown that T1 values increase with 
increasing myocardial water content and thus with ischaemia and infarction (45) By directly 
quantifying T1 values for each voxel in the myocardium, a parametric map can be generated 
representing the T1 relaxation times of any region of the heart. The most widely used T1-
mapping sequence is based on the Modified Look- Locker Inversion-recovery (MOLLI) 
technique that consists of a single shot TrueFISP image with acquisitions over different 
inversion time readouts allowing for magnetization recovery of a few seconds after 3 to 5 
readouts(55).In addition to MOLLI, a shortened breath-hold adaptation with conditional 
curve fitting (ShMOLLI) (56) was proposed as a means of mitigating some of the potential 
issues with MOLLI such as the heart rate dependence. However, MOLLI remains the most 
widely used of the T1 mapping techniques.   
 
1.2.4 Dark Blood versus Newer T1/T2 Techniques for Area at Risk Assessment 
 Our group has recently demonstrated the superior accuracy of bright blood T2 weighted 
imaging to detect the ischemic AAR when compared to conventional dark blood STIR 
imaging. In this cohort of 54 consecutive AMI patients Bright-blood T2 weighted imaging 
had greater accuracy for the identification of the infarct related artery as well as more 
accurate assessment of the ischaemic area at risk.  However, this was a study performed at 
1.5Tesla with the majority of patients presenting with STEMI (44 patients 81%) (57). 
 In a canine model of ischaemia and using a microsphere reference standard, Ugander and 
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colleagues compared T1 (ShMOLLI) and T2 maps at 1.5 T for defining the area at risk. Both 
imaging modalities demonstrated equivalence with excellent correlation(45)Ferreira and 
colleagues investigated the diagnostic performance of dark blood imaging when compared to 
Bright Blood (ACUT2E) imaging as well as a novel T1 mapping method (ShMOLLI) in 
patients with Takotsubo cardiomyopathy and oedema syndromes without infarction at 1.5 
Tesla (58). The group demonstrated superior diagnostic accuracy with T1 mapping when 
compared to both dark blood and bright blood T2 imaging methods. Verhaert and colleagues 
have also demonstrated superior accuracy of a novel T2 mapping technique when compared 
with dark blood imaging at 1.5 Tesla (54). Amongst 27 patients - only 11 of whom presented 
with NSTEMI, the use of T2 maps was associated with more reliable and improved detection 
of oedema. 
 Recently, Dall’Armellina and colleagues assessed the use of T1 with T2 mapping 
amongst 41 patients presenting with myocardial infarction at 3.0 Tesla (48). 73% of the study 
cohort presented with STEMI. There was a similar diagnostic performance of T1 vs. T2 maps 
for detecting edematous injured myocardium. In a subgroup analysis performed in only 9 
patients with NSTEMI, the authors demonstrated a superior diagnostic performance of T1 
maps over T2 maps and also less variability in T1 compared with T2 maps. 
 Thus although the shortcomings of dark blood imaging are well described, there is a 
lack of published data in a large NSTEMI cohort particularly at 3.0 Tesla. There is also a lack 
of data comparing T1 versus T2 maps in the NSTEMI population. Previous studies 
comparing dark blood imaging with newer T2 or T1 methods have included only small 
numbers of patients with NSTEMI.   
 
1.2.5 The Angiographic Area at Risk 
 Using CMR and tracing the endocardial surface area of an infarct, several 
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angiographic scores have been developed and validated amongst patients with ACS to reflect 
the AAR (59).  Moreover, the APPROACH score has been shown to correlate with T2 
weighted myocardium at risk using bright blood imaging (44). In general, there is increasing 
strength of relationship between the angiographic area at risk and a greater degree of infarct 
transmurality (59). Typically, NSTEMI patients have smaller, less transmural, sub-
endocardial infarcts and thus it is unclear whether angiographic scores describing the AAR 
will correlate with CMR AAR in NSTEMI. In the populations studied and reported on thus 
far, the mean infarct size in these subpopulations have been moderate; 16.7% reported by 
Payne et al (57) with a mean troponin of 50mg/dl reported by Verhaert and colleagues(54). 
Whether the relationship between angiographic area at risk will hold true for smaller infarcts 
seen in NSTEMI is unknown. 
 
1.2.6 Potential Utility of CMR in NSTEMI 
 Since edema persists for days or weeks after an acute ischaemic injury, STEMI 
patients have generally been studied following revascularisation, a time when potential 
benefit of identifying the AAR is limited. NSTEMI is a condition typified by smaller degrees 
of myocardial injury and non-occlusive culprit lesions. Compared with STEMI, the clinical 
utility of identifying the AAR in NSTEMI patients could theoretically have a greater 
diagnostic and clinical role since NSTEMI is a more heterogeneous condition and MRI can 
be performed prior to revascularisation. However, data allowing direct comparison of T1/T2 
mapping sequences and T2W STIR in NSTEMI, particularly at 3.0 Tesla, are lacking. 
Furthermore, the use of edema imaging suggests a further role for cardiac MRI in the 
diagnosis and early assessment of patients presenting with chest pain syndromes(37). This 
may enable patients who have unstable angina but with no changes in troponin levels to be 
identified and further direct the interventional cardiologist towards the likely culprit vessel 
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(39).  
 
Myocardial Haemorrhage 
 T2W imaging detects regions of myocardial haemorrhage, as identified by a 
hypointense core within regions of high-signal myocardial oedema. Myocardial haemorrhage 
occurs during the successful post-reperfusion phase of MI, representing severe microvascular 
injury, specifically damage to the endothelial barrier, which allows blood to leak into the 
surrounding myocardial tissue(60). 
 The presence of myocardial haemorrhage in patients with AMI has been shown to 
have a greater AAR, lower pre-PCI thrombolysis in myocardial infarction (TIMI) flow and a 
larger final IS (61). Furthermore, myocardial haemorrhage has also been shown to be the 
strongest predictor of LV remodelling at 3 months, independent of the IS (62). 
In recent years, new cardiac MRI techniques have become increasingly recognised to detect 
myocardial haemorrhage, namely T2* weighted sequencing and T2* mapping(63, 64). These 
have been historically used to detect iron overload in patients with haematological disorders 
dependent on regular blood transfusions, such as those with thalassaemia or myelodysplasia 
(64). These techniques are more specific than T2W imaging for the detection of myocardial 
haemorrhage. This gives a unique perspective on infarct pathology, with myocardial 
haemorrhage potentially having a role as an outcome measure and may represent a novel 
therapeutic target. However, published work has been almost exclusively been in the STEMI 
cohort with very little in NSTEMI. Thus, not only is the impact of myocardial haemorrhage 
on prognosis unknown amongst patients with NSTEMI, the incidence of haemorrhage in this 
population is not well studied. 
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1.2.7 Late Gadolinium enhancement (LGE): assessment of scar and viability  
 LGE images are T1 weighted sequences that involve the acquisition of a series of 
short-axis slices of the ventricles as well as 2-chamber, 3-chamber and 4-chamber axis views. 
These images are obtained approximately ten to fifteen minutes after an intravenous 
administration of a gadolinium (extracellular) based contrast agent (65).  
In the acute phase of MI, gadolinium enters the intracellular space through damaged cell 
membranes where it is retained (66). Conversely, in normal myocardium, the presence of 
densely packed healthy myocytes means that gadolinium is “washed out,” more rapidly. The 
effect is an increase in gadolinium concentration, in infarcted myocardium, shortening T1 
relaxation time and thus resulting in hyper-enhancement compared to non-enhanced viable 
regions (67). In other words, it assumes a bright signal as opposed to the dark viable 
myocardium, identifying areas of irreversible myocardial injury (67). This is currently the 
gold standard for in vivo infarct visualisation. Essentially, LGE differentiates irreversibly 
damaged (non-viable) myocardium, from myocardium which is simply stunned following an 
acute ischaemic insult, with acute reversible myocardial injury being oedema positive but 
LGE negative.  
 Furthermore, LGE imaging can evaluate the extent of transmural necrosis. The 
transmural extent of MI is an important predictor of functional recovery, with an inverse 
relationship seen between the transmural extent of MI and the recovery of contractile 
function (68, 69). This information provides the cardiologist with insights as to the potential 
benefit from revascularisation, in patients with AMI(69). As a general rule of thumb, if the 
transmural extent of LGE is greater than 50%, then there is less likely to be functional 
recovery following revascularisation(34). 
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1.2.8 Microvascular Obstruction (MVO) 
 LGE imaging also has the ability to identify another microvascular injury 
characteristic known as microvascular obstruction (MVO) (68, 69). The presence of MVO 
represents more severe ischemic injury and is directly correlated with larger infarct size(70). 
This can be seen on MRI as a central hypo-intense core, as shown by the dark zones, within 
bright regions of LGE (71) 
 Moreover, a strong relationship exists between MVO and myocardial haemorrhage, 
with the size of the “dark zones,” on LGE images correlating with the extent of myocardial 
haemorrhage (72). Interestingly, MVO is present in all patients with myocardial haemorrhage 
but not every patient with MVO will have myocardial haemorrhage. MVO has not been well 
studied in NSTEMI compared with STEMI. The recently published Effect of Aspiration 
Thrombectomy on Microvascular Obstruction in NSTEMI (TATORT-NSTEMI) trial 
examined the impact of routine aspiration thrombectomy for patients with NSTEMI (73). The 
study failed to show a benefit of aspiration thrombectomy but did show a prevalence of MVO 
of approximately 31%. However, this was a highly selected population of high risk NSTEMI 
patients who had thrombus containing culprit lesions. Thus the reporting of MVO may be 
higher in this population compared with a more broad NSTEMI population undergoing 
invasive evaluation and CMR. Indeed Guerra and colleagues reported an incidence of MVO 
of 13.8% amongst 190 patients with NSTEMI undergoing CMR (74). 
 
1.2.9 Perfusion imaging  
 Perfusion imaging is used in the assessment of myocardial blood flow, including 
patency of the microvasculature hence identifying MVO (75). This technique recognises 
regional blood flow within the myocardium, through changes in T1 weighted signal intensity, 
after the bolus of contrast administered passes through the myocardium.  
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Stress perfusion imaging, performed after administration of a vasodilator medication, such as 
adenosine, can accurately identify flow-limiting lesions within the coronary arteries (76). 
Plein and colleagues examined the use of stress perfusion MRI amongst patients with 
NSTEACS of which only 53% had a positive troponin (75). The group compared stress 
perfusion CMR defects with an angiographic stenosis of at least 70% on coronary 
angiography.  The group found a sensitivity of 88%, specificity of 83%, negative predictive 
value of 59% and a positive predictive value of 96%. Whilst encouraging, the results of 
perfusion CMR in this population were not optimal. One major methodological concern with 
the study however, is the use of stenosis severity at coronary angiography as a gold standard. 
The patients were also lower risk with only 50% having a positive troponin.  Thus the use of 
stress perfusion CMR may be more accurate at predicting haemodynamically significant 
stenosis if a more robust marker e.g. FFR was utilised.  
 
 Potential Limitations of cardiac MRI 
 For all that cardiac MRI has to offer, it is constrained by a few important limitations. 
Cardiac MRI is a high specification technology that involves strong magnetic fields (typically 
1.5 – 3.0 Tesla), a protocol of radiofrequency pulse sequences and administration of an intra-
venous contrast agent. MRI is not possible in patients who are claustrophobic or who have 
metallic implants. Unlike echocardiography, MRI cannot be performed at the bedside and 
requires a skilled multidisciplinary team for each scan. MRI may not be possible in the 
sickest patients including those with pulmonary oedema (who may be unable to lie flat), 
patients with arrhythmias or those who may not be able to breath-hold to minimise 
cardiorespiratory motion.  New pulse sequences, such as T2-mapping (for the detection of 
myocardial oedema and AAR), use motion-correction and arrhythmia rejection algorithms to 
help overcome these limitations. 
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 As discussed, cardiac MRI may involve the use of a gadolinium based contrast agent, 
which has been related to nephrogenic systemic fibrosis (NSF), especially in patients with 
severe renal impairment. NSF is a systemic fibrosing disorder of the skin, connective tissue, 
joints, liver muscles and heart, progressing rapidly within a short space of time. Therefore, it 
is of importance to evaluate renal function prior to MRI, particularly if there are signs of 
renal complications post-angiography. However, this complication is rare and no reports of 
NSF have occurred in patients with a glomerular filtration rate of >30ml/min.  
 Finally, cardiac MRI is expensive compared to other imaging methods such as 
echocardiography and even nuclear imaging. More research is needed to determine whether 
or cardiac MRI may be cost effective when used in this way in routine clinical practice. 
 
Summary 
 The use of CMR in patients with NSTEMI holds a promising future and is fast 
becoming a widely used tool in the assessment of STEMI, providing more than just standard 
anatomical, functional and haemodynamic information. There remains a lack of data in the 
utility of novel edema imaging methods amongst patients with NSTEMI and their diagnostic 
utility compared with established dark blood techniques. Furthermore, there is a lack of 
robust data on the use of stress perfusion CMR in this population. 
 
1.3 Role of Coronary Angiography 
 Coronary angiography has vastly improved our understanding of coronary artery 
disease providing an unrivalled appreciation of coronary anatomy and plaque distribution. It 
It has a temporal resolution of 7.5 – 20 frames/second and a spatial resolution of ~150 – 300 
µm. Invasive coronary angiography is the reference diagnostic tests for determining the 
presence and extent of coronary artery disease. However, due to the inherent complications 
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involved with invasive coronary angiography it is not recommended for every patient with 
ischaemic heart disease. In general, coronary angiography is recommended for patients with 
symptomatic stable angina with high pretest probability for coronary artery disease (1). It is 
also recommended for all intermediate to high risk NSTEMI patients in order to qualify 
coronary artery anatomy and identify patients who would benefit from revascularisation (77). 
For patients presenting with STEMI coronary angiography is also indicated in the setting of 
emergency primary PCI (78).  It is also indicated following an initial non-invasive 
reperfusion strategy (78).  
 Although regarded as the gold standard in the evaluation of coronary artery anatomy, 
coronary angiography possesses limitations. Autopsy and intravascular ultrasound studies 
have demonstrated the shortcomings of coronary angiography in determining the extent of 
atherosclerotic disease (79). Coronary arteries are three-dimensional structures and 
fluoroscopic coronary angiography provides a planar silhouette of the contrast filled lumen. 
The coronary angiographic severity of lesions is also described in relation to a distal ‘normal’ 
reference segment. Necropsy studies have demonstrated that in patients with atherosclerosis, 
disease is frequently diffuse without normal segments (80). This has obvious implications in 
interpreting angiographic images. Lesion eccentricity, foreshortening and vessel overlap are 
also factors contributing to the subjective angiographic evaluation of coronary arteries (79). 
Furthermore, coronary angiography only provides information on the epicardial circulation, 
providing little data on other major constituents of myocardial blood flow that has recently 
been shown to be of significant importance at determining prognosis over and above 
epicardial flow(81).  
 Intravascular ultrasound has also allowed in-vivo appreciation of this extent of plaque 
burden as well as the nature of arterial remodelling, a process defined by changes in the 
vascular dimensions that occur early in the development of atherosclerosis. Positive 
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remodelling refers to an increase in the diameter of the external elastic membrane to 
compensate for underlying atheroma in order to pre- serve luminal size [13]. This may also 
conceal the extent of disease displayed with coronary angiography [11]. 
 The assessment of intermediate lesions defined as a luminal narrowing with a 
diameter stenosis ≥40% but ≤70% [10] are particularly challenging and incorrect 
management decisions can be made if based solely on angiographic severity in this 
intermediate group. Specifically, in patients with NSTEMI, rather than vessel occlusion as is 
usually the case with STEMI, patients may present with non-occlusive, intermediate severity 
stenosis. Thus decision-making that relies solely on coronary angiography may be 
problematic. 
 
1.3.1 Pitfalls in visual assessment  
 Invasive management strategies are generally delivered around visual interpretation of 
coronary stenoses and revascularization decisions mediated at the discretion of the 
angiographer. This visual approach has been challenged in light of the evolving and 
burgeoning role of fractional flow reserve (FFR) in stable coronary artery disease. Clinical 
judgments as to the haemodynamic severity of coronary stenoses performed visually are 
subjective and inaccurate leading to misdiagnosis and altered treatment decisions, which can 
be of prognostic significance (82, 83). In ACS, this challenge is exacerbated in multi-vessel 
disease found at angiography in trying to identify the culprit vessel since discriminating flow-
limiting disease from non-culprit disease can be difficult (84). Up to 60% of patients with 
NSTEMI can have multi vessel disease and therefore treatment decisions based solely on the 
angiogram can lead to sub-optimal health outcomes (85). 
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1.3.2 Multi-vessel Disease 
 Multi-vessel coronary disease (MVD) is observed in approximately 30-50% of 
patients presenting with acute ST elevation myocardial infarction (STEMI) and is associated 
with a worse prognosis(86). In the recently published PRAMI trial, 54% of STEMI cases had 
MVD as defined by a stenosis of 50% or more in one or more coronary arteries other than the 
infarct related artery(87). Likewise, in patients with non-ST elevation myocardial infarction 
(NSTEMI), 30–59% of patients have MVD(88). In patients with STEMI and MVD, the 
culprit artery is generally obvious but the functional significance of non-culprit lesions may 
be difficult to determine. The ability to accurately assess the functional significance of non-
culprit stenoses at the time of primary PCI for STEMI would potentially facilitate a strategy 
of complete revascularisation during the index procedure with consequent health and 
economic benefits. In patients with NSTEMI and MVD, the same scenario applies but often 
with the additional difficulty of correctly identifying the culprit itself, an issue that may also 
be addressed by functional testing in the cath lab.   
 
1.3.2.1 Revascularisation Strategies in Patients with ACS and Multi-vessel Disease 
 Contemporary guidelines recommend in patients stabilized after an episode of ACS, 
the choice of revascularization modality can be made as in stable CAD(89). The European 
Society of Cardiology (ESC) guidelines suggest basing the revascularization strategy in 
UA/NSTEMI (either culprit only PCI or multi-vessel PCI or CABG) on clinical status and 
disease severity according to local heart team policy (Class 1/Level of Evidence C)(23). In 
approximately one-third of patients’ angiography will reveal single- vessel disease, allowing 
ad hoc PCI in most cases. Multivessel disease will be present in another 50%. Here the 
decision is more complex and the choice has to be made between culprit lesion PCI, 
multivessel PCI, or CABG. Culprit lesion PCI usually is the first choice in most patients with 
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multivessel disease. The strategy of multivessel stenting for suitable significant stenoses 
rather than stenting the culprit lesion only has not been evaluated appropriately in a 
randomized fashion. Culprit lesion PCI does not necessarily require a review by the heart 
team when on clinical or angiographic grounds the procedure needs to be performed ad hoc 
after angiography(23). 
 In patients with STEMI, it is recommended that primary PCI should be limited to the 
culprit vessel with the exception of cardiogenic shock and persistent ischaemia after PCI of 
the supposed culprit (Class 2a/Level of Evidence B). If staged PCI to non-culprit vessels is 
being considered non-invasive stress testing (myocardial perfusion scintigraphy, stress 
echocardiography, PET or MRI) should be used for ischaemia and viability testing prior to a 
decision to proceed with PCI(90) 
 These latter recommendations were based on observational data suggesting that PCI 
of a non-culprit artery at the time of PPCI in patients with STEMI was associated with 
increased mortality at 90 days(91, 92). Specifically in a cohort analysis from the 
HORIZONS-AMI trial, multi-vessel PCI at the time of PPCI was associated with a higher 1-
year mortality (9.2% vs. 2.3.%) and stent thrombosis rate (5.7% vs. 2.3%) than staged 
PCI(92). Controversy in this area due to conflicting evidence has led to numerous clinical 
trials, which are in progress at present, as well as the recently published PRAMI trial. This 
study demonstrated that in a group of 234 STEMI patients randomised to preventive PCI in 
non-culprit arteries versus 231 randomised to culprit only PCI there was an absolute 14% risk 
reduction in the primary outcome (a composite of death from cardiac causes, non-fatal MI, or 
refractory angina) in favour of preventive-PCI (HR=0.35; 95% CI, 0.21 to 0.58; 
P<0.001)(87). PRAMI used conventional angiographic indices of lesion severity (diameter 
stenosis > 50%) to identify non-culprit targets for PCI. It is highly likely that some of these 
lesions were not functionally significant. As such, FFR guidance has the potential to further 
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target the group of patients/lesions who may benefit from immediate multi-vessel PCI. If 
however, some or indeed all of the benefit in PRAMI was related to “sealing” of non-culprit 
but vulnerable plaques then it may be that FFR guided PCI will not be superior to 
angiographic guidance in this setting (see below). In a similar fashion, there is a lack of data 
available to guide management of patients with multivessel disease and NSTEMI. Whilst ad-
hoc PCI for culprit lesions is suggested, there are no clear guidelines for the management of 
non-culprit disease. 
1.3.3 Identification of the culprit and non-culprit vessels in patients with ACS 
 Whilst this is frequently straight forward in cases of acute STEMI it can often be 
difficult to identify the infarct related artery in cases of UA/NSTEMI especially when no 
localising ECG changes have been observed and no regional wall motion abnormalities are 
notable on echo. Angiographic features suggestive of acuity include haziness, irregularity, 
and eccentricity, ulceration, filling defects, thrombus, flow disturbances and sub-total 
occlusion. Invasive imaging such as optical coherence tomography (OCT) and intravascular 
ultrasound (IVUS) may enable identification of a ruptured plaque or dissection in difficult 
cases. FFR has the ability to identify the vessel with physiologically restricted coronary flow 
and may be useful in identifying the culprit lesion/artery in difficult cases with 
angiographically diffuse and/or intermediate severity disease. However such a strategy has 
not been studied prospectively in a randomized control trial. 
 
1.3.3.1 Anatomical and functional lesion assessment in patients with ACS 
 There are well-founded concerns that the angiographic severity of non-culprit lesions 
may be overestimated in STEMI due to diffuse vasoconstriction poorly responsive to 
conventional vasodilators. A study evaluating lesion severity in non culprit vessels in 48 
patients imaged within 9 months post STEMI demonstrated that lesion severity decreases 
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with time, (presumably as thrombus is resorbed and vascular tone normalizes) with minimal 
lumen diameter on QCA improving from 1.53 +/- 0.51 mm to 1.78 +/- 0.65 mm, (p < 0.001) 
and diameter stenosis from 49.3 +/- 14.5% to 40.4 +/-16.6%, (p < 0.0001) (93).  This is of 
concern for patients with NSTEMI where identifying the culprit lesion can be difficult and 
thus interpreting the angiogram may be even more challenging. 
 
1.3.4 Predicting future events in ACS: Plaque vs. Flow? 
 It has been demonstrated that up to 80% of patients who present with ACS will have 
had a stenosis on prior coronary angiography of ≤70% that would traditionally be regarded as 
non-obstructive plaque (94). Further evidence for this originates from two recent landmark 
studies. The multi-centre prospective natural-history study of coronary atherosclerosis 
(PROSPECT) study followed 697 patients post ACS who received three vessel virtual 
histology intravascular ultrasound (IVUS) at baseline and repeat IVUS after presentation with 
a recurrent ACS. In the follow up period there was a 3 year MACE of 20.9% of which 11.6% 
were related to the non-culprit artery. Mean stenosis in the non-culprit vessel was only 
32±20.6% at baseline and therefore likely to be visually interpreted as mild. Plaques 
responsible for MACE were likely to have elevated plaque burden of >70%, minimal luminal 
area <4.0mm2 or to contain thin capped fibroatheromas (TCFA)(95). 
 The Acute Catheterisation and Urgent Intervention Triage strategy (ACUITY) trial 
included 7789 patients with ACS who underwent percutaneous intervention following 
coronary angiography (96). A sub analysis of this trial examined the role of complete versus 
incomplete revascularization in determining MACE. MACE rates were higher amongst 
patients who did not achieve complete revascularization. Of interest, a diameter stenosis of 
≥50% was an independent predictor of MACE at 1 year in the incomplete revascularization 
group but events also occurred in stenosis <50% (97).  
 34 
Clearly these trials emphasise two potential determinants of future events in patients 
presenting with ACS. Firstly the characteristics of the plaque itself; TCFA is generally 
accepted to be the main precursor lesion associated with so called vulnerable plaques and 
PROSPECT demonstrated that these high-risk plaques were associated with morbidity. 
Secondly, the extent of residual coronary disease; whether this relates to plaque 
characteristics or the extent of residual ischaemia is unknown and was beyond the scope of 
the ACUITY trial. However, they highlight two important areas of future research in patients 
with ACS i.e. whether residual ischaemia, plaque characteristics or a combination of the two 
are the main determinants in future morbidity in patients with ACS.  
 Currently, no prospective study has utilized an invasive anatomical test for vulnerable 
plaque assessment with concomitant intracoronary haemodynamic testing in either stable or 
unstable coronary syndromes. The upcoming Fractional Flow Reserve or Optical Coherence 
Tomography guidance to revascularize intermediate coronary stenosis using angioplasty 
(FORZA) trial (98) will attempt to assist in answering this question. 
 
1.4 Role of Percutaneous Coronary Intervention 
 Following Gruentzigs first angioplasty in 1977 the growth of percutaneous 
intervention (PCI) with the use of stents has been exponential.  In Europe the number of 
stents implanted increased from 3000 in 1992 to 777,000 in 2004 (99). However, this 
exponential increase has not been met with a corresponding reduction in mortality across all 
presentations of ischaemic heart disease. Clearly PCI has beneficial effects in specific patient 
populations but it is not a universal panacea without consequence. Recent evidence has 
demonstrated that apart from select high-risk subgroups, rather than improve survival, PCI 
only improves symptoms in patients with stable angina (100). Such equivocal results may be 
ascribed to the inherent subjectivity that coronary angiography provides in determining the 
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haemodynamic importance of a coronary stenosis(79). Supportive evidence for this is evident 
from the nuclear sub-study of the COURAGE trial. In this study patients with a greater 
reduction in ischemia at clinical follow up had an improved unadjusted survival(101). PCI 
was superior to optimal medical therapy at reducing the ischaemic burden suggesting that had 
only ischaemia producing lesions received PCI, the optimal medical therapy with or without 
PCI for stable coronary disease (COURAGE) trial may have had a different conclusion. 
 In the NSTEMI cohort, the influence of PCI in determining outcome remains 
controversial. However, the majority of evidence supports the use of PCI at improving short-
term outcomes particularly the need for repeat revascularisation (77). There is also evidence 
for a survival advantage offered by PCI in certain high-risk NSTEMI subgroups (102). In the 
STEMI cohort, the evidence for PCI over thrombolysis is well established with PCI offering 
a more effective strategy for improving both short and long term outcomes(103).  
 Being an invasive procedure, there is an inherent risk involved with PCI that has been 
quoted as between 1% and 2% (1). Notwithstanding this risk, there are further complications 
that can occur as a direct result of coronary intervention that effect the distal coronary 
microcirculation. These include distal embolisation, microvascular spasm, microvascular 
thrombosis, inflammation and ischaemia-reperfusion injury (104). Such complications can 
lead to myocardial ischaemia and infarction. Some investigators have observed that 
myocardial infarction as a consequence of PCI is associated with reduced survival (105).   
 
1.5 Fractional Flow Reserve 
 Fractional flow reserve is a validated, simple method of assessing the haemodynamic 
importance of an epicardial stenosis that can be performed at the time of coronary 
angiography guiding appropriate revascularisation decisions. Indeed, amongst lesions that are 
less than 90% in severity, current guidelines mandate the demonstration of ischaemia prior to 
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revascularization. Both the recent AHA and ESC guidelines have therefore given FFR Level 
A evidence for guiding revascularization strategy in intermediate lesions(23). 
 Given the risks of PCI, unnecessary PCI procedures should be avoided wherever 
possible and objective decision making during coronary angiography is highly desirable. 
Gould made an important contribution to our understanding of coronary physiology by 
reporting that resting myocardial blood flow remains normal until an epicardial stenosis 
reaches ≥85% and that hyperaemic blood flow reduces with a >50% stenosis (figure 2) (106). 
Using a flow transducer in a dog model, he attempted to define the effect of a stenosis on 
maximal myocardial flow, rather than resting flow. He defined the coronary flow reserve 
(CFR) as the ratio of hyperaemic to resting coronary flow and demonstrated that CFR 
decreased as stenosis severity increased. CFR was later validated against non invasive testing 
and a value of <2.0 was shown to correlate with the haemodynamic severity of a stenosis 
(107). However, CFR encompasses both the epicardial and microvascular compartments and 
is significantly influenced by prevailing haemodynamics and patient specific factors making 
its routine use unreliable for individual patients at a point in time in the cath lab (108). This 
conundrum led researchers to investigate other methods for stenosis assessment and it wasn’t 
long before pioneering work from Pijls and De Bruyne developed the concept of an epicardial 
specific index known as Fractional Flow Reserve (FFR). FFR is defined as the ratio of 
hyperaemic myocardial flow in the stenotic territory to normal hyperaemic myocardial flow 
if, theoretically there was no stenosis present (109). More simply it represents the extent to 
which maximal myocardial blood flow is limited by a stenosis (110). 
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Figure 2:Coronary flow reserve versus arteriographic percent diameter stenosis in canine 
experimental model. (B) Coronary flow reserve in open-chest humans at bypass surgery 
versus arteriographic percent diameter stenosis. Solid or open circles or squares indicate 
different coronary arteries. Reproduced, with permission, from White et al. (12). RCA   
right coronary artery. 
 
1.5.1 Fractional Flow Reserve Theory (Fig. 3) 
 As with many calculations in cardiovascular physiology, central to the calculation of 
fractional flow reserve is Ohm’s law which states: 
I = ∆V/R 
(where I=current, V = potential difference R = resistance).  
 
This can be extrapolated to the coronary circulation so that: 
Coronary flow (I) = ∆ Pressure/Resistance (111), 
 
whereby change in pressure is derived from aortic pressure (Pa) minus coronary venous 
pressure (Pv). In the normal coronary circulation the aortic pressure (Pa) is transmitted to the 
distal coronary artery without pressure loss and so coronary artery pressure (Pd) is equal to 
aortic pressure (112). Based upon the Ohm’s law coronary derivation, if resistance is kept to 
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a minimum (with the attainment of maximal hyperaemia), and we assume that venous 
pressure is constant, we can measure coronary pressure to derive coronary flow. Put another 
way, during maximal hyperaemia, the coronary pressure-flow relationship is linear at 
physiological pressures such that measures of coronary pressure made at hyperaemia, most 
often achieved with intravenous adenosine, are proportional to coronary flow (Figure 4).  
 
 
 
 
 
 
Figure 3: Methodology for FFR calculation 
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Figure 4: Relationship between coronary flow and Coronary Perfusion Pressure 
 Central to the calculation of FFR is the ability to measure both pressure proximal to a 
stenosis (Pa) and pressure distal to a stenosis (Pd) that is achieved with commercially 
available pressure wires. At hyperaemia, Pa represents myocardial flow in the absence of a 
stenosis and Pd represents myocardial flow in the presence of a stenosis. FFR is then given as 
Pd/Pa. An FFR value of 0.5 infers that maximal myocardial blood flow is only 50% of 
expected and that restoring epicardial patency with revascularisation should improve flow in 
the territory. 
 Unlike CFR, FFR has been shown to be a highly reproducible technique. De Bruyne 
examined the reproducibility of FFR in 13 patients with single vessel disease and normal left 
ventricular function under differing loading conditions. FFR was relatively insensitive to 
changes in haemodynamics and contractility with a coefficient of variation of 4.8% as 
compared with 10.4% (coronary flow reserve) and 27.7% (hyperaemic flow vs. pressure 
slope index) for other established invasive measures for assessing epicardial stenoses(113). 
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1.5.2 Measuring Fractional Flow Reserve (FFR) in the Cath Lab (Fig 5) 
 FFR is a simple cath lab based pressure derived index that is easy to perform. 
The Technique 
 Firstly, the coronary artery being studied is engaged with a guiding catheter specific 
for the arterial system of interest. Diagnostic catheters can be used, but due to potential 
inaccuracies, it is recommended that a normal guiding catheter be used in order to perform 
FFR(110). Patients require systemic anticoagulation with intravenous heparin (40–
60units/kg) and the use of intracoronary GTN (100–200 mcg) to abolish any residual 
epicardial vasoconstriction and maintain coronary volume (114). Measurements are 
performed most commonly with wires that have a pressure sensor at the distal tip.   Emerging 
methods to measure pressure in the coronary artery include the use of fiber-optic sensor 
technology and these are currently being evaluated in clinically. For standard wires, there is a 
distal pressure sensor at the junction of the radio- opaque and radiolucent portions of the 
wire. 
 
Performing*FFR*
•  GTN*
•  Careful*
calibra6on*of*
pressures.*
Figure 5: Coronary Angiogram Still frame depicting how to perform FFR 
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 The pressure wire is then calibrated outside of the patient and advanced through the 
guide catheter and into the artery. Equalization of pressure from the guiding catheter and 
pressure wire is undertaken prior to the sensor entering the artery. Aortic pressure (Pa) is 
taken from the guide-catheter and distal pressure (Pd) from the pressure sensor placed beyond 
the stenosis. The wire itself is a standard 0.014inch wire with similar handling characteristics 
to conventional angioplasty wires and as such can be used for PCI when necessary. 
Induction of maximal hyperaemia through minimisation of coronary resistance is a pre-
requiste for measurement of FFR. This topic is covered later in the thesis but briefly this is 
most often achieved with the use of adenosine although papaverine and nitroprusside may 
also be used. Adenosine can be given as an intracoronary bolus (usually 60–200 mcg) or via 
an intravenous infusion (140 mcg/kg/min). Continuous monitoring of Pa and Pd is 
undertaken and FFR is taken as the ratio of hyperaemic Pd/Pa at steady state. The normal 
FFR value is 1 since the epicardial vessels do not contribute significantly to coronary 
Example(of(FFR(
Figure 6: Example of FFR Recording from RadiView 
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resistance and so aortic pressure is transmitted entirely to the distal vessel (112). Therefore in 
vessels without stenosis Pa will be equal to Pd. This holds true for all vessels in all patients. 
Fig. 6 shows an example of an FFR recording. 
 
1.5.2 Validation of Fractional Flow Reserve (FFR) 
 Following initial exploratory work in animal models (115), numerous clinical studies 
comparing FFR with non-invasive stress tests established an ischaemic FFR threshold of 
≤0.75 (116, 117). Pijls and colleagues looked at 41 consecutive patents with an intermediate 
lesion on coronary angiography and compared FFR with exercise bicycle stress testing, 
dobutamine stress echocardiography and thallium scintigraphy (116). All patents with an FFR 
value ≤0.75 demonstrated reversible myocardial ischaemia in at least one non-invasive 
modality. In contrast, 21 of the 24 patients with an FFR ≥0.75 had negative testing for 
reversible ischaemia on all three stress tests. The sensitivity of FFR at predicting reversible 
ischaemia was 88%, specificity 100% with a positive predictive of 100%, the overall 
accuracy was 93% (116). Likewise FFR values ≥0.80 are associated with negative ischaemic 
results with a predictive accuracy of 95% (112). Other studies have shown that an FFR value 
of 0.78 may be more predictive of reversible ischaemia on myocardial perfusion imaging 
(118). Therefore there is a ‘grey zone’ of FFR values between 0.75 and 0.80 that produces an 
area of uncertainty in FFR prediction of reversible ischaemia (110). An important 
consideration is that the validating studies for FFR were performed in highly selected patients 
with single vessel coronary artery disease with normal left ventricular function and no 
previous myocardial infraction. Thus it becomes difficult to extrapolate the validity of FFR 
outside of these strict parameters to other patient populations e.g. NSTEMI. Recent studies 
have utilised a cut off value of ≤0.8 (119) to determine the physiological importance of a 
lesion since a proportion of patients with an FFR value between 0.75 and 0.80 who had an 
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abnormal stress test, normalised following revascularisation. Indeed some authors advocate 
the use of an FFR cut off of ≤0.80 for main epicardial vessels whereby revascularisation may 
be prognostic and ≤0.75 for smaller branch vessels (120). Recent guidelines advise the use of 
an FFR ≤0.8 as an appropriate cut-off value (89). 
 
1.5.3 Use of FFR in patients with NSTEMI: The Ability to Achieve Maximal 
Hyperaemia 
 As already mentioned, FFR is an increasingly important technique to guide 
revascularisation strategies in patients with stable coronary artery disease undergoing elective 
PCI. A fundamental aspect of FFR is the ability to achieve maximal hyperaemia in order to 
achieve a linear relationship between pressure and flow (121).   
 Maximal coronary hyperaemia is dependent on an intact microcirculation and an 
adequate hyperaemic stimulus (121).  Factors affecting the coronary microcirculation (e.g. 
severe left ventricular hypertrophy) may impact on the ability to achieve maximal 
hyperaemia (122). Myocardial infarction (MI) can affect the distal coronary microcirculation 
secondary to a variety of mechanisms that include distal embolic phenomenon, microvascular 
stunning and acute ischaemic microvascular dysfunction(123).  Due to the heterogeneous 
nature of MI, this affect may vary according to the size of myocardial infarction and the time 
from infarction to FFR assessment.  Thus the validity of utilizing FFR in patients with recent 
MI is not fully established. 
 Although contemporary guidelines incorporate the use of FFR specifically in patients 
with NSTEMI to guide revascularisation (89) it remains a controversial topic in 
interventional cardiology (124). Several small studies have shown that FFR assessment is 
reliable and valid from between 4 and 6 days following the index event (118, 125) and the 
larger, multinational FAME study also included patients with NSTEMI (126).  However 
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these patients were generally stable without symptoms in the previous 5 days and had 
unreported infarct sizes. Thus it remains uncertain whether patients with acute NSTEMI can 
mount a sufficient hyperaemic response to vasodilator stimuli to maintain the diagnostic 
accuracy of FFR. Furthermore, there is a paucity of data concerning factors involved in 
determining the hyperaemic response in this population. 
 
1.5.4 Concerns with Using FFR in ACS 
 The attainment of maximal hyperaemia is based on the assumption of a normal distal 
microvascular bed. However PET studies have demonstrated impaired microcirculatory 
function in the infarcted territory compared with healthy controls up to 6 months following 
AMI(127).  Thus in patients with recent MI, microvascular injury, stunning and oedema can 
result in a failure to achieve minimal resistance and FFR values may be falsely elevated(127).   
 The effect of acute microcirculatory impairment is exemplified in acute STEMI, a 
syndrome characterized by distal embolization, inflammation and injury to the 
microcirculation. Tamita and colleagues described a higher post-PCI FFR in acute STEMI 
patients compared with stable CHD with similar IVUS parameters. Patients with more 
pronounced microcirculatory dysfunction as demonstrated by a reduction in TIMI flow (TIMI 
II) also had a higher FFR compared to those patients with TIMI III flow (128). Furthermore 
by using a surrogate of a hyperaemic response in 40 patients with acute STEMI, it has been 
shown that such patients have lowered vasodilatory capacity when compared to stable 
patients. Intuitively, there was also lower coronary flow reserve and higher IMR in acute 
STEMI (129). Thus in patients with acute STEMI the assessment of FFR in the culprit vessel 
is not recommended.  
 The resistive reserve ratio (RRR) is a measure of the ability to achieve maximal 
hyperaemia. It is the ratio of basal resistance (BR) to the index of hyperaemic 
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microcirculatory resistance (IMR). RRR quantifies the response of the coronary 
microcirculation to hyperaemia (adenosine) and addresses the question of whether or not the 
corresponding FFR values are accurate. Emerging data suggest this ratio has discriminatory 
value in patients with stable and unstable coronary disease. A prospective study by our group 
analyzing RRR in 50 patients with stable angina, 40 patients with acute STEMI and 50 
patients within 1-4 days of NSTEMI showed no significant difference between non-culprit 
vessels in stable angina [2.9 (2.3-3.9)] and either culprit vessels in stable angina [2.8 (1.7-
4.8), p=0.75] or culprit vessels in NSTEMI [2.46 (1.6- 3.9); p=0.75. RRR was significantly 
lower in the STEMI patients [1.7 (1.2-2.3]); p<0.0001]. There was no difference in IMR in 
patients with SA in the non-culprit vs. culprit vessel (16.8 ± 9.1 vs. 18.3 ± 9.2; p=0.44). 
However, as expected, IMR was higher and thus microcirculatory function worse in NSTEMI 
and STEMI compared with the non-culprit SA vessel (NSTEMI, 22.7 ± 11.3; p=0.015, 
STEMI, 36.5 ± 35.8 p<0.0001)(129).  
 
1.5.5 FFR – Use in late AMI 
 As the microcirculation recovers, so does the ability to achieve maximal hyperaemia 
and FFR measurement made at this time point reflect a definitive reduction in perfused 
myocardium rather than a transient phenomenon. De Bruyne and colleagues highlighted this 
in 57 patients who were ≥6 days after AMI comparing single photon emission computed 
tomography (SPECT) performed before and after PCI with FFR. They established 100% 
specificity using an FFR cut off value of 0.75 against truly positive and truly negative SPECT 
i.e. tests that were positive that reverted to completely negative post PCI (130). 
 Other groups have shown that rather than recover, the microcirculation remains 
persistently abnormal in both the culprit and non-culprit territories up to 6 months following 
myocardial infarction (127).  However, this was in a small number of patients and predated 
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the later FFR threshold studies and thus whilst thought provoking, do not detract from the 
diagnostic capacity of FFR in chronic MI. 
 
1.5.6 FFR in NSTEMI 
 Ntalianis et al performed a small prospective cohort analysis on 75 STEMI and 26 
NSTEMI patients with non-culprit FFR performed post-PCI to the culprit vessel (131). FFR 
was repeated at 35±4 days post procedure. There was no significant difference in percentage 
stenosis or minimal luminal area between studies despite improvements in left ventricular 
ejection fraction (LVEF). There was also no demonstrable difference in FFR between studies 
and in only 2 lesions did an FFR >0.80 decrease to <0.75. The lack of change in FFR was not 
affected by the improvement in LVEF. This was an important study as it demonstrated that 
FFR could be used accurately in non-culprit lesions in patients with ACS when measured 
acutely, important in considering the design of future studies.  
 The potential clinical utility of using FFR to guide decision-making in NSTEMI was 
investigated by Carrick and colleagues(82).  They performed a retrospective study of 100 
patients where FFR was used in the clinical case. The angiograms were analyzed by 5 
cardiologists who made an initial treatment decision.  Following FFR disclosure the 
cardiologists were then asked to re-evaluate their original decision. The use of FFR in this 
manner led to an increase in prescription of medical therapy and improved conformity in 
decisions amongst cardiologists (82). Potvin et al demonstrated in 201 unselected patients for 
invasive coronary angiography, the use of an FFR threshold of ≤0.75 was safe to allow 
deferral of stenting.  However only 21% of patients had a recent ACS and the use of FFR was 
neither blinded nor randomized (132).  
 The only randomized study to date specifically addressing the utility of FFR guided 
decision-making in NSTEMI was performed by Leesar et al (133). They reviewed the effect 
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of treatment decisions guided by FFR against stress perfusion scintigraphy. 70 patients with 
single vessel disease and a history of unstable angina were recruited. There was a significant 
reduction in duration and cost of index hospitalization in the FFR arm. However, this was not 
a genuine NSTEMI population with only two-thirds having a diagnosis of AMI, patients were 
medically stable for 48 hours or more, and the impact of multi-vessel disease was not 
assessed.  Thus although helpful, these studies were in relatively stable patients and not 
powered to detect any impact of FFR-guided management on health outcomes or to 
determine the clinical utility of FFR in patients with ACS. 
  
1.5.7 Current FFR Thresholds in NSTEMI 
 There is currently a lack of data addressing whether the contemporary thresholds for 
FFR retain their diagnostic accuracy in patients with NSTEMI.  Intuitively, the data in 
STEMI will hold true for NSTEMI yet patients are generally treated within 72 hours of 
presentation resulting in potential uncertainty. However, there have been several studies that 
have aimed to establish and validate FFR thresholds for ischaemia in patients with ACS. In 
48 stabilised patients with recent MI, Samady and colleagues compared FFR in the infarct 
related artery to non-invasive findings using SPECT and myocardial contrast 
echocardiography (MCE)(125). Patients had a mean time to angiography of 3.7 days with 
73% of patients with STEMI. The group demonstrated that an FFR ≤0.75 had 91% 
sensitivity, 93% specificity and a diagnostic accuracy of 92% for detecting reversible 
ischaemia. They provided an optimal cut off FFR value of ≤0.78 for detecting reversible 
ischaemia using ROC analysis.  De Bruyne et al demonstrated that an FFR ≤0.75 in a culprit 
vessel ≥ 6 days following an AMI was still predictive of reversible ischaemia shown on non-
invasive SPECT imaging(118). Thus, there is some evidence for the use of FFR to determine 
ischaemia in the culprit territory 4-6 days following ACS. Clearly although the resistance 
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indices can be higher in NSTEMI it appears that the microcirculation can dilate sufficiently to 
enable maximal hyperaemia and allow valid FFR measurements. 
 
1.5.8 FFR Guided Decision Making in Patients with UA/NSTEMI 
 The FAME study showed that in patients with multi-vessel disease there was a 30% 
reduction in adverse cardiac events (death, MI, target vessel revascularization) with an 
absolute risk reduction of 5% in the group undergoing FFR guided PCI compared to those 
undergoing angiographically guided PCI(119). A secondary analysis in 2011 clarified that the 
benefit observed in the overall trial population was also seen in the UA/NSTEMI group. 
Overall, FAME included 328 patients with UA/NSTEMI of whom 178 were randomised to 
angiographically guided PCI and 150 to FFR guided PCI. An absolute reduction in adverse 
cardiac events of 5.1% was observed in the FFR guided group as well as less contrast useage 
and on average 1 stent less per patient (1.9 ± 1.5 vs. 2.9 ± 1.1, p < 0.01)(126). However, this 
was only a subgroup analysis of the larger FAME study with a lack of data on the degree of 
myocardial injury reported and with patients being stable prior to randomization. Thus there 
remains an ongoing need for a prospective randomized study to determine the clinical utility 
of routine FFR use in patients with STEMI. 
 In a separate observational study of 106 patients with NSTEMI, PCI was deferred as 
the culprit vessel FFR was >0.75. The 1 year event rate was 1.9% mortality, 0.9% target 
vessel revascularisation and 4.7% for readmission with a cardiac cause(134).  
 
1.5.9 Ongoing Clinical Trials of FFR Guided PCI in Patients with ACS 
 Despite the theoretical considerations outlined above, the weight of evidence suggests 
that non-culprit FFR can provide useful information regarding functional significance in a 
high proportion of patients with ACS. On this basis, FFR guided decision making in patients 
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with STEMI and MVD is now being tested in a series of randomized controlled trials. The 
COMPARE ACUTE study (NCT01399736) is a randomised controlled trial (RCT) in STEMI 
patients with MVD in the Netherlands with estimated enrolment of 885 patients divided into 
immediate FFR guided complete revascularization versus staged non-culprit PCI (ischemia 
driven) by proven ischemia or recurrent symptoms. The primary endpoint will be a composite 
of death, non-fatal MI, CVA or revascularization at 12 months and this study is estimated to 
end in 2018. 
 The COMPLETE study (Complete vs. Culprit-only Revascularization to Treat Multi-
vessel Disease After Primary PCI for STEMI, NCT01740479) is a RCT comparing FFR 
guided revascularisation within 72hrs of primary PCI versus optimal medical therapy for the 
endpoint of a composite of cardiovascular death or MI at 4 years. It began recruiting in 
2012and is due to report its findings in 2018. 
 The Primary PCI in Patients With ST-elevation Myocardial Infarction and Multi-
vessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization 
(PRIMULTI, NCT01960933) study is a RCT of patients with STEMI and MVD with a 
comparison of the clinical outcome after complete FFR guided revascularisation versus 
treatment of the infarct-related artery only during primary PCI. The primary outcome is all 
cause death, MI or revascularization at 48 months. This study, which is based in Denmark, 
has finished recruiting and is due to report its findings later this year. 
However, despite multiple STEMI trials there is a lack of prospective data on the use of FFR 
in a specific NSTEMI population. In addition, the randomized use of FFR to guide 
revascularization decisions in the culprit vessel is unknown. 
 
Summary  
 NSTEMI is the most common cause of myocardial infarction and increasing in 
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incidence.  Amongst high-risk patients undergoing an invasive approach, decision-making is 
heavily weighted on interpretation of the coronary angiogram. We have learned from IVUS 
and paradigm-changing clinical trials such as DEFER and FAME that our interpretation of 
the angiogram is subjective and the ability for cardiologists to predict the haemodynamic 
importance of a lesion is at best moderate. The use of FFR to guide revascularization 
decisions has great promise to improve decision-making and perhaps outcomes in patients 
with NSTEMI by way of reducing unnecessary revascularization. However, to date there is 
no prospective randomized trial that has focused on higher-risk NSTEMI patients.  
 
1.6 Methods of Achieving Hyperaemia – The Case for Adenosine  
 Adenosine is a ubiquitous extracellular signalling molecule with essential functions in 
human physiology. From providing the backbone for basic energy transfer through its 
adenosine triphosphate (ATP) and adenosine triphosphate interactions to its role in cell 
signaling, adenosine is a fundamental component of human biology (135). Adenosine has far 
reaching effects as an extracellular signaling molecule inducing vasodilation in most vascular 
beds, regulating activity in the sympathetic nervous system, having antithrombotic properties, 
and reducing blood pressure and heart rate. Such properties are some of the reasons why 
adenosine and its derivatives have therapeutic effects in most organ systems. 
Although adenosine has pleiotropic effects, much of our understanding of adenosine has 
come through observations of its action in the cardio- vascular system. Pioneering work by 
Drury and Szent-Gyorgy (136)in the past century pointed to the fact that an adenine 
compound caused disturbances in heart rate when injected intravenously. It is likely that this 
adenine compound was in fact adenosine. However, it was not until 60 years later that the use 
of this property of adenosine was used clinically to treat patients presenting with 
supraventricular tachycardia (137). 
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 One of the most common reasons for using adenosine in the cardiovascular system is 
for the production of vasodilation in the coronary microcirculation to produce 
hyperaemia(121). This property of adenosine to modify microcirculatory function has been 
used for diagnostic and therapeutic effects for many years and is widely adopted as the 
reference-standard method of diagnosing ischaemia invasively and noninvasively. 
1.6.1 Adenosine Pharmacology 
 
Figure 7: Adenosine Metabolism 
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 Adenosine is a naturally occurring endogenous purine nucleoside composed of an 
adenine molecule attached to a ribose sugar moiety(135)(ribofuranose) via a beta-N9-
glycosidic bond (6-amino-9-b-D-ribofuranosyl-9-H-purine) (Figure 7). It is the nucleoside 
base of both ATP and the signalling molecule cyclic adenosine monophosphate (cAMP). 
Adenosine is rapidly transported into vascular endothelial cells and erythrocytes where it is 
catabolized by adenosine deaminase to inosine (138). Dipyridamole, a commonly used 
vasoactive medication(139)exerts its effects through inhibition of adenosine deaminase. 
Adenosine is (re)phosphorylated by adenine kinase forming adenosine monophosphate, 
which is incorporated into the high-energy phosphate pool (140). Adenosine levels can rise 
rapidly in ischaemic tissue due to adenosine kinase inhibition (135). 
 In the intracellular space, adenosine can be synthesized de novo during purine 
biosynthesis or accumulate as a result of ATP breakdown. Intracellular adenosine 
concentrations increase when there is a mismatch between ATP synthesis and use as in 
ischaemia or hypoxia (141). Adenosine does not freely pass across the cell membrane and 
requires the use of nucleoside transporters to facilitate the process. Extracellular adenosine 
arises from active trans- port of intracellular stores or from breakdown of adenine nucleotides 
outside the cell (135). 
 Adenosine binds with 4 evolutionary well-conserved receptor subtypes that are 
ubiquitously expressed: A1, A2A, A2B, and A3 (142, 143). These receptors interact with G-
protein receptors. Activation of the Gi protein–bound A1 and A3 receptors reduces adenyl 
cyclase activity and decreases intracellular cAMP. Activation of the Gs protein–bound A2A 
and A2B receptors increases adenyl cyclase activity and cAMP levels. Adenosine has highest 
affinity for the A1 and A2a receptors. 
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Figure 8: Cardiovascular Effects of Adenosine 
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 Activation of A2A and A2B adenosine receptors produces potent vasodilation of most 
vascular beds including the coronary circulation, resulting in an increase in myocardial blood 
flow(144). However, A2A and A2B activation produces vasoconstriction in renal afferent 
arterioles, splenic arteries, hepatic veins(145). 
 A1 receptors generally have an inhibitory function on most tissues. Activation of 
cardiac A1 receptors has a myocardial depressant effect with negative chronotropic and 
dromotropic effects. A1 receptor activation also mediates inhibition of atrioventricular (AV) 
node conduction and prolongation of the refractory period via inhibition of cAMP-mediated 
calcium influx and enhances potassium conduction (146)(Figure 8). 
 A2A receptor activation also produces anti-inflammatory effects and acts as a major 
target of caffeine. A2B receptors are found on human mast cells and are thought to produce 
mast cell degranulation and bronchial constriction (147). A3 receptors are mainly 
peripherally located but are thought to play a role in mediating pre-conditioning. 
The use of adenosine for stress testing and induction of systemic (and coronary) hyperaemia 
is primarily related to the activation of A2A receptors and the resultant increase in 
myocardial blood flow. 
 
1.6.2 The Human Coronary Microcirculation and Adenosine 
 The coronary microcirculation is a key regulator of myocardial blood flow. Through 
alterations in microvascular resistance, the microcirculation controls the delivery of blood to 
the myocardium over a wide range of perfusion pressures and myocardial oxygen demand 
through the process of autoregulation (148). In humans, coronary blood flow can increase up 
to 5 times the basal flow to meet increased demand (149). Such an increase in blood flow is 
referred to as a hyperaemic response and in humans is commonly observed in response to 
ischemia and exercise (150, 151). Quantifying the hyperaemic response is a critical step in 
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understanding the coronary circulation and is applied in most physiological assessments of 
myocardial blood flow. Maximal hyperaemia can be achieved through a variety of methods. 
Exercise is commonly used, but the ability of some patients to exercise is limited. Vessel 
occlusion to produce ischaemia (152) (and thus reactive hyperaemia) is another method used 
in animal models but is not practical or safe to be used in humans not undergoing 
percutaneous coronary intervention (PCI) due to the inherent risk of vessel injury. 
Pharmacologically induced vasodilation is a commonly used method of achieving 
hyperaemia in the noninvasive and catheter laboratory settings. Available agents include 
adenosine, papaverine, sodium nitroprusside, adenosine 5-triphosphate, and dobutamine. 
Practically, the ideal hyperaemic agent should have a rapid onset of action, short duration of 
action, low cost with no significant side effects (153). For these reasons, adenosine, 
administered via either the intracoronary or IV route, has become the most widely used 
method of achieving hyperaemia in clinical practice. 
 
1.6.3 The Case for Adenosine 
 Despite extensive use of adenosine in animal experiments, there was some reluctance 
to use it for interrogating the human coronary circulation due to concerns over hypotension 
and heart block. However, work performed by Wilson et al. (113, 154) and others 
demonstrated that the use of adenosine was safe via both the intracoronary and IV routes and 
that it could reliably induce near-maximal coronary hyperaemia in most patients with little 
effect on systemic blood pressure. Although it was evident that adenosine produced coronary 
microcirculatory vasodilation, the exact mechanism of action remained incompletely 
understood.  
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1.6.3.1 Functional and anatomic aspects of hyperaemia.  
 The coronary circulation can be thought of in terms of a 3-compartment model, each 
of which contributes to the overall resistance to flow. The large epicardial vessels (0.5- to 
5.0-mm diameter) make up the first compartment (R1) and divide into progressively smaller 
branches known as the resistance microvessel (155). This second compartment (R2) consists 
of small coronary arteries/pre-arterioles (100- to 500-mm diameter) and arterioles (<100-mm 
diameter), which branch into intramyocardial capillaries to create the third compartment 
(R3). Ultimately, these drain into the coronary venous system (156). Under non-pathological 
resting conditions, the epicardial vessels offer little resistance to coronary flow, acting as 
passive conduits only. Approximately 60% of resistance is provided at the arteriolar level, 
25% at the capillary level, and the remaining 15% in the venular compartment. During 
hyperaemia, total resistance decreases across the coronary circulation by 70%. In the 
arteriolar and venular compartments, resistance decreases by 86% and 98%, respectively, 
resulting in minimal alteration of capillary hydrostatic pressure such that the capillaries offer 
the most resistance to coronary blood flow at hyperaemia. Thus, the capillaries provide the 
ceiling for the hyperaemic response. 
 Adenosine exerts its predominant vasodilatory effect on coronary microvessels <150 
um in diameter. Whether this is an endothelium-dependent process is unclear. An intact 
endothelium is not necessary for an adenosine response in vitro (157). However, work 
performed in humans in vivo has demonstrated that the vasodilator effect of adenosine in the 
forearm can be inhibited by a nitric oxide synthase inhibitor (158). 
 For the assessment of coronary stenoses, the effect of adenosine on the coronary 
microcirculation is to produce vasodilation to counteract the influence of autoregulation and 
ensure that resistance is minimal. In the assessment of fractional flow reserve (FFR), the use 
of adenosine in this manner allows for a near-linear relationship between pressure and flow to 
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be achieved. However, in the presence of severe stenoses, some have argued that there is a 
limited vasodilatory response to adenosine such that basal flow may equal hyperemic flow 
(159). However, others have shown in animal models that even in the presence of severe 
stenosis, there exists some retention of vasodilatory capacity of the microcirculation to 
adenosine (160). Regardless, it is of limited clinical importance because in most catheter 
laboratory settings, FFR is really only used for intermediate stenoses (40% to 70%). 
Adenosine is widely available worldwide and relatively in- expensive, producing stable and 
reproducible effects, hence, its increasing use in both diagnostic and interventional 
cardiology over the past 20 years. Furthermore, the availability of pre-made adenosine 
infusion bags that are stable at room temperature and suitable for short-term storage adds to 
its appeal (161). 
 
1.6.4 Methods of Administration 
 The most common method of administration is the IV route frequently used for the 
termination of AV node–dependent tachycardias and for the attainment of hyperaemia in 
noninvasive stress testing. In the context of achieving maximal hyperaemia in the catheter 
laboratory, both the intracoronary (IC) and intravenous (IV) routes are used. 
IC adenosine. IC administration of adenosine is simple and quick. Its peak effect occurs <10 
seconds after administration, and it has a duration of 20 seconds (162). For this reason, the IC 
route is not used in cases in which a longer period of steady-state hyperaemia is required such 
as when performing an FFR pullback or more complex assessments of microvascular 
function (122). Earlier studies had suggested a maximal IC dose of adenosine of 16 µg for the 
left coronary artery and 12 µg for the right coronary artery (163) with increasing doses of 2 
orders of magnitude to ensure maximal vasodilation(164). These protocols were challenged 
by animal data suggesting that higher doses of adenosine may be needed to achieve maximal 
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hyperaemia(165, 166)and clinical studies that suggested that standard adenosine dosing failed 
to achieve maximal hyperaemia compared with papaverine and IV adenosine(163, 166). 
Current recommendations for IC adenosine dosing are 100 µg in the right coronary artery and 
150 - 200 µg in the left coronary artery, increasing the doses incrementally by 30 µg to a 
maximum of 200 µg(114). 
 Whether the IC route is as efficacious at producing maximal hyperaemia compared 
with the IV route is a controversial area that has been addressed in several clinical studies. 
The lower efficacy of IC adenosine compared with IV adenosine was highlighted in a study 
by Casella et al (167). They compared the effects of IC versus IV adenosine in 50 stable 
patients; 60 mg of adenosine was used with increasing doses up to 150 mg. At the lower, 
“standard” doses, 10% of vessels with an initial FFR value >0.75 had a subsequent value less 
than this cutoff point with higher IC doses or IV administration. 
 Leone et al. (168) also examined the dose-response of IC adenosine compared with IV 
adenosine. They demonstrated that only the higher doses of IC adenosine (600 µg) produced 
hyperaemic efficacy similar to that of IV adenosine and that standard dosing (60 to 300 µg) 
with IC adenosine was not sufficient. Importantly, lower doses of adenosine were associated 
with inferior diagnostic accuracy compared with IV adenosine. However, at higher doses of 
IC adenosine, transient AV block developed in nearly 25% of patients. 
De Luca et al. (169) demonstrated similar results in 46 patients with intermediate coronary 
stenoses undergoing diagnostic FFR evaluation. They showed that FFR values progressively 
decreased with increasing doses of IC adenosine up to 720 µg. With this, the number of 
patients identified with FFR values <0.75 increased. Of interest, and in contradiction to 
Leone et al.(168), increasing the adenosine dose did not increase the incidence of side effects, 
which was very low. 
 Thus, it appears from studies to date that the IV route of administration has a greater 
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efficacy for achieving maximal hyperaemia compared with the conventional IC dosing with 
the added advantage that FFR pullback and more complex physiological assessments can be 
made. Furthermore, standard adenosine dosing may not be sufficient to produce a hyperaemic 
response, and higher doses may be required.  
 
1.6.4.1 Central versus peripheral route of administration 
 Central venous infusion of adenosine through the femoral vein has been the gold-
standard method of hyperaemia induction, particularly in the assessment of FFR (116). 
However, it re- quires femoral vein access and is inconvenient during transradial 
catheterization, which is an increasingly preferred method of arterial access. In a study by 
Seo et al.(170), involving 71 patients, no difference was found in the hyperaemic efficiency 
of IV administration of adenosine via the forearm compared with the femoral vein. The 
number of functionally significant stenoses (FFR <0.75) was also not different between the 2 
routes, and there was no difference between the hyperaemic mean transit time and index of 
microcirculatory resistance, suggesting that minimal resistance and thus maximal hyperaemic 
response was achieved with both routes of administration. Consistent with these findings, De 
Bruyne et al.(171) showed that the hyperaemic efficacy of adenosine was similar in both 
central and peripheral venous infusions, and increasing the dose to >140 mg/kg/min did not 
improve the vasodilatory action of adenosine. In both of these studies, the time to maximal 
hyperemia was longer with forearm vein infusion of adenosine than with the femoral vein 
infusion, with a mean difference of 15 seconds, suggesting that when a peripheral venous 
route is selected, adenosine should be infused for a greater length of time. 
In contrast to these findings, Lindstaedt et al.(172)compared the hyperaemic efficacy 
of adenosine infusion between the femoral vein and the antecubital vein in 50 patients and 
reported that a 140-mg/kg/min infusion of adenosine via the antecubital vein was slightly less 
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effective than the femoral vein infusion with a higher frequency of lesion severity 
underestimation. However, the mean FFR difference between the 2 routes was only 0.013. Of 
interest, the group administered adenosine at higher doses (170 mg/kg/min) peripherally and 
found no difference in hyperaemic efficacy compared with the femoral route. For this reason, 
they recommended administering a higher dose of adenosine via the antecubital vein to 
achieve hyperaemic efficacy similar to that via the femoral route. 
 The concept of increasing the dose of adenosine to improve hyperaemic efficacy 
appears intuitive. However, unlike the findings of Lindstaedt et al.(172)described previously, 
other groups have not found such a relationship. In 1 study, the addition of an additional IC 
bolus of adenosine did not result in any change in FFR compared with standard adenosine 
infusion, although it did increase the incidence of transient AV block (170). These findings 
were in agreement with other investigators who also showed no evidence of any change in 
FFR with doses of up to 240 mg/kg/min (171). We recommend the use of IV adenosine at a 
dose of 140 mg/kg/min and either the peripheral (via a large-caliber vein) or central route 
depending on operator preference. If using the peripheral route, it may take longer for a 
hyperaemic response to develop, and thus a longer infusion time may be required. 
Furthermore, if the FFR is borderline, higher doses of adenosine may be used, but we do not 
advocate this for all patients. 
 During the initial phase of adenosine infusion, there can be differential changes to 
proximal and distal coronary pressure such that the FFR value may fluctuate during this 
period. This is a critical point because, if FFR values are taken without the attainment of 
steady-state hyperaemia, the value may be inaccurate and lead to incorrect assumptions 
regarding the hemodynamic significance of a lesion.  
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1.6.5 Adenosine in the setting of myocardial infarction and reperfusion 
 There is a strong body of experimental evidence to suggest that adenosine can protect 
the myocardium from both ischaemic (173-175) and reperfusion injury via its potent 
vasodilatory effects and possibly by anti-inflammatory and antiplatelet properties (175, 176). 
However, clinical studies with adenosine in humans have yielded mixed results. IV adenosine 
during primary PCI was tested in 2 large randomized trials (177, 178) (AMISTAD I and II, 
including 218 and 2,118 patients, respectively). Both of these trials demonstrated that 
adenosine reduced infarct size, but did not reduce the primary clinical endpoint, with in-
hospital and 6-month clinical outcome being similar to those in the placebo group. However, 
in a post-hoc subgroup analysis, a benefit was seen in those receiving reperfusion therapy 
within 3 hours (179). These data are consistent with the results of a small trial of IC infusion 
of adenosine in patients with acute ST-segment elevation myocardial infarction (STEMI) 
undergoing primary angioplasty, which showed favourable effects on the incidence of no-
reflow, left ventricular ejection fraction, and clinical course(180).  
 Improved myocardial reperfusion, as assessed by ST-segment elevation resolution 
after primary PCI, was observed in other smaller studies(181, 182). Conversely, a 
randomized, placebo-controlled trial of 112 patients found no evidence that selective high-
dose IC administration of adenosine distal to the occlusion site in the culprit vessel in STEMI 
patients resulted in any incremental myocardial salvage or reduction in microvascular 
obstruction (183). In addition, a single-blind study of 448 STEMI patients randomized to 2 
bolus injections of IC adenosine (2x120 mg) or matching placebo after manual thrombus 
aspiration failed to show any difference in the primary endpoint of residual ST-segment 
elevation after primary PCI(184). Recently, these data were again tested in a randomized 
study comparing adenosine, sodium nitroprusside, and saline solution. The use of 120 mg of 
adenosine as a bolus followed by 2 mg administered in 33-ml of saline solution over 2 min as 
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a slow bolus was associated with improved ST-segment elevation resolution on 
electrocardiography but not angiographic microvascular obstruction or major adverse cardiac 
events(185). Despite these mixed findings, IC adenosine is recommended by both the 
European Society of Cardiology (89) and the American Heart Association (186)guidelines for 
the treatment of no-reflow. 
 
Pre- and post-conditioning 
 Transient episodes of ischemia render the myocardium more resistant to subsequent 
ischemia, a phenomenon known as ischaemic pre-conditioning (187). This effect is thought to 
be partly mediated by endogenous adenosine. The pre-conditioned state is triggered through 
activation of A1 and A3 receptors by adenosine before the onset of ischaemia (188, 189). 
Pre-conditioning has been shown to improve outcomes in patients undergoing coronary artery 
bypass graft and elective PCI (190). In a small study of 30 patients undergoing PCI, Leesar et 
al.(191) demonstrated that a 10-min IV adenosine infusion (dose of 2 mg/min) administered 
before the PCI pre-conditioned the myocardium(191). However, among stable elective 
patients undergoing PCI, the randomized administration of 120 mg and 180 mg of adenosine 
into the right and left coronary arteries, respectively, was not associated with a reduction of 
periprocedural myocardial infarction, Thrombolysis In Myocardial Infarction frame count, or 
in-hospital death(192). 
 For obvious reasons, ischemic pre-conditioning is limited to patients who are due to 
have planned ischemia as in the case of coronary artery bypass graft and PCI. 
Post-conditioning refers to a time-sensitive cardioprotective strategy induced by brief 
repetitive interruptions in blood flow applied immediately at the onset of reperfusion(193). 
Evidence suggests that, like pre-conditioning, post- conditioning involves endogenous 
activation of A2a and A3 receptor subtypes. Several small studies on acute STEMI patient 
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groups have shown a cardioprotective effect of post- conditioning (194). Hahn et al. (195), 
using a protocol that consisted of 4 cycles of 1 min of balloon inflation followed by 1 min of 
balloon deflation within 1 min of reflow after coronary stent deployment, demonstrated that 
patients in the post-conditioning group were found to have 36% smaller infarctions as 
determined by serum creatine kinase release during the first 72 h of reperfusion and lower 
peak creatine kinase. However, the recent POST (Ischemic Post- conditioning During 
Primary Percutaneous Coronary Inter- vention: the Effects of Post- Conditioning on 
Myocardial Reperfusion in Patients With ST-Segment Elevation Myo- cardial Infarction) trial 
in 700 patients undergoing primary PCI demonstrated that ischemic post-conditioning with 4 
cycles of 1 min of balloon inflation after restoration of coronary blood flow was not 
associated with improved myocardial reperfusion. 
Adenosine levels can rise rapidly in ischemic tissue due to adenosine kinase 
inhibition, and this pathway is involved in mediating ischemic pre-conditioning. To date, 
cyclosporine is the most promising pharmacological post-conditioning mimetic drug(196). 
Cyclosporine is thought to derive its cardioprotective effects from inhibiting formation of the 
mitochondrial permeability transition pore, a key component of lethal reperfusion injury. The 
mitochondrial permeability transition pore appears to form in the early stages of reperfusion 
in response to the calcium overload and reactive oxygen species generation that develops 
with reperfusion.  
 
1.6.6 Paroxysmal supraventricular tachycardia.  
 Therapeutically, IV adenosine in a bolus dose of 6 to 12 mg (or higher) slows AV 
nodal conduction and by this mechanism interrupts re-entrant pathways involving the AV 
node and restores sinus rhythm in most patients with supraventricular tachycardia(197). 
Included in this group are typical AV nodal re-entrant tachycardia, AV reciprocating 
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tachycardia with a concealed bypass tract, and AV reciprocating tachycardia in Wolff-
Parkinson-White syndrome. Diagnostically, by causing transient AV block, adenosine may 
unmask atrial flutter/atrial fibrillation (AF) and permit the correct diagnosis of broad complex 
tachycardias(197). Adenosine can also terminate some ventricular tachycardias, particularly 
those mediated by triggered activity(198). 
 
1.6.7 Safety concerns and side effects of adenosine.  
  As the half- life of adenosine is brief, both its desired and unwanted effects are 
generally short lived. Side effects are common with adenosine and reflect the ubiquitous 
nature of adenosine receptor expression. In general, they are more prevalent with IV than 
with IC adenosine. In the Adenoscan study, a large multicenter registry with >9,000 patients, 
examining the safety and tolerability of IV adenosine infusion for stress imaging studies, side 
effects due to adenosine were reported in 81% of patients(198). Standard IV dosing via a 
peripheral venous catheter was used. Commonly reported side effects included flushing 
(36.5%), dyspnoea (35.2%), chest pain (34.6%), gastrointestinal discomfort (14%), and 
headache (11%). AV block and arrhythmias occurred in 7.6% and 3.3%, respectively. 
Bronchospasm occurred in 0.1% of the study group. Importantly, there were no deaths in the 
cohort. Side effects were more common in female patients, younger patients, and those with a 
higher body mass index. Age older than 70 years was the only independent predictor of AV 
block after adenosine administration(198). Of note, side effects reported in this study are far 
higher than those reported in other studies and reflect the fact that the adenosine infusion was 
continued for 6 minutes, which is longer than is required for invasive physiology protocols. 
 Furthermore, in a study of 574 patients undergoing cardiac stress magnetic resonance 
imaging, the incidence of side effects was much lower(199). Chest pain and dyspnoea were 
reported in only 14% of the patient group, with nausea and vomiting in 5%(199). Adenosine 
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was infused for only 3 min at 140 mg/kg/min, which could explain the disparate results com- 
pared with the previously cited study. The incidence of patient-reported side effects with a 
novel selective A2 agonist was still 73%, with only a marginal improvement in symptom 
score when directly compared with adenosine (see later) (200). 
 In patients with recent unstable coronary disease, non- culprit lesions may be 
particularly difficult to assess. On the one hand, information from previous stress testing may 
be lacking, and thus tools such as FFR could be particularly useful; on the other hand, altered 
hemodynamics during adenosine or side effects may be less well tolerated. How- ever, 
despite such concerns, the use of adenosine, specifically for patients undergoing 
comprehensive invasive coronary physiological assessment appears safe(119, 126) 
In November 2013 the United States (US) Food and Drug Administration (FDA) issued a 
safety announcement on the risk of myocardial infarction (MI) and death in patients receiving 
Adenosine for stress testing. This announcement followed from reports in the FDA Adverse 
Event Reporting System (FAERS) and medical literature of serious adverse events (SAE) 
from 1995 to 2013, including 6 cases of MI and 27 cases of death following adenosine 
administration (typically within 6 hours).  Therefore despite a large body of evidence in the 
established literature demonstrating clear safety of adenosine there remain concerns with its 
ongoing safety both in the office base and amongst higher acuity patients. 
 
1.6.7.1 Arrhythmias.  
 Adenosine has proarrhythmic potential. AF is well recognized(201)and in some 
reports is the most common arrhythmia (2.7% after IV administration)(201). Adenosine is 
thought to provoke AF through shortening of the atrial action potential duration. Its incidence 
varies depending on the population being studied. For example, in patients with known 
conductive system disease undergoing electrophysiological assessment, the incidence of AF 
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was 12%. However, it is a rare occurrence in the catheter laboratory and in noninvasive 
assessments (202). In a retrospective dataset of 1,948 patients undergoing adenosine stress 
myocardial perfusion studies, the incidence of AF was 0.41% (203). AF was usually preceded 
by either increasing atrial ectopy or significant bradycardia. When AF occurs, it is usually 
well tolerated unless associated with an accessory pathway, where it may produce unstable 
arrhythmias requiring direct current cardioversion (204). 
Ventricular arrhythmias have also been reported with adenosine. This is usually as a 
consequence of adenosine- induced bradycardia and is more likely to occur in patients with a 
propensity for bradycardia-related arrhythmias such as those with a prolonged QTc interval 
(205). 
 The main contraindications to the use of adenosine infusion are documented allergy to 
adenosine or severe asthma. Inhaled adenosine monophosphate and ATP are known to cause 
bronchospasm in asthmatics, most likely a result of mast-cell mediator release(206). Despite 
case reports of bronchospasm developing in asthmatic patients after adenosine(207), these 
instances are very rare, and such an entity requires distinguishing from the more frequently 
encountered occurrence of benign dyspnoea. Adenosine causes a sensation of dyspnoea in 
healthy patients but has not been shown to objectively produce bronchospasm (208). This 
dyspnogenic property has been proposed to be a result of direct stimulation of pulmonary C 
fibers by adenosine (208). In patients with mild to moderate persistent asthma, the IV 
infusion of adenosine did not cause any significant change in lung function compared with 
placebo and healthy control groups. However, asthmatic patients had a greater intensity of 
dyspnoea in response to adenosine. Thus, the use of IV adenosine in well-controlled, mild to 
moderate asthma appears to be safe. 
 The presence of chronic obstructive pulmonary disease has also been suggested as a 
contraindication to adenosine use, but we and others believe that the use of IV adenosine for 
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mild to moderate airway disease, is safe (121). If chronic obstructive pulmonary disease 
severity is a major concern, then IC adenosine or an alternate agent can be used. When using 
the IC route, bradycardia/transient AV block may be observed, particularly at higher doses 
and when administering into the right coronary artery (114). In most reported cohorts, the 
incidence varies from 0%(163)to 16%(168) with standard dosing. 
 
1.6.7.2 Adenosine Interactions 
 Experimental data have confirmed that methylxanthines can cause an attenuated 
hyperaemic response through blockade of arteriolar A2a receptors(209). Caffeine (1,3,7 
trimethylxanthine) is thought to competitively inhibit the adenosine receptor and thus may 
also attenuate the hyperaemic response(210). This has been highlighted in animal studies in 
which caffeine led to a blunted hyperaemic vasodilator response (211). One study suggested 
that increasing the adenosine dose to 210 mg/kg/min abolished any caffeine effect (212). 
Some earlier studies failed to show this relationship between caffeine and the hyperaemic 
response, but such studies tended to have lower caffeine concentrations (213). Caffeine 
appears to have a dose-dependent affinity for the adenosine receptor, and this may explain 
these discordant findings. Theophylline, a xanthine derivative commonly prescribed for 
reactive airway disease also antagonizes adenosine and may need to be withheld before any 
imaging/invasive assessment. We advocate the avoidance of caffeine for at least 12 hours in 
patients undergoing stress perfusion imaging or invasive coronary flow assessment if 
adenosine is the hyperaemic agent to be used. Furthermore, a full drug history should be 
taken to make sure that there are no potential interactions that could affect the hyperaemic 
response. Aminophylline and theophylline, both nonselective adenosine antagonists, may be 
used in situations where the effect of adenosine requires reversal. However, due to the short 
half-life of adenosine, this is rarely required in a catheter laboratory setting but is often used 
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in myocardial perfusion imaging where the longer acting dypyridamole is used. 
 
1.6.8 Novel Agents for Achieving Hyperaemia 
 In addition to the agents that we have already mentioned, there are new agents 
available to achieve hyperaemia. Regadenoson is a selective adenosine A2a receptor agonist 
and in theory should produce hyperaemic effects similar to those of adenosine without the 
additional side effects often seen with A1, A2b, and A3 receptor activation(214). It is 
administered as an IV bolus and, because of its longer half-life compared with adenosine (2 
to 3 min), has a longer duration of action. Importantly, there is similar efficacy in terms of the 
time taken to achieve hyperaemia compared with adenosine(214). Regadenoson produces 
blood pressure–lowering effects similar to adenosine but causes a significantly higher heart 
rate response. The adoption of regadenoson for perfusion imaging followed 2 large 
randomized studies showing that it produced diagnostic information similar to that of a 
standard adenosine infusion (200, 215). Furthermore, although side effects were common, 
they appeared to be fewer than those reported in patients receiving adenosine. Because of its 
A2a receptor selectivity, regadenoson appears to be safe in patients with mild asthma (216). 
However, as yet there is a lack of data to support its use in more severe forms of airway 
obstruction. 
 Arumugham et al. (217)compared regadenoson with adenosine for the assessment of 
FFR in 20 patients with intermediate coronary stenoses and showed an excellent correlation 
between the 2 drugs (r =0.93, p < 0.0001). Furthermore, the minimal value of FFR appeared 
to be achieved earlier with regadenoson compared with adenosine. More recently, Prasad et 
al. (218)demonstrated that in 57 patients undergoing clinically indicated FFR assessment in 
the catheter laboratory, regadenoson was as efficacious as adenosine for inducing 
hyperaemia, with the FFR in both groups being 0.79. There were fewer (but not statistically 
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significantly fewer) side effects with regadenoson, and the nadir to hyperaemia was shorter in 
the regadenoson group. 
 Nicorandil, a drug with nitrate-like effects through its increase in cyclic guanosine 
monophosphate and also Kβ ATP channel modulation, was also compared with adenosine in 
210 patients with an intermediate coronary stenosis(219). Hyperaemic efficacy was compared 
with IC and IV adenosine versus IC nicorandil. The investigators found that the hyperaemic 
efficacy of IC nicorandil (2 mg) was non-inferior to that of IV adenosine. There was also no 
significant difference between the index of microvascular resistance with IV adenosine 
compared with IC nicorandil, suggesting that similar levels of steady-state minimal resistance 
were obtained with both drugs. Moreover, there were no side effects/adverse reactions with 
nicorandil, whereas with adenosine, AV block occurred in 12 patients with IC administration 
and 4 patients with the IV administration (219). 
 
Summary 
Adenosine has a critical role in the noninvasive and invasive assessment of 
myocardial perfusion as well as having therapeutic efficacy in patients with no-reflow. In the 
electro- physiological setting, it has an important role in both the diagnosis and treatment of a 
range of arrhythmias. Although side effects are frequently reported, they are seldom 
troublesome and due to the short half-life of the drug are transient. The recently published 
FDA concern for stress testing using adenosine is unexpected given the wealth of evidence in 
support of safety. However, more data on adenosine safety is required. Newer agents show 
promise and may attenuate concerns regarding adenosine use but require further data before 
they replace adenosine as a first-line agent. 
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Aims of Thesis	  
1. To assess the clinical utility and difference in health outcomes using fractional flow 
reserve in patients with NSTEMI compared with angiographic guided management. 
2. To assess the relationship between the visual angiographic severity of coronary 
artery stenosis and haemodynamic severity as defined by FFR amongst patients 
with NSTEMI 
3. To assess the accuracy of fractional flow reserve for predicting perfusion defects on 
stress perfusion CMR amongst patients with recent NSTEMI 
4. To compare the utility of differing oedema imaging methods in patients with 
NSTEMI 
5. To assess the safety of adenosine and coronary pressure wires in patients with 
recent acute coronary syndromes. 
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Due to the heterogeneity of studies involved in this thesis, the main methods for each study 
are presented in the individual results chapters.  Below is a broad overview of the main 
methods for the thesis. 
 
2.1 FAMOUS-NSTEMI Study 
2.1.2 Setting and Design.  
 A prospective multicenter parallel-group 1:1 randomized controlled superiority trial 
was conducted across 6 UK centers including 3 academic cardiothoracic centers and 3 
nonacademic regional hospitals: West of Scotland Heart and Lung Centre, Golden Jubilee 
National Hospital, Glasgow, UK; University Hospital Southampton, Southampton, UK; 
Hairmyres Hospital, East Kilbride, UK; Royal Blackburn Hospital, Blackburn, UK; Freeman 
Hospital, Newcastle, UK; City Hospitals Sunderland NHS Foundation Trust, Sunderland, 
UK. The first patient was randomized on October 25, 2011; and the trial completed follow-up 
in November 2013.  An overview of the key trial timelines if provided in figure 9. 
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Figure 9: Gantt Chart for FAMOUS NSTEMI study 
2.1.3 Consent 
 Patients were consented on the ward either the day before or on the morning of their 
coronary angiogram.  Patients were provided with an information sheet explaining the nature 
of the study and the potential risks involved.  They were given sufficient time to read the 
information sheet before myself or one of the research nurses went back to answer any 
questions the patient may have regarding the study.  If the patient was happy then consent 
was taken, if not then the patient was thanked for considering and the screening data 
recorded.  
2.1.4 Study population.  
Consecutive NSTEMI patients with a clinical diagnosis of confirmed or suspected 
type 1 MI were screened before coronary angiography. A NSTEMI was defined according to 
the occurrence of acute ischemic symptoms (e.g., chest discomfort) and elevated cardiac 
biomarkers but without ST-segment elevation on the electrocardiogram. Type 1 represents 
spontaneous MI due to a reduction in myocardial blood flow secondary to atherosclerotic 
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plaque rupture and/or coronary thrombosis in one or more arteries. To be eligible for the 
study patients had to have a clinical diagnosis of recent NSTEMI and at least one risk factor 
for coronary artery disease (e.g. diabetes mellitus); urgent invasive management planned 
within 72 hours of the index episode of myocardial ischaemia or a history of recurrent 
ischaemic symptoms within 5 days. The main exclusion criteria were the presence of 
ischaemic symptoms that were not controlled by medical therapy, haemodynamic instability, 
MI with persistent ST elevation, intolerance to anti-platelet drugs, ineligible for coronary 
revascularisation, a treatment plan for non-coronary heart surgery (e.g. valve surgery), a 
history of prior CABG, angiographic evidence of severe (e.g. diffuse calcification) or mild (< 
30% severity) coronary disease, a life expectancy < 1 year and an inability to give informed 
consent (Table1).  
Patients who gave informed consent but who were not randomized were included in a 
registry. The reasons for exclusion from the trial after consent but before randomization (e.g., 
coronary angiogram findings) and inclusion in the registry were prospectively recorded. We 
aimed to maximize participant retention and follow-up through telephone contact and use of 
national electronic databases for long-term follow-up. 
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Table 1: Inclusion and Exclusion Criteria for FAMOUS NSTEMI 
 
 
 Once the coronary angiogram has been obtained, the cardiologist assessed whether or 
not the patient was eligible to be randomized based on angiographic criteria (Table 1).  
The main angiographic inclusion criterion is the presence of one or more non-critical 
coronary stenoses ≥30% severity which are associated with (1) normal coronary blood flow 
(i.e. TIMI grade III), (2) amenable to revascularization by PCI or CABG and (3) FFR 
measurement is feasible and may have diagnostic value. A minimum stenosis severity of 30% 
is adopted for FFR measurement in our study because visual assessment of the angiogram 
may underestimate stenosis severity. Inclusion of a more severe stenosis (e.g. >90% severity) 
is permissible provided the cardiologist believes FFR has the potential to influence the 
treatment decision based on coronary and patient characteristics. We included patients with 
left main stem disease, however, if visually it was thought that disease was critical (i.e. 
>80%), then these patients were excluded. The pressure wire (Certus, St Jude Medical, 
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Uppsala) will be used in all patients to provide an FFR value across all coronary narrowings 
≥30% severity as appropriate. Our aim is to maximize inclusion of eligible patients to 
minimize selection bias. 
 Once the coronary angiogram was obtained, the cardiologist established an intended 
treatment plan based on all of the available clinical information and the angiographic 
findings. The cardiologist's interpretation of the diagnostic angiogram and the treatment plan 
was then recorded at that time in the catheter laboratory. Therefore, the initial treatment 
decision was established before randomization or treatment group assignment was known and 
before the pressure wire was passed into the coronary arteries. Therefore, no FFR 
measurements were acquired before randomization. 
 
2.1.5 FFR Measurement 
 FFR was measured according to best practice as described in contemporary 
guidelines(114). The cardiologist passed the pressure wire across the target coronary stenosis 
and itwas calibrated initially to ensure standardized measurements. When the radio-opaque 
marker was positioned at the distal end of the guide catheter the pressure wire recording was 
equalized with the aortic pressure. The wire was then passed into the coronary artery of 
interest and advanced at least 6 cm distal to the coronary stenosis using standard techniques. 
Once the marker was appropriately positioned and after an initial 2 minute rest period, an 
intravenous infusion of adenosine (140 µ/kg/min – 210 µ/kg/min) via a central vein or large 
antecubital vein was started to establish coronary hyperaemia. Typical changes in blood 
pressure (i.e. fall in systolic pressure >10%), heart rate (i.e. rise in heart rate >20%) and 
symptoms will be recorded prospectively to confirm a hemodynamic response to adenosine 
during a period of at least 2 minutes. When there is an inadequate response with the standard 
dose of adenosine (140 µ/kg/min) then the dose was increased up to 210 mcg/kg/min in order 
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to best ensure maximal hyperaemia. If intravenous adenosine was not tolerated then 
intracoronary adenosine could be administered. 
 All patients received an initial intravenous bolus of 5000 units of unfractionated 
heparin with additional bolus as required to maintain an activated clotting time of 250 
seconds. All patients had been pre-treated with aspirin and clopidogrel. A 6F coronary 
guiding catheter was used routinely and 200 µg of intracoronary nitroglycerin was 
administered during left and right coronary angiography.  
Myocardial FFR was taken as the ratio of distal coronary to proximal aortic pressure during 
steady state hyperaemia. An FFR≤ 0.8 was used as a measure of stenosis significance. In 
order to facilitate the inclusion of patients with complex disease, an FFR of 0.5 was assigned 
without requirement to pass the pressure wire in occluded/sub-totally occluded arteries, left 
main lesions >80% and critical severe epicardial coronary lesions (e.g. >95% severity). This 
approach is intended to facilitate and maximise the inclusion of all eligible patients(220).  
According to eligibility criteria in the protocol, FFR was measured in all coronary arteries 
with one or more stenoses ≥30% of the reference vessel diameter based on visual assessment 
of the angiogram, with normal coronary blood flow (TIMI grade III) and in the opinion of the 
attending cardiologist FFR measurement will be feasible and may have diagnostic value.  
 
2.1.6 Randomisation. 
 Once the coronary angiographic findings and treatment plan were recorded and if, in 
the opinion of the treating cardiologist, the patient remained eligible to continue in the study, 
randomization was then performed. Randomization took place immediately in the catheter 
laboratory using a web-based computer randomisation tool provided by the independent 
Clinical Trials Unit. The randomization sequence was created using the method of 
randomized permuted blocks. 
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Patients who gave informed consent but who are not randomised were included in a 
registry. The reasons for exclusion from the trial after consent but before randomisation (e.g. 
coronary angiogram findings) and inclusion in the registry were prospectively recorded. Age 
and sex were recorded in all of the registry participants, and other clinical data were collected 
wherever possible. 
 
2.1.7 FFR-guided group 
 Fractional flow reserve was measured by the cardiologist immediately after 
randomization, and the FFR result was used to guide treatment decisions based on a threshold 
of 0.80. An FFR ≤.80 resulted in a treatment decision for revascularization by PCI or CABG 
combined with optimal medical therapy; and an FFR ≥0.80 resulted in treatment with optimal 
medical therapy alone, in line with contemporary guidelines for optimal secondary prevention 
drug therapies, cardiac rehabilitation, and risk factor modification. Any changes in treatment 
following FFR disclosure compared with the initial treatment plan prior to FFR disclosure 
were recorded. 
 
2.1.8 Angiography-Guided Group and Blinding 
 In those patients randomized to the angiographic-guided arm, FFR was still measured 
in all vessels with at least a 30% stenosis. However, the treating cardiologist was not privy to 
the FFR results. The RadiAnalyzer Xpress (St Jude Medical) was turned out of view by the 
research team such that it was impossible for the clinical team to see the pressure wire 
recording. The pressure wire recording was not displayed on any other monitor in the catheter 
laboratory, and the clinicians and patients did not know the results. When the coronary 
pressure display was out of view of the clinical team, the cardiologist measured FFR as 
described above, guided by the research staff who monitored and recorded the pressure wire 
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data. Therefore, the patient and the clinical team responsible for the patient, including the 
interventional cardiologists and nurses, were blinded to the pressure wire recording. Quality 
control checks, including assessments of equalized pressure recordings and verification of 
symptoms and hemodynamic changes with intravenous adenosine, were conducted in the 
usual way, with the guidance of the unblinded research team. These steps were followed for 
all FFR measurements. 
 
2.1.9 Standard care of NSTEMI patients in the National Health Service 
 The participating hospitals adhere to current guidelines for optimal medical therapy 
and optimal revascularisation (23). Oral dual anti-platelet therapy and other secondary 
prevention therapies were recommended in all participants once the diagnosis of NSTEMI 
had been confirmed. Intravenous nitrate therapy was recommended for patients whose 
symptoms were not initially controlled by oral anti-ischaemic drug therapy. 
In this study, a diseased artery was defined as an epicardial artery with one or more lesions ≥ 
30% of the reference vessel diameter and amenable to PCI or CABG. An angiographically 
significant artery was defined as an artery with one or more lesions ≥ 50% of the reference 
vessel diameter. A left main stenosis of ≥50% and an epicardial coronary stenosis >70% are 
usually taken to be obstructive lesions for which revascularization should be considered(89). 
Patients who were considered candidates for CABG were discussed at the Multidisciplinary 
Heart Team meeting in each centre.  In the angiography-guided group, the FFR data were 
not disclosed at this meeting. If staged PCI was planned then the second procedure was 
recommended to take place during the index hospitalisation. 
The radial artery is the standard route for invasive angiography and PCI in our 
hospitals and the radial artery was used according to operator and patient preference. Arterial 
blood pressure and the ECG were monitored in the Cardiac Catheter Laboratory and 
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cardiology ward. Drug eluting or bare metal stents were used according to operator 
judgement and in line with clinical guidelines. After the index invasive procedure was 
completed the patients returned to the cardiology ward and were treated with optimal 
secondary prevention measures. 
 
2.1.10 Trial Management 
 The initial treatment decision was prospectively recorded before randomisation and 
any change to this decision after randomization, such as after FFR disclosure in the FFR-
guided group was recorded prospectively in the catheter laboratory during the procedure. At 
this time, the protocol also required prospective confirmation that in the 'angiography-guided 
control group', the clinical team were blinded to the pressure wire recordings and FFR values 
throughout. The investigator was also required to confirm that the protocol was preserved. 
Adherence to the blinding protocol was monitored with site visits performed by the trial 
coordinator (Dr Jamie Layland). 
 The trial was conducted in line with Guidelines for Good Clinical Practice (GCP) in 
Clinical Trials. Trial management included a Trial Management Group (TMG), Trial Steering 
Committee (TSC), Clinical Event Committee (CEC), and Data and Safety Monitoring Board 
(DSMB). Day to day study activity was coordinated by the TMG, which were responsible to 
the TSC. The TSC were responsible for overall trial supervision. In order to adjudicate and 
validate adverse clinical events, source clinical data were reviewed by an independent CEC 
comprised of at least 3 cardiologists. The DSMB followed an agreed charter prepared 
according to the DAMOCLES guidelines (221). The DSMB had access to unblinded data 
including the FFR results. The DSMB included one interventional and one non-interventional 
cardiologist and a biostatistician (Chair), not affiliated to any of the institutions involved in 
the study and therefore independent of the study team. Progression during the study required 
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approval from the DSMB after the 35th randomized patient. 
 
2.1.11 Primary outcome 
 The between-group difference in the proportion of patients allocated to medical 
therapy only instead of revascularization at baseline. The treatment decision was made by the 
clinical team in the cardiac catheter laboratory during the index procedure or shortly 
afterward during the index hospitalisation including when a multidisciplinary heart team 
review was indicated. 
 
2.1.12 Secondary outcomes 
. 1) The safety and feasibility of routine FFR measurement in NSTEMI; 
. 2) The percentage rate of discordance between an FFR ≤ or ≥0.80 and coronary stenosis 
severity; 
. 3) Major adverse cardiac events are defined as cardiac death or hospitalization for MI or 
heart failure after randomization. Therefore, emphasis has been placed on “spontaneous” 
“hard” outcomes. Because the decision for revascularisation may be susceptible to bias, 
this event is not included in the primary outcome. Information on hospitalisations for 
other adverse events (i.e., unstable angina, renal failure, stroke, PCI, CABG) was 
prospectively recorded.  
. 4) Health care costs (including revascularisation procedures, stents, bed days) were 
prospectively recorded for the index and any subsequent hospitalizations.  
. 5) Quality of life (EuroQoL, EQ-5D).  All patients were asked to complete an EQ-5D 
form at Baseline and at follow up (minimum 6 months). 
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2.1.13 Health status and frailty 
 Health-related quality of life (HRQoL; EuroQol 5-Dimensions 3-Level (EQ-5D-
3L)was assessed at baseline and again at 6 and 12 months. The participants were interviewed 
by the research nurses and provided responses for the EQ-5D-3L questionnaire and EQ visual 
analog scale (EQ-VAS). The EQ-5D-3L questionnaire comprises 5 dimensions: mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 
levels: no problems, some problems, extreme problems. The EQ-VAS records the 
respondent’s self-rated health on a vertical, visual analogue scale where the outcomes are 
labelled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This information 
can be used as a quantitative measure of health outcome as judged by the individual 
respondents. 
 Frailty was assessed using the Canadian Study of Health and Aging (CSHA) Clinical 
Frailty Scale(222). 
1 Very fit – robust, active, energetic, well motivated and fit; these people commonly exercise 
regularly and are in the most fit group for their age 
2 Well – without active disease, but less fit than people in category 1.  
3 Well, with treated co-morbid disease – disease symptoms are well controlled compared 
with those in category 4. 
4 Apparently vulnerable – although not frankly dependent, these people commonly complain 
of being “slowed up” or have disease symptoms. 
5 Mildly frail – with limited dependence on others for instrumental activities of daily living. 
6 Moderately frail – help is needed with both instrumental and non-instrumental activities of 
daily living.  
7 Severely frail – completely dependent on others for the activities of daily living, or 
terminally ill. 
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These scores were summarised into 3 groups: Well (scores 1-3), Vulnerable (score 4) and 
Frail (scores 5 - 7). 
 
2.1.14 ECG analysis 
 A 12 lead electrocardiogram (ECG) was obtained in all participants following 
admission to hospital. The ECGs were recorded at 100 Hz and 25 mm/s with an amplitude of 
10.0 mm/mV. The ECGs were de-identified, scanned and sent to the lead site for central 
analysis. 
 A physician (M.L.) who was blind to treatment group assignment analysed the ECGs 
for evidence of ischaemia.M.L. had been trained in the University of Glasgow ECG Core 
Laboratory that is certified to ISO 9001: 2008 standards as a UKAS Accredited Organisation. 
The ECG criteria for ischaemia were ST-segment depression ≥ 0.1 mV in two contiguous 
lead. Global ischaemia was taken to represent  ≥6 leads with ST depression, maximally in V4 
and with accompanying T-wave inversion in these leads. Transient ST-segment elevation was 
taken to represent new ST elevation at the J point in two contiguous leads (≥0.1 mV in all 
leads other than leads V2–V3 where≥0.2 mV in men ≥40 years; ≥0.25 mV in women <40 
years).The criteria were similar to those used in the TIMACS trial.(223) 
 
2.1.15 Biochemical assessment of infarct size 
 Troponin I or T were measured as a biochemical measure of infarct size. Blood 
samples were obtained on admission to hospital before enrolment, at the start of the 
procedure and 12 - 24 hours afterwards. Different troponin assays were used in each hospital. 
Troponin T (Elecsys Troponin T, Roche) was measured in patients treated in the Golden 
Jubilee National Hospital, Hairmyres Hospital, Freeman Hospital and Sunderland City 
Hospital. A troponin T concentration of 14.0 pg/ml corresponds to the 99th percentile of a 
 84 
reference population for this assay. Troponin I (Abbott Architect) was measured in patients 
admitted to acute hospitals in Glasgow. The upper limit of normal for this assay is 0.04 µg/L. 
In the Royal Blackburn Hospital, troponin I was measured with the high-sensitivity Siemens 
assay and the upper limit of normal for this assay was < 30 ng/L. In Southampton University 
Hospital, troponin I was measured (Beckman Coulter Dxi 800) and the upper limit of normal 
was 0.07 µg/L. 
2.1.16 Statistical methods 
 Analyses will be carried out with R for Windows v3.0.0, SAS for Windows v9.2. The 
numbers of patients randomised, and the numbers and percentages providing data at each 
follow-up point will be presented. The number and percentage who withdrew from the study 
will be presented, and the reasons for withdrawal summarized 
The following baseline characteristics will be summarised: 
- age (years), sex, ethnic group (white/other), smoking; 
- history of cardiac arrhythmia, history of treated hypercholesterolemia, history of 
hypertension, history of renal impairment, family history of CAD, diabetes mellitus, 
objective evidence of ischaemia, previous diagnostic angiogram, previous PCI, 
previous MI, history of congestive cardiac failure; 
- current CCS Angina class, current NYHA functional class, Killip class, GRACE 
score, ejection fraction; 
- medications at the time of angiogram (aspirin, anti-platelet, statin, other lipid lowering 
drug, beta blocker, calcium channel blocker, long acting nitrate, nicorandil, ACE 
inhibitor, angiotensin receptor blocker, alpha blocker, diuretic, other cardiac 
medication; 
- time from index event to procedure (<5 days or ≥5 days). 
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Vessels Affected (separate summaries to be provided for all vessels, culprit vessels 
only, non-culprit vessels only): 
- whether each vessel affected (RCA prox, RCA mid, RCA distal, PDA from RCA, 
Post-lat from RCA, left main stem, LAD prox, LAD mid, LAD distal, 1st diagonal, 
2nd diagonal, Cx prox, OM, Cx distal, Post-lat from Cx, PDA from Cx, Additional 
OM, Intermediate); 
- the level of stenosis, and whether each vessel affected with severe stenosis (>70% or 
>50% for the left main stem); 
- the FFR value, and whether each vessel affected with FFR <0.80; 
- number of vessels affected; 
- number of vessels affected with severe stenosis; 
- number of vessels affected with FFR <0.80; 
- maximum stenosis of affected vessels; 
- minimum FFR of affected vessels. 
 
 With 322 randomized subjects (161 subjects in the FFR disclosed and non-disclosed 
groups), the study will have 90% power at a 5% level of significance to detect a 50% relative 
increase in the proportion of patients assigned to medical treatment in the disclosure group 
from about 15% to 30%. This difference is based on observations made in a pilot 
study(82)performed to inform the design of the current trial. We have assumed zero loss to 
follow up since the primary outcome is measured during the initial procedure. Allowing for 
any technical difficulties or loss of data at the time of the procedure the total sample size will 
be 350 patients (Figure 10). 
 We anticipated approximately 1400 patients will be screened and 350 patients will be 
randomized in <2 years. We thought that potentially 25% of screened patients may be 
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ineligible (e.g. unsuitable for PCI or CABG). Furthermore, a minority of patients may not 
wish to take part (~25%) and following initial angiography a further 25% may be ineligible 
based on coronary anatomy and disease resulting in 350 randomised patients. We anticipated 
the rate of major adverse cardiac events in the control group will be ~20% during ~1.5 years 
mean follow-up (or at least 35 events in 175 patients) such that the relationship between FFR 
and cardiac outcome in NSTEMI can be evaluated. The Glasgow Clinical Trials Unit 
(Robertson Centre for Biostatistics) acted as an independent coordinating center for data 
management and will conduct the statistical analyses. 
 The primary outcome of the between group difference in the proportions of patients 
allocated to medical therapy will be assessed using Fisher's Exact test and the differences in 
proportions estimated with a 95% confidence interval. Secondary outcomes will also be 
recorded. Clinical event rates will be presented for each follow up assessment point and 
compared between groups using the same methods as the primary outcome. Clinical events of 
interest (as determined by the Clinical Events Committee) will be: 
1. Major Adverse Cardiovascular Events (MACE) – the composite of cardiovascular 
death, non-fatal MI, unplanned hospitalisation for TIA or stroke; 
2. Major Adverse Cardiac Events – cardiac death, non-fatal MI or unplanned 
hospitalisation for heart failure; 
3. Death from any cause. 
The rate of discordance between FFR and coronary stenosis severity assessments will be 
estimated over all patients and segments and a 95% confidence intervals calculated taking 
into account the within subject clustering. For both randomised groups combined, scatterplots 
will be produced showing the FFR value vs. the level of stenosis, overall and for culprit/non-
culprit vessels separately. The rate of discordance between FFR and visual assessment of 
coronary stenosis severity will be presented. 
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 Quality of Life, represented by the EQ-5D health utility score will be summarised at 
each time point and compared between randomised groups using two-sample t-tests. The 
Quality-Adjusted Life Years (QALYs) accrued over 12 months will be estimated by the area 
under the health utility curve. The mean QALY difference between groups will be estimated 
using the method of recycled predictions from an appropriated generalised linear regression 
model with bootstrapping. 
 The following cost-related variables will be summarised and compared between 
groups, using bootstrap estimates of mean differences: 
- number of guiding catheters, ordinary guidewires and pressure wires; 
- number of adenosine doses; 
- number of balloon catheters; 
- number of drug eluting stents and bare metal stents; 
- use of (and type of) GP IIb/IIIa inhibitor; 
- use of bivalirudin; 
- use of IVUS and OCT; 
- use of intra-aortic balloon pump; 
- total radiation dose and contrast use; 
- total procedure time; 
- days on CCU, ITU and general ward; 
- number of echocardiograms, chest x-rays, invasive CV procedures and use of 
ventilation. 
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2.1.17 Safety Analysis 
 The incidence of intra-procedural, post-procedural and in-hospital complications, as 
recorded on the eCRF, will be summarised. Patient symptoms, changes in haemodynamics 
and any adverse effects related to the use of adenosine will also be reported. 
In addition, the Clinical Events Committee will adjudicate the occurrence of the following 
safety outcomes: 
1. MI associated with revascularisation procedures (Types 4 and 5) (25),  
2. Contrast-induced nephropathy (defined as either a greater than 25% increase of serum 
creatinine or an absolute increase in serum creatinine of 0.5 mg/dL after a radiographic 
examination using a contrast agent); 
3. Bleeding (defined according to the ACUITY criteria: major bleed = intracranial or intraocular 
bleeding; bleeding at the site of angiography requiring intervention; a haematoma of 5 cm in 
diameter; a reduction in haemoglobin level of at least 4 g/dL in the absence of overt bleeding 
or 3 g/dL with a source of bleeding; or transfusion. Non-major bleeding by ACUITY criteria 
will not be recorded as SAEs (and so would not be reportable to the sponsor) but would be 
recorded in the eCRF. 
These will be summarised and listed. 
 
2.1.18 Follow-up and Timetable 
 A quality-of-life assessment will be completed at 6-month intervals (EuroQoL, EQ-
5D). Clinical follow-up will continue for an average of 1.5 years (range 6-30 months).  
Follow-up assessments for adverse events will be performed by the clinical research staff by 
telephone or in person (eg, outpatient clinic review), as appropriate. Medical records will also 
be checked. Follow-up contact will occur at 6 monthly intervals until the last patient has 
achieved a minimum of 6 months of follow-up. Follow-up in the longer term will be 
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supported by electronic record linkage with central government health records. The active 
phase of the project is intended to last about 30 months. 
 
2.1.19 Resource use and costs during index hospitalisation 
 Material use included: catheters, balloons, stents, and drugs. Procedures included: 
CABG, x-rays, echocardiograms and intravascular ultrasounds. Hospitalization use included: 
days spent in the Coronary Care Unit (CCU), Intensive Treatment Unit (ITU) and general 
ward as well as catheterization laboratory time. Events included: severe bleeding, stroke and 
MI. 
The use of a pressure wire in patients randomised to coronary angiography alone was 
removed from the cost estimates as it was protocol driven. Instead, coronary guidewire use 
was included. 
 Equipment costs were derived from National Procurement. Average drug dosages 
were estimated using NICE guidance (www.evidence.nhs.uk) while unit costs were derived 
from the British National Formulary (www.bnf.org). Procedure unit costs (except CABG) as 
well as CCU and ITU unit costs were derived from the Golden Jubilee National Hospital. 
Catheterization laboratory time (per hour) was derived from Information Services Division 
Scotland. To estimate the general ward day cost, inpatient excess bed day costs were taken 
from the NHS Reference Costs for acute or suspected myocardial infarction (Healthcare 
Resource Group [HRG] code EB10Z). The procedure cost of CABG (HRG EA14Z) was 
derived from the NHS Reference Costs. Event costs were derived from NHS Reference 
Costs. The HRG code used for stroke was AA22A and AA22B; for myocardial 
infarction,EB10Z. No patients experienced a severe bleed and thus it was not included. All 
costs were presented in 2014 pound sterling.  
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 To incorporate uncertainty, trial results were bootstrapped with stratification by 
randomization group. We used 10,000 resamples. Where costs were uncertain, they were 
randomly sampled from gamma distributions using Monte Carlo simulation methods. 
Confidence intervals were reported as the 2.5th and 97.5th percentiles of the bootstrapped 
results. Two-sided p-values were calculated on the bootstrapped replicates. They represent 
the probability of getting something more extreme than what was observed. This is calculated 
as the proportion of replicates less than and greater than the observed mean cost difference: 𝑝 = !"# !!!!! !!"#(!!!!!)#  !"#$%&'(")  ,  
X is a vector of bootstrapped mean cost differences, 𝑋 is the mean cost difference and 𝛿 is the 
extreme value which is the absolute value of 𝑋. This method is analogous to a one-sample t-
test on the bootstrap replicates of mean cost differences where 𝛿 is tested on the distribution 
X. 
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Figure 10: Flow Diagram of FAMOUS NSTEMI Study 
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2.2 MRI Study 
 As part of the FAMOUS-NSTEMI trial, we performed an MRI substudy in selected 
patients. The cardiac MRI scanner was located at the British Heart Foundation cardiovascular 
research centre at the university of Glasgow. This was at a remote location in relation to the 
main study site (Golden Jubilee National Hospital). Patients who were admitted to the Golden 
Jubilee National hospital and Hairmyres hospital were eligible for the study. Patients eligible 
for the study had to provide their own transport to the research centre. During the CMR 
examination, a study doctor, a physicist and a radiographer supervised all scans. 
The purpose of the CMR substudy was to compare FFR measured invasively with adenosine 
stress perfusion CMR.  We also wanted to compare traditional edema imaging methods with 
more contemporary parametric mapping sequences in NSTEMI. 
 
 
2.2.1 Informed consent 
 
Obtaining written consent for MRI 
 Patients were approached by a member of the healthcare team (myself or research 
nurse) during the course of routine healthcare provision. Participants were invited to have an 
MRI scan in the MRI Facility in the BHF Glasgow Cardiovascular Research Centre. For the 
CMR to take place, at least two members of staff who were trained and experienced in MRI 
were present. Following informed consent, a standard MRI checklist was completed. The 
purpose of this checklist was to ensure that the subject did not have any contraindications to 
MRI, such as a metal foreign body (e.g. replacement heart valve or metal implant), and that 
the scan was safe to perform. The subject was provided with headphones both in order to hear 
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the MRI scanner operator (who was in the neighbouring control room) and also to listen to 
music if desired. 
 
Where possible serial adenosine stress perfusion cardiac MRI at 3 Tesla were be performed 
on 3 occasions:  
1) Before angiography: early after acute MI (≤7 days after hospital admission) to determine 
the initial extent of injury,  
2) After coronary angiography/PCI: 7 – 10 days after admission to assess the outcome of 
revascularisation (if performed), including new procedure-related MI and determine the early 
evolution of myocardial pathology (MVO, haemorrhage and oedema) 
3) Longer-term follow-up: MRI 6 months post-MI to determine final LV outcomes (function 
and remodelling).  
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Figure 11: Flow diagram of the FAMOUS - NSTEMI 3.0 Tesla MRI sub-study 
 
2.2.2 CMR protocol 
 CMR was performed on a Siemens MAGNETOM Verio (Erlangen, Germany) 3.0 
Tesla scanner with a 8-element phased array cardiac surface coil. The CMR protocol  
included localisers then: 
1) cine MRI with steady state free precession, LV short axis stack, 2 chamber, 4 chamber and 
3 chamber views 
2)  T2 maps, T1 maps, T2* maps  (short axis slice at base, mid, apex and 4 chamber)  
 - WIP  561B – MOLLI Siemens Healthcare 
3) dark blood STIR (short axis slice of base, mid, apex and 4 chamber) 
4) first pass gadolinium during rest and adenosine stress (short axis base, mid, apex and 4 
chamber) 
 - WIP 713 perfusion improvements Siemens Healthcare 
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5) 2, 3, 4 and 5 minute short axis stack for early gadolinium enhancement 
6) 15-20min for late gadolinium enhancement (short axis stack, 2chamber, 4chamber, 
3chamber) 
A bolus of gadolinium contrast (Gadovist, Bayer) was administered at 0.1 mmol/kg using a 
dual-bolus I.V. contrast injection technique.  
 
2.2.2.1 CMR imaging parameters 
 Cardiac mass and function were assessed using retro-gated (trueFISP) cine breath-
hold sequences. The in-plane resolution was ~2 mm (26 µl/voxel) and the temporal resolution 
was ~40 ms within the cardiac cycle. The heart was imaged in multiple parallel short-axis 
(SAX) planes 7-mm thick separated by 3-mm gaps, as well as in the 2-, 3-, and 4-chamber 
long-axis views.  
First-pass adenosine (140 µg/kg/min) -stress perfusion MRI was performed with a fast low-
angle shot (FLASH) sequence. Segmented phase-sensitive inversion recovery (PSIR) Turbo-
FLASH were used for late gadolinium enhancement. 
 
2.2.2.2 CMR image analyses 
 The CMR scans were anonymised and analysed in random order on a Siemens 
workstation by a team of staff, including four cardiologists (J.L., C.B., S.W., N.T.), two MRI 
radiographers (K.L., T.S.), one MRI physicist (C.M.) and one image analyst (S.R.). The team 
has considerable MRI experience in patients with acute MI, including protocols with bright 
blood T2-weighted MRI. Total LV and late contrast enhanced infarct mass were calculated by 
multiplying volumes by myocardial density (1.05 g/cm3). 
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Reference ranges used in the laboratory were 105-215g for male left ventricular mass, left 
ventricular mass for women 70 – 170 g, left ventricular end-diastolic volume for men 77 – 
195 ml, left ventricular end-diastolic volume for women 52 – 141 ml, left ventricular end-
systolic volume for men 19 – 72 ml and left ventricular end-systolic volume for women 13 – 
51 ml.  
MRI data was stored on PACS and on secure University databases.  
 
2.2.2.3 Ventricular mass and function 
 Left ventricular dimensions and volumes and ejection fraction were analysed using 
computer-assisted planimetry.   
2.2.2.4 T1, T2 and T2* Measurements and Area-at-Risk 
 Quantitative T1, T2 and T2* assessments were independently analysed by two 
cardiologists.  Discordance between observers was resolved by a third cardiologist.  
 
2.2.2.5 T2, T1 and Dark Blood STIR Measurements and Area-at-Risk 
 A threshold of x2 SD difference in mean signal intensity was adopted to delineate an 
affected area for both T1 and T2 maps and dark blood imaging(57). The jeopardized area-at-
risk on each short axis image was defined as the percentage of left ventricular area delineated 
by the hyperintense zone on T2-weighted images(57).  
 
2.2.2.6 Infarct definition and size   
 Acute infarction and assignment of culprit artery territory: The presence of acute 
infarction was established with MRI based on abnormalities in cine wall motion, rest first-
pass myocardial perfusion, and delayed-enhancement imaging. In addition, supporting 
changes on the ECG and coronary angiogram were also required. Acute infarction was 
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considered present only if late gadolinium enhancement (LGE) was confirmed on both the 
short and long axis acquisitions. The myocardial mass of LGE (grams) was quantified by 
asemi-automatic detection method using a signal intensity thresholdof >5 SD above a remote 
reference region.  Infarct regions with evidence of microvascular obstruction were included 
within the infarct area. Microvascular obstruction was classified as relevant (central dark 
zone with a sub-endocardial or intra-mural distribution) and non-relevant (dots or nil) and 
also expressed as a percentage of total left ventricular mass. 
 
2.2.2.7 Myocardial salvage and Microvascular obstruction 
 Myocardial salvage was calculated by subtraction of percent infarct size from percent 
area-at-risk. The myocardial salvage index was calculated by dividing the initial myocardial 
salvage area by the initial area-at-risk.MVO was defined as a dark zone present on MRI 2, 
3,4 and 5mins post-contrast injection and also present within an area of late gadolinium 
enhancement. 
 
2.2.2.8 Perfusion 
 Regional myocardial perfusion was evaluated dynamically during rest and adenosine 
stress perfusion MRI. We correlated quantitative parametric findings from stress perfusion 
MRI with invasive 'gold standard' measurements of regional lesion level ischaemia (FFR).  
We implemented the latest methods to optimise sequence performance and image acquistion 
(CV improvement_713, Siemens Healthcare). The main developments with this new package 
include: 
• accelerated MR imaging with T-PAT / enhanced parallel imaging reconstruction 
• improved crusher gradients for noise reduction from stimulated echoes 
• phase corrections 
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• motion correction 
• real time cine protocol 
• proton density map for surface coil correction for dynamic imaging 
• arterial input function TurboFLASH 
 
2.2.2.9 Stress/rest perfusion data processing 
 
Baseline stress and rest perfusion MRI images were analysed side-by-side using dedicated 
software (Argus Dynamic Signal, Siemens, Erlangen, Germany). The stress and rest 
perfusion scans were viewed simultaneously, and areas of hypoperfusion were assigned to 
coronary territories using the American Heart Association coronary arterial 16-segment 
model (224, 225). In each patient, the coronary artery territories with abnormal perfusion 
were recorded. In cases of disagreement between observers, a third blinded observer 
adjudicated.  
 
A perfusion defect was classified as significant according to the presence of ischaemia in 2 
segments of a 32 segment model (16-segment AHA model divided into sub-endocardial and 
sub-epicardial layers) i.e.:  > 60 degrees in either the basal or the midventricular slices or  > 
90 degrees in the apical slice or any transmural defect or two adjacent slices(225). 
 
2.2.3 MRI endpoints 
 Image analyses was standardised according to left ventricular segmentation based on 
the AHA model.  
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Definition of remote zone: The remote zone was defined as an area of myocardium in a non-
neighbouring territory, typically 180º from the affected region on an axial scan as 
appropriate. For serial comparisons, the same territory was evaluated based on anatomical 
landmarks (e.g. papillary muscles) and position in the long axis of the heart (e.g. % LV length 
from mitral valve annulus). 
 
 
2.3 Sample size and duration of follow-up 
We hypothesised that at least 100 NSTEMI patients would be enrolled within 2 years. This 
sample size is sufficiently large to provide robust surrogate MRI information at 6 months. We 
anticipated that recruitment would be achieved within 2 years and data analyses and statistics 
would be completed by 2.5 years (end of study).  
 
2.3.1 Statistical analyses  
 Statistical analyses were carried out using IBM SPSS Statistics software, version 21.0 
(Armonk, USA). Normality was tested with the Shapiro-Wilk test. All results are given in a 
format of mean±SD, unless otherwise mentioned.  
 
2.3.2 Area at Risk Sub-Study 
 Correlations between AAR quantified with T1/T2maps and T2W STIR and 
APPROACH lesion scores were tested by Pearson or Spearman’s methods as appropriate. 
The level of agreement between AAR quantified with T1/T2 maps and T2W STIR was 
assessed using Bland-Altman plots and 95% limits of agreement. The 95% limits of 
agreement were calculated using the mean difference between AAR quantified by the two 
imaging modalities ±2 SD of these differences, and contained approximately 95% of all such 
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differences. The McNemar exact test was used to compare diagnostic accuracy of  T1 and T2 
maps and T2W STIR imaging in identifying the infarct-related artery, when compared to 
current gold-standard method of clinical history, ECG and coronary angiography. An inter-
observer agreement reliability analysis, using the Kappa statistic (κ), was performed to 
determine consistency of infarct-related artery diagnosis among observers. p<0.05 was 
considered statistically significant. 
 
2.3.3 FFR Vs MRI substudy 
 Receiver-operator characteristic (ROC) analysis was used to determine the optimal 
cut-off value for FFR to predict a perfusion defect on MRI. The area under the ROC curve  
(AUC) was used as a measure of test accuracy. 
2.3.3.1 Sample Size Calculation for FFR vs. MRI 
We estimated approximately 40% of study participants would have an FFR value ≤ 0.80 at 
the index coronary angiogram and approximately 20% of the participants would have 
significant residual obstructive coronary disease after the PCI and the prevalence of perfusion 
defects overall by stress perfusion MRI will be 30%. Theoretically, there should be close to a 
1:1 correspondence agreement with an inducible perfusion abnormality on stress MRI and an 
FFR ≤ 0.80. Assuming a true underlying agreement rate of 90% and only one artery studied 
per patient, a sample size of 104 patients would have approximately 85% power to exclude an 
agreement rate below 80% based on a one sided 95% confidence interval. In reality more 
than one artery was studied in many patients, hence increasing the power further. 
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Chapter 4: The Clinical Utility of Fractional Flow Reserve in Patients with NSTEMI 
 
.Summary 
 Aim: We assessed the management and outcomes of non-ST segment elevation 
myocardial infarction (NSTEMI) patients randomly assigned to fractional flow reserve 
(FFR)-guided management or angiography-guided standard care. 
 Methods and Results: We conducted a prospective, multicentre, parallel group, 1:1 
randomized, controlled trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% of the 
lumen diameter assessed visually (threshold for FFR measurement) (NCT01764334). 
Enrolment took place in 6 UK hospitals from October 2011 – May 2013. FFR was disclosed 
to the operator in the FFR guided-group (n=176). FFR was measured but not disclosed in the 
angiography-guided group (n=174). FFR ≤0.80 was an indication for revascularisation by 
percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG).  
The median (IQR) time from the index episode of myocardial ischaemia to angiography was 
3 (2, 5) days. For the primary outcome, the proportion of patients treated initially by medical 
therapy was higher in the FFR-guided group than in the angiography-guided group (40 
(22.7%) vs. 23 (13.2%), difference 9·5% (95% CI 1.4%, 17.7%), p=0.022). FFR disclosure 
resulted in a change in treatment between medical therapy, PCI or CABG in 38 (21.6%) 
patients. At 12 months, revascularisation remained lower in the FFR-guided group (79.0% vs. 
86.8%, difference 7.8% (-0.2%, 15.8%), p=0.054). There were no statistically significant 
differences in health outcomes and quality of life between the groups. 
Conclusion: In NSTEMI patients, angiography-guided management was associated with 
higher rates of coronary revascularisation compared with FFR-guided management. A larger 
trial is necessary to assess health outcomes and cost effectiveness. 
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3.1 Introduction 
 
 Non-ST segment elevation myocardial infarction (NSTEMI) is the commonest form 
of acute coronary syndrome (ACS), the most common indication for invasive coronary 
angiography, and a leading global cause of premature morbidity and mortality(23).Coronary 
angiography in ACS patients can detect obstructive coronary artery disease and identify 
patients who may benefit from coronary revascularisation(23, 89). Usual care is based on 
visual interpretation of coronary disease severity and management decisions include medical 
therapy, percutaneous coronary intervention (PCI) or coronary artery bypass surgery 
(CABG). Visual assessment of lesion severity with coronary angiography may be inaccurate 
resulting in over- or underestimation of the physiological significance of the lesion (84, 226). 
Hence judgements made by cardiologists in every day practice are subjective, potentially 
leading to misdiagnosis and incorrect treatment decisions(227). 
An alternative approach involves measurement of the myocardial fractional flow 
reserve (FFR) using a pressure-sensitive coronary guidewire. FFR assesses the physiological 
significance of a coronary stenosis and is expressed as the ratio of maximal blood flow in a 
stenotic artery to maximal flow in an unobstructed artery(116). Recent studies (DEFER 
(228), FAME (119), FAME-2 (229), and RIPCORD (230)) have evaluated the value of FFR 
to guide treatment decisions. An FFR ≤0.80 is an evidence-based physiological threshold that 
correlates with the presence of inducible ischaemia on non-invasive testing (116). FFR values 
>0.80 indicate that patients can be managed safely with medical therapy without the need for 
coronary revascularisation.  
FFR measurements require maximal coronary hyperaemia which may be less readily 
achieved in patients with acute coronary disease because of coronary microvascular 
dysfunction (127). Recent clinical studies indicate that FFR in this setting may be valid (126, 
 103 
129)but in the absence of evidence from randomised prospective trials, a routine 
physiological approach for the management of patients with recent MI is not recommended in 
guidelines (23).We hypothesised that management decisions in patients with NSTEMI 
undergoing coronary angiography guided by routine FFR measurement would be feasible and 
safe, and would provide additive clinical utility compared to standard care based on visual 
interpretation of the angiogram. 
3.2 Methods 
Trial design 
We performed a prospective 1:1 randomised controlled parallel group trial in 350 
NSTEMI patients enrolled from October 2011 to May 2013. 
Participants and eligibility criteria and Setting 
The inclusion and exclusion criteria as well as the setting are documented in the methods 
section  of this thesis. 
 
 
Coronary angiogram acquisition and analyses 
Coronary angiograms were acquired during usual care with standard cardiac catheter 
laboratory equipment. The angiograms were assessed visually by the attending clinicians who 
made the treatment decision for medical therapy, PCI or CABG.  
Randomisation, implementation and blinding 
Participants were enrolled by research staff on the ward before the angiogram was 
obtained. The standard care management strategy was established and recorded before FFR 
was measured. The treatment plan was based on all of the clinical information including the 
results of the angiogram and before FFR was measured. If the angiographic eligibility criteria 
were fulfilled, the patients were then randomised by the research nurse in the catheter 
laboratory to FFR-guided and angiography- guided strategies using a web-based 
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randomisation system. The randomisation sequence was created using randomised permuted 
blocks of length 4, without stratification. The allocation sequence was on a 1:1 basis between 
the FFR-guided group and the angiography-guided group and the sequence was concealed 
electronically. The participants were blinded to the treatment group allocation. 
3.2.1 Interventions 
The randomised participants had FFR measured in all coronary arteries with a lesion 
of ≥30% diameter stenosis that were amenable to instrumentation with a pressure-sensitive 
coronary guidewire (St Jude Medical, Uppsala). FFR was measured during coronary 
hyperaemia induced by intravenous adenosine (140 µg/kg/min). The FFR intervention in this 
study, including assessment of adenosine effect, measurement of FFR, vessel selection, 
blinding and disclosure of the FFR results, has been previously described(231). 
FFR-guided group: FFR ≤ 0.80 was an indication for revascularisation by percutaneous 
coronary intervention (PCI) or coronary artery bypass surgery (CABG), as appropriate, and 
FFR > 0.80 was an indication for medical therapy only. Any changes in management strategy 
following FFR disclosure were prospectively recorded. 
Angiography-guided group and blinding: In patients randomised to the angiography-guided 
group, FFR was measured in the same way as in the FFR-guided group except that the FFR 
results were not disclosed. The research staff obscured the haemodynamic monitor 
(RadiAnalyzer Xpress (St Jude Medical, Uppsala)) from the clinicians, nurses and patients 
such that it was impossible for them to observe the pressure wire information either in the 
catheter laboratory or afterwards. Electronic displays of distal coronary pressure on other 
haemodynamic monitors that may have been visible in the catheter laboratory were also 
disabled. Quality control checks, including assessments of equalised pressure recordings and 
verification of symptoms and haemodynamic changes with intravenous adenosine, were 
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conducted in the usual way. The quality assurance procedures have been previously described 
(231). 
3.2.2 Outcomes 
Primary outcome 
The pre-specified primary outcome was the between-group difference in the 
proportion of patients allocated to medical management. The final treatment decision was 
made by the clinicians in the cardiac catheter laboratory during the index procedure or shortly 
afterwards if a multidisciplinary heart team review was indicated. 
Secondary outcomes 
 
1) The feasibility and safety of routine FFR measurement. 
2) The relationship between FFR and coronary stenosis severity by visual assessment of the 
angiogram. 
3) Major adverse cardiac events (MACE) during follow-up over 12 months, defined as 
cardiac death or hospitalisation for myocardial infarction or heart failure after randomisation. 
Cardiovascular death, stroke, transient ischaemic attack, contrast nephropathy and bleeding 
were also prospectively recorded. All of these events were adjudicated by a Clinical Event 
Committee (CEC) comprised of 3 cardiologists who were independent of the trial and blinded 
to the treatment allocations. Coronary revascularisation, including PCI and CABG, were 
prospectively recorded in the clinical report form. Information on serious adverse events 
during follow-up was obtained by contacting the patients by telephone and reviewing their 
primary and secondary care records. All complications that were potentially related to the 
invasive procedure were prospectively recorded.  
4) Index hospitalisation resource use including: material, procedure, hospitalisation and in-
hospital event costs.  
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5) Health-related quality of life (HRQoL; EuroQol 5-Dimensions 3-Level (EQ-5D-3L). 
Healthcare resources and costs 
Costs during index hospitalisation were calculated by applying resource use or events 
at the individual level to unit costs derived from NHS National Procurement, NHS Reference 
Costs, Information Services Division Scotland, the British National Formulary 
(www.bnf.org) and the Golden Jubilee National Hospital.  
 
Sample size  
We calculated that 322 randomised subjects (161 subjects in each group) would 
provide 90% power at a 5% level of significance to detect a 50% relative increase in the 
proportion of patients assigned to medical treatment in the FFR disclosed group from 15% to 
30%. This difference was based on observations made in a pilot study(82) intended to inform 
the design of the current trial. Allowing for loss of data at the time of the procedure the 
number of participants in the randomised trial was increased to 350.  
 
3.4 Statistical methods 
 
Mean (standard deviation) or median (inter-quartile range) were used to summarise 
continuous data. Counts and percentages were used to summarise categorical data. All 
testswere two-tailed and assessed at the 5% significance level.  
The primary outcome of the proportion of patients allocated to medical therapy was 
assessed in terms of the difference in proportions and the relative risk between groups 
estimated with exact 95% confidence intervals and p values. The proportion of patients with 
major adverse cardiovascular events (MACE) within 12 months and other binary outcomes 
were analysed using the same methods, and time to events within 12 months was compared 
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between groups using log rank tests. Health related quality of life was compared between 
groups using baseline-adjusted linear regression. Length of stay was compared between 
groups using a Wilcoxon Rank Sum test. Costs were compared using bootstrapping (details in 
Supplementary Methods). The statistical analyses were performed using R version 3.0.0 and 
StatXact version 5.0.3. 
 
3.5 Results 
 Eight hundred and fifty three NSTEMI patients were referred for invasive 
management and gave informed consent from October 2011 to May 2013 (Figure 12). Of 
these, 350 patients (mean age 62 years, 74% male) were randomised (n=176 FFR-guided, 
n=174 angiography-guided).  
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Figure 12: Flow diagram of the clinical trial. 
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FFR was measured in all (100%) participants but only disclosed in the FFR-guided group. 
The clinical and treatment characteristics of the patients included in the FFR-guided group 
and the angiography-guided group were similar (Table 3).   
322 (92%) of 350 randomised participants had a history of angina at rest (Canadian 
Cardiovascular Society Angina Class IV angina) and 280 (80%) patients had ECG evidence 
of ischaemia. The median (interquartile range) time from the index episode of myocardial 
ischaemia to the invasive angiogram was 3 (2, 5) days and 81% of the participants underwent 
angiography within 5 days of the index event or most recent episode of chest pain. Further 
detail on the relationship between time from index event to procedure and its impact on FFR 
are provided in table 2.All patients were followed up for 12 months and all of the randomised 
participants were included in the analysis. 
 
Table 2: Relationship between Time of Index Event and FFR   
    Time from index event to procedure  
    >3 days ≤3 days  
  
  
n; mean FFR (SD) 
 
n; mean FFR (SD) 
 
p 
 
FFR Segments 336; 0.71 (0.18) 368; 0.68 (0.18) 0.063 
  Vessel Groups 326; 0.70 (0.18) 358; 0.68 (0.18) 0.095 
  Arteries 306; 0.70 (0.19) 338; 0.67 (0.18) 0.065 
  Patients 
 
166; 0.62 (0.18) 
 
184; 0.57 (0.15) 
 
0.008 
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Table 3: Baseline clinical and angiographic characteristics of all-comers. 
   Randomly assigned groups 
Baseline characteristics*  FFR-guided 
group 
n = 176 
Angiography-guided 
group 
n = 174 
Clinical    
Age, years  62.3 (11.0) 61.6 (11.1) 
Male sex, n (%)  133 (75.6%) 127 (73.0%) 
Heart rate, bpm  73 (15) 74 (17) 
ECG evidence of ischaemia at initial presentation, n (%)  137 (77.8%) 143 (82.2%) 
Peak troponin concentration before the procedure*    
> x5 upper limit of normal   129 (73.3) 137 (78.7) 
> x10 upper limit of normal  107 (60.8) 115 (66.1) 
GRACE score for death or myocardial infarction within 6 months of admission  146 (131, 173) 146 (122, 172) 
Patients with a GRACE score for death or myocardial infarction within 6 months > 140, n (%)  102 (58.0%) 97 (55.7%) 
Diabetes mellitus‡, n (%)  26 (14.8%) 26 (14.9%) 
History of atrial fibrillation or flutter, n (%)  12 (6.8%) 7 (4.0%) 
History of stroke or transient ischaemic attack‡, n (%)  15 (8.5%) 9 (5.2%) 
History of peripheral vascular disease‡, n (%)  14 (8.0%) 14 (8.0%) 
Previous myocardial infarction, n (%)  22 (12.5%) 24 (13.8%) 
Previous percutaneous coronary intervention, n (%)  19 (10.8%) 19 (10.9%) 
History of treated hypertension‡, n (%)  78 (44.3%) 81 (46.6%) 
History of treated hypercholesterolaemia‡, n (%)  71 (40.3%) 56 (32.2%) 
History of smoking‡, n (%) 
Current 
Former (stopped > 3 months) 
Never 
  
72 (40.9%) 
55 (31.2%) 
49 (27.8%) 
 
71 (40.8%) 
47 (27.0%) 
56 (32.2%) 
Angina, Canadian Cardiovascular Society angina class at presentation, n (%) I 
II 
III 
IV 
1 (0.6%) 
1 (0.6%) 
7 (4.0%) 
166 (94.3%) 
0 (0%) 
2 (1.1%) 
15 (8.6%) 
156 (89.7%) 
New York Heart Association functional class at presentation, n (%) I 
II 
III 
IV 
154 (87.5%) 
17 (9.7%) 
2 (1.1%) 
3 (1.7%) 
154 (88.5%) 
16 (9.2%) 
3 (1.7%) 
1 (0.6%) 
Frailty, n (%)* Well 
Vulnerable 
Frail 
148 (87.1%) 
20 (11.8%) 
2 (1.2%) 
144 (87.8%) 
17 (10.4%) 
3 (1.8%) 
Health-related quality of life, EQ-5D score  0.78 (0.29) 0.81 (0.25) 
Medication at procedure    
Aspirin, n (%)  175 (99.4%) 173 (99.4%) 
P2Y12 inhibitor, n (%)  176 (100%) 173 (99.4%) 
Statin, n (%)  168 (95.5%) 167 (96.0%) 
Beta-blocker, n (%)  161 (91.5%) 147 (84.5%) 
Calcium channel blocker, n (%)  27 (15.4%) 25 (14.4%) 
Isosorbide mononitrate, n (%)  18 (10.2%) 20 (11.5%) 
Intravenous nitrate, n (%)  32 (18.2%) 21 (12.1%) 
Low molecular weight heparin, n (%)  165 (93.8%) 168 (96.6%) 
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 Footnote: ECG = electrocardiogram. Means±SD or median (interquartile range) for 
normal and non-normally distributed data, respectively. Categories for peak troponin I and T 
concentrations were determined based on the upper limit of normal (99th centile) for each 
hospital; ‡ At least one risk factor for coronary artery disease was required for eligibility. 
Diabetes mellitus was defined as a history of diet-controlled or treated diabetes. Frailty was 
assessed using the frailty index score (Supplementary Methods37) and the 6 categories were 
summarised into 3 groups: Well, Vulnerable, or Frail. 
 
 
 
3.5.1 FFR-guided vs. Angiography-guided treatment groups 
FFR was measured in 704 (99.7%) of 706 lesions with a stenosis severity ≥30%, and 
was measured in at least one artery in all (100%) patients. Of lesions with an FFR result 
(n=704), 430 (61.1%) were physiologically significant (FFR ≤ 0.80) (Table 4 and figure 13) 
 
Table 4: Procedure characteristics and findings. 
  Randomly assigned groups 
Characteristics*  FFR-guided group 
n = 176 
Angiography-guided group 
n = 174 
Procedure    
Time from index episode of myocardial ischaemia to the invasive 
angiogram, days 
 3 (1, 4) 4 (2, 5) 
 
Procedure characteristics    
Radial artery access, n (%)  158 (89.8%) 157 (90.2%) 
Procedure time (including angiography and PCI), min  66.5 (23.4) 70.5 (33.5) 
Volume of contrast used, ml  218.7 (97.3) 221.9 (110.4) 
Number of stents per patient  1.1 (1.1) 1.4 (1.2) 
Total stent length per patient, mm  24.4 (24.7) 29.4 (26.9) 
Total number of stents  203 245 
Total number of lesions with a stenosis ≥ 30% of the reference 
diameter of the artery 
 355 351 
Total number of lesions with a stenosis ≥ 50% of the reference 
diameter of the artery (% of all lesions) 
 331 (93.2%) 314 (89.5%) 
Patients with at least one lesion ≥ 50% severity in the left main 
artery, n (%) 
 2 (1.1%) 6 (3.4%) 
FFR findings    
Lesions successfully measured for FFR, number / total number (%)  355 (100%) 349 (99.4%) 
Number of physiologically significant (FFR ≤ 0.80) lesions (% of 
all lesions) 
 208 (58.6%) 222 (63.6%) 
Arteries with at least one physiologically significant (FFR ≤ 0.80) 
lesion, n (%) 
   
 0 34 (19.3%) 29 (16.7%) 
 1 91 (51.7%) 90 (51.7%) 
 2 39 (22.2%) 42 (24.1%) 
 ≥ 3 12 (6.8%) 13 (7.5%) 
    
Patients with at least one physiologically significant lesion (FFR ≤ 
0.80), n (%) 
 142 (80.7%) 145 (83.3%) 
Patients with at least one physiologically significant lesion (FFR ≤ 
0.80) in the proximal or middle left anterior descending artery, n 
(%) 
 72 (40.9%) 86 (49.4%) 
Mean FFR in lesions with FFR ≤ 0.80  0.56 (0.12) 0.58 (0.13) 
Lesion characteristics based on visual interpretation of the 
angiogram 
   
Stenosis, n (%)    
 30 - 49% of diameter 24 (6.8%) 37 (10.5%) 
 50 - 69% of diameter 76 (21.4%) 73 (20.8%) 
 70 - 89% of diameter 113 (31.8%) 88 (25.1%) 
 ≥ 90% of diameter 111 (31.3%) 124 (35.3%) 
 Total occlusion 31 (8.7%) 29 (8.3%) 
 
 113 
Footnote: TIMI = Thrombolysis in Myocardial Infarction grade. Mean±SD or median 
(interquartile range) for normal and non-normally distributed data, respectively. A diseased 
artery was defined as an epicardial artery with one or more lesions ≥ 30% of the reference 
vessel diameter and amenable to PCI or CABG. An angiographically significant artery was 
defined as an artery with one or more lesions ≥ 50% of the reference vessel diameter. 
 
Ten participants (2.9%) had no lesions (stenosis severity < 50%) when assessed by 
angiography and 63 (18.0%) patients had no lesions when subsequently assessed by FFR 
(>0.80). The number of patients with 0, 1, 2, or ≥ 3 vessel coronary disease is shown in 
Figure 13.  
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Figure 13: Number of Affected Vessels in Angiographic and FFR Guided Arms 
3.5.2 Primary outcome 
The proportion of patients treated by medical therapy was higher in the FFR-guided 
group than in the angiography-guided group (40 (22.7%) vs. 23 (13.2%), difference 9.5% 
(95% CI 1.4%, 17.7%), p=0.022; relative risk 1.72 (1.08, 2.82)) (Table 5).  
The initial treatment decisions before randomisation and after FFR disclosure in the 
FFR-guided group are shown in Figure 14. FFR-disclosure resulted in a change in treatment 
plan in 38 (21.6%) of 176 patients. The relationship between FFR and stenosis severity is 
shown in Figure 15 and 16. 
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Table 5: Outcomes in FFR guided and Angio Guided Groups 
 Randomly assigned groups   
Outcome* FFR-
disclosure 
group 
n = 176 
Angiography group 
n = 174 
Risk Difference 
(95% CI) 
p value† 
Primary outcome¢     
Medical management, n (%) 40 (22.7%) 23 (13.2%) 9.5% (1.4%, 
17.7%) 
0.022 
Coronary revascularisation during the index admission 136 (77.3%) 151 (86.8%)   
     
Percutaneous coronary intervention, n (%) 125 (71.0%) 139 (79.9%) -8.9% (-18.1%, -
0.2%) 
0.057 
Coronary artery bypass graft, n (%) 11 (6.2%) 12 (6.9%) -0.7% (-6.2%, 
4.8%) 
0.87 
In-hospital adverse events     
Contrast nephropathy 2 (1.1%) 1 (0.6%) 0.6% (-2.2%, 
3.5%) 
0.69 
Major Bleeding 2 (1.1%) 1 (0.6%) 0.6% (-2.2%, 
3.5%) 
0.69 
Health outcomes at 12 months     
Cardiovascular death, non-fatal myocardial infarction, 
unplanned hospitalisation for stroke or transient ischaemic 
attack (MACCE) 
13 (7.4%) 16 (9.2%) -1.8% (-7.9%, 
4.2%) 
0.56 
Cardiac death, non-fatal myocardial infarction or unplanned 
hospitalisation for heart failure (MACE) 
14 (8.0%) 15 (8.6%) -0.7% (-6.7%, 
5.3%) 
0.89 
MACE, excluding procedure-related myocardial infarction†† 10 (5.7%) 5 (2.9%) 2.8% (-1.6%, 
7.6%) 
0.25 
All-cause death 5 (2.8%) 3 (1.7%) 1.1% (-2.4%, 
5.0%) 
0.54 
Fatal or non-fatal myocardial infarction†† 11 (6.2%) 15 (8.6%) -2.4% (-8.2%, 
3.3%) 
0.49 
Myocardial infarction related to coronary revascularisation 
(Type 4a, Type 4b and Type 5 myocardial infarction) 
5 (2.8%) 11 (6.3%) -3.5% (-8.5%, 
1.1%) 
0.12 
Spontaneous myocardial infarction 7 (4.0%) 5 (2.9%) 1.1% (-3.1, 5.5%) 0.69 
Heart failure 1 (0.6%) 0 (0.0%) 0.6% (-1.6%, 0.51 
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3.2%) 
Stroke or TIA 0 (0.0%) 1 (0.6%) -0.6% (-3.2%, 
1.5%) 
0.52 
     
Other secondary outcomes   Mean Difference 
(95% CI) 
p value 
Health-related quality of life: EQ-5D health status at 12 
months 
0.844 (0.236) 0.804 (0.284)   
Change from baseline health status at 12 months 0.066 (0.357) -0.010 (0.276) 0.055 (-0.010, 
0.120) 
0.095 
Cost through index hospitalisation, mean (SE) £ 7,289 (608) 7,484 (632) -194 (-961 to 
575) 
0·61 
Material cost, mean (SE) £** 1,095 (39) 822 (46) 274 (157 to 389) <0.01 
Procedure cost, mean (SE) £** 467 (111) 502 (118) -35 (-307 to 227) 0.78 
Hospitalisation cost, mean (SE) £** 5,701 (585) 6,117 (611) -415 (-1,069 to 
239) 
0.21 
In-hospital event cost, mean (SE) £** 25 (19) 43 (19) -18 (-69 to 37) 0.46 
Duration of hospital stay at baseline admission, days 6.1 (3.3) 6.5 (3.1) -0.44 (-9.41 to 
8.51) 
0.09 
 
 Means±SD and median (interquartile range) are used for normal and non-normally 
distributed data. Cost data are reported as mean±SE† FFR was measured in all participants 
and disclosed in the FFR-guided group but not disclosed in the angiography-guided group. 
The P value is the comparison between the FFR-guided group and angiography-guided 
group. ¢ The index treatment decision as per randomised strategy occurred in 171 (97.2%) of 
the participants in the FFR guided group and 173 (99.4%) of the participants in the 
angiography-guided group. ¥  The odds ratio calculations are described in the Methods.  
†† Of the 10 patients with spontaneous MACE in the FFR group, FFR disclosure changed the 
initial treatment plan from PCI to medical therapy for the culprit artery in 4 patients. These 
events happened from 3 - 11 months after randomisation. The excess of 5 patients with a 
spontaneous MACE in the FFR group is due to 2 deaths, 2 patients with spontaneous MI and 
1 patient with a heart failure hospitalisation. †† Myocardial infarction:  28 non fatal MI 
 117 
events and 2 fatal MI events occurred within 12 months of randomisation in 26 patients, 
including 17 procedure - related MIs in 16 patients (one standard care patient had two 
procedure-related MIs (index procedure and a subsequent procedure during follow-up)) and 
11 spontaneous MIs in 10 patients (one FFR patient had two of these events)). Twenty six 
patients had at least one MI event. Four patients had two MI events (n=2 FFR-guided group, 
n=2 angiography-guided group). In summary, one patient had two procedure-related MIs, one 
patient had two spontaneous MIs and two patients had both types of MI. 
** Material costs includes: guide catheters, ordinary guidewires, pressure wires, adenosine, 
balloon catheters, drug eluting stents, bare metal stents, GP inhibitors and bivalirudin; 
Procedure costs includes: CABG, intravascular ultrasound, optical coherence tomography, 
echocardiogram and chest x-ray; hospitalisation costs includes: catheterisation laboratory 
time, CCU days, ITU days and general ward days; in-hospital events included MI and stroke. 
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Figure 14: FFR-guided group: treatment decisions initially based on angiography alone 
and then finally after FFR disclosure. 
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Figure 15: Relationship between angiographic stenosis severity assessed visually before 
  randomisation and FFR (all lesions). 
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Figure 16a: Relationship between angiographic stenosis severity assessed visually before 
  randomisation and FFR in culprit vessels. 
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Figure 16b: Relationship between angiographic stenosis severity assessed visually before 
  randomisation and FFR in non-culprit vessels. 
 
 
3.5.3 Resource use and material costs during the index hospitalisation 
The duration of the index invasive procedure, the volume of radiographic contrast 
medium, and the number, type (drug eluting stent vs. bare metal stent) and length of stents 
were similar in the FFR-guided group and angiography-guided groups (Table 5). Mean 
material costs were higher in the FFR-guided group (£1,095, 95% confidence interval £1,021 
to £1,171) compared to the angiography-guided group (£822, 95% confidence interval £737 
to £914). Mean in-hospital healthcare costs were similar in the FFR-guided group (£7,289, 
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95% confidence interval£6,173 to £8,549) and the angiography-guided group (£7,484, 95% 
confidence interval £6,325 to £8,777) (Table 5). 
3.5.4 Clinical events and safety 
In-hospital adverse events relating to procedure safety are described in Table 5. 
According to independent adjudication based on review of the coronary angiograms, 8 
coronary artery dissections occurred in 7 (2.0%) of 350 patients during the index procedure. 
Six dissections were attributed to coronary instrumentation during PCI and 2 were attributed 
to the pressure wire.  
The follow-up assessments were completed in June 2014. Vital status at 12 months 
was obtained for all (100%) participants (Table 5). Fourteen (8.0%) of 176 patients in the 
FFR-guided group and 15 (8.6%) of 174 in the angiography-guided group experienced 
cardiac death, non-fatal myocardial infarction or heart failure hospitalisation (p=0.89) (Table 
3; Figure 17). Myocardial infarction relating to PCI (Type 4a or Type 4b) or CABG (Type 5) 
occurred in 5 (2.8%) patients in the FFR-guided group and 11 (6.3%) patients in the 
angiography-guided group (p=0.12) (Table 5). MACE excluding MI related to 
revascularisation occurred in 10 (5.7%) patients in the FFR-guided group and 5 (2.9%) 
patients in the angiography-guided group (p=0.25) (Table 5; Figure 17 and 18). Table 6 
shows the clinical vignettes for those patients in the FFR guided arm who had a MACE 
event. 
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Figure 17: Kaplan-Meier plots for major adverse cardiac events (MACE) during 12 months 
follow-up in the FFR-guided group and angiography-guided group. 
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Figure 18: Kaplan-Meier plots for major adverse cardiac events (MACE) during 12 
months follow-up in the FFR-guided group and angiography-guided group. MI events 
associated with revascularisation (Types IV and V MI) are excluded so the MACE 
outcome includes spontaneous MI events post-randomisation only. 
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Table 6 – Adverse Events in FFR guided Patient
Participant (age, 
sex) 
Invasive findings for culprit lesion 
(location, angiographic stenosis severity) 
Invasive findings for non-culprit lesion 
(location, angiographic stenosis severity) 
Initial treatment plan 
based on the angiogram 
FFR result and 
treatment plan after 
FFR disclosure 
Adverse 
cardiovascular event 
and treatment* 
      
60, male 
 
Intermediate artery, 70% focal stenosis, 
FFR = 0.86 
No lesions PCI Medical therapy NSTEMI 7 weeks 
after randomisation 
PCI performed to 
culprit intermediate 
artery stenosis  
49, male 
 
Proximal circumflex, 70% stenosis Mid left anterior descending artery, 60% 
stenosis 
PCI Circumflex artery FFR = 
0.94, 
Left anterior descending 
artery FFR = 0.83; 
Medical therapy 
NSTEMI 8 months 
after randomisation 
Medical management. 
46, male 
 
 
Right coronary artery, 100% stenosis Mid left anterior descending artery, 60% 
stenosis 
CABG FFR = 0.87 
Medical therapy 
Severe left ventricular 
dysfunction at 
baseline (LV ejection 
fraction < 30%) but no 
implantable 
defibrillator; sudden 
cardiac death 
63, male 
 
 
Proximal left anterior descending coronary 
artery, 75% focal stenosis. 
No lesions PCI to culprit lesion FFR = 0.86 
Medical therapy 
Coronary guidewire 
related dissection 
during the index 
procedure; FFR-
guided decision for 
medical therapy 
changed to PCI in 
order to treat the 
dissection. 
PCI was performed 
but MI did not occur. 
  
 
 
 
 
 
 
 
3.5.5 Health outcomes in patients treated initially with medical therapy alone 
 
Sixty three (18.0%) of 350 randomised participants were initially managed medically 
without revascularisation. Of these, 3/40 (7.5%) in the FFR-guided group had a MACE event 
during 12 months follow-up vs. 0/23 (0%) in the angiography-guided group (p=0.22; Table 
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3.5.6 Revascularisation within 12 months 
Compared with the angiography-guided group, the percentage of patients who were free from coronary 
revascularisation remained higher in the FFR disclosure group at 12 months (37 (21.0%) vs. 23 (13.2%), 
difference 7.8% (-0.2%, 15.8%), p=0.054; relative risk 1.59 (0.99, 2.62)).  
3.5.7 Health-related quality of life 
Health-related quality of life scores were similar in each group at 12 months (Table 5). 
3.6 Discussion 
In this trial we assessed a routine physiological approach combined with coronary angiography to diagnose 
and treat coronary artery disease in patients with recent NSTEMI undergoing invasive management.  
Compared with an anatomical approach based on visual interpretation of the coronary angiogram 
(standard care), FFR-guided management was feasible and safe in the catheter laboratory. The FFR-guided 
approach resulted in changes in stenosis classification and patient management in one fifth of the patients. 
The rate of coronary revascularisation was reduced at the index procedure and most of this difference was 
maintained at 12 months. Material costs during the index procedure increased because of the cost of the 
pressure wire but overall healthcare costs during the index hospitalisation were similar. MI related to 
revascularisation tended to be more frequent in the standard care group whereas MACE events unrelated to 
revascularisation tended to be more common in the FFR group. There was no evidence for differences in the 
other health outcomes or in health-related quality of life between the randomised groups. 
The results of this trial have several implications. Firstly, routine FFR measurement in appropriately selected 
NSTEMI patients was feasible in all of the participants and relatively safe. Radial artery access was the 
norm and bleeding complications were rare. Secondly, on an individual patient basis, FFR disclosure 
commonly changed patient management (Figure 14), and overall, revascularisation was reduced. Thirdly, 
compared with the angiography guided group, the increased adoption of medical therapy at the expense of 
revascularisation in the FFR disclosure group was associated with similar overall health outcomes and 
quality of life at 1 year. Representing a balance of competing risks, the reduction in procedure-related MI 
events in the FFR group should be considered against the increase in spontaneous cardiac events during 
follow-up. Finally, based on the combination of coronary angiography and the use of FFR, the diagnostic 
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work-up of patients admitted with NSTEMI could be simplified ruling out the need for deferred 
management and non-invasive stress testing in NSTEMI patients with a broad range of stenosis severities 
(≥30%). 
In invasively managed NSTEMI patients, the standard care approach involves visual interpretation of 
the anatomical severity of disease disclosed by the coronary angiogram. Adoption of a physiological 
approach to inform treatment decisions in invasively managed NSTEMI patients is not the standard of care 
mainly because of a lack of evidence. The specific uncertainties for FFR adoption relate to a lack of 
evidence for FFR measurement in culprit arteries(23). When coronary resistance is reduced by vasodilator 
drugs, such as adenosine, the curvilinear relationship between coronary pressure and flow becomes 
approximately linear in the physiological range of blood pressure(232). Following STEMI, vascular injury 
may limit microvascular vasodilatation(127) and this may limit the validity of FFR which is by definition a 
hyperaemic index. In NSTEMI, the pathophysiology of the culprit artery is typically non-occlusive 
thrombotic plaque rupture and subendocardial infarction(16). Since FFR was measured in coronary arteries 
with normal blood flow, microvascular dysfunction may have been limited, transient or absent in the 
participants in this trial(129). The post-hoc analysis of medically stabilised ACS patients in the FAME trial 
also supports the validity of FFR.  
A further area of uncertainty that was addressed in this trial relates to the management of NSTEMI 
patients with non-obstructive culprit lesions and potentially rupture-prone non-culprit lesions. Stenting to 
seal a non-flow limiting ruptured coronary plaque might reduce the risk of recurrent MI. Alternatively, 
optimal medical therapy might suffice and unnecessary stenting can be harmful (e.g. stent thrombosis, 
restenosis). The likelihood of MI increases with coronary stenosis severity and revascularisation guided by 
FFR reduces this risk in stable patients(119, 233). Whether FFR-guided management has prognostic benefits 
in ACS patients is uncertain and controversial. On the one hand, a reduction in revascularisation may reduce 
procedure-related MI. On the other hand, the risk of spontaneous MI might increase in the longer term in 
non-revascularised patients since plaque with rupture-prone biology may be non-flow limiting (FFR >0.80). 
In our trial, 4 of the 10 patients with spontaneous MACE in the FFR group had an initial treatment plan for 
PCI in a culprit artery changed to medical therapy based on an FFR >0.80. The spontaneous MACE events 
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in these patients occurred later during follow-up (3 - 11 months) in keeping with remodelling in the culprit 
artery and late spontaneous MI rather than a false-negative FFR result. The FFR results in the other patients 
with spontaneous MACE in the FFR group did not influence the initial management of these patients based 
on angiography alone implying the FFR strategy was not associated with the MACE events. In the FAME 
trial, nearly one third of participants in the FAME trial had a history of recent MI(126). 
The potential for FFR disclosure to impact on physicians’ treatment decisions in patients with recent 
unstable coronary disease is also uncertain(82).We found that FFR disclosure changed the treatment plan in 
over one in five patients with a reduction in revascularisation on a patient basis. However, late spontaneous 
MACE tended to be more common in the FFR-group, calling into question the longer term safety of an FFR-
guided change from PCI to medical therapy in culprit arteries. These observations place emphasis on the 
need for a larger trial with a design that is informed by these results and powered to definitively assess 
health outcomes and cost-effectiveness. 
The FAMOUS-NSTEMI trial differed from recent trials of FFR-guided management (DEFER,(228) 
FAME,(119)FAME-2,(229) and RIPCORD(230)) in a number of important ways. Firstly, the primary 
diagnosis of the patients differed between the trials. DEFER, FAME and FAME-2 trials enrolled patients 
with stable coronary artery disease. In FAME,NSTEMI patients were included within 5 days of the index 
event provided the peak creatine kinase was less than 1000 U per litre.  In FAME-2, patients with Canadian 
Cardiovascular Society angina class IV or an NSTEMI were only included if the symptoms had been 
controlled for more than 7 days. Secondly, the treatment strategies in these trials were not the same. In 
DEFER, FAME, and FAME-2, the patients were selected for PCI whereas FAMOUS patients were 
randomised upstream at an earlier stage in the treatment pathway when all treatment options were possible, 
including medical therapy, PCI and CABG. Thirdly, the angiographic criteria for FFR measurement differed 
between the trials. In the FAME trials, FFR was measured in stenoses assessed visually to be at least 
intermediate (≥50% reference diameter) in severity whereas in FAMOUS even very mild narrowings (≥30% 
reference diameter) were included. The characteristics of the participants in the FAMOUS trial were similar 
to those of other ACS trials, such as TIMACS(223) (e.g. 80% of participants in both trials had an ischaemic 
ECG). Finally, compared with standard care, health outcomes were improved by FFR-guided management 
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in the FAME trials whereas in FAMOUS, MI events were different and overall MACE were similar at 12 
months. 
Balancing against the potential benefits, use of a diagnostic coronary guidewire may come at the 
expense of cost and potential harm, including procedure-related coronary dissections. In this study, 2 
coronary artery dissections were due to pressure wire instrumentation, as attributed by an independent 
clinical event committee which reviewed the angiograms. In the RIPCORD study(230), in which all 
coronary arteries were instrumented, 3 clinically important complications attributable to the pressure wire 
occurred in 200 patients.  
In the angiography-guided group, the proportion of patients revascularised at baseline (86.8%, Table 
4) was lower than the proportion of patients with an angiographically significant stenosis (96.6%, Table xx). 
By contrast, in the FFR-guided group, the proportion of patients with at least one physiologically-significant 
lesion (FFR≤0.80; 80.7%, Table 4) and the rate of revascularisation at baseline (81.7%, Table 4) were 
similar. In the sample size calculated we had anticipated a 15% difference in medical management between 
the randomised groups. The smaller actual difference (10.1%, Table 5) could be in part be explained by the 
lower than expected rate of revascularisation in the angiographic control group. 
The rate of change of the initial treatment plan in our trial was lower than in other studies(119, 229, 
230). This discrepancy is explained by the lower rate of lesion re-classification by FFR disclosure in patients 
with very mild (<50%) or very severe (>90%) lesions (Figure 15). Lesions at the extremes of coronary 
stenosis severity were included by design in order to assess the diagnostic impact of FFR across the full 
range of stenosis severities. The relationship between lesion severity and the health economic value of the 
FFR-guided strategy should inform whether this strategy has more economic value within an intermediate 
range of coronary stenosis severities (e.g. 50 - 90%). The health economic implications of this trial will be 
assessed in a future planned analysis.(231) 
3.7 Limitations 
The randomised participants in this trial were included because the cardiologist believed coronary 
instrumentation with the pressure wire was feasible, but this decision is subjective and some patients may 
not have been included due to operator preference. Even though some features of severe coronary disease 
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were exclusion criteria (e.g. a severely calcified coronary artery), some patients with severe coronary disease 
were still included supporting generalisability of the trial findings. For example, 6.6% of the participants 
were referred for CABG. 19% of the participants underwent angiography 5 or more days from the index 
episode of myocardial ischaemia. This time interval is explained by clinical service pressures that delayed 
access to the catheter laboratory in some of the hospitals in this trial.  
Most of the participants in our trial received clopidogrel whereas ticagrelor,which improves 
cardiovascular outcomes in ACS patients compared to clopidogrel,is now recommended in NSTEMI 
patients(234). We have reported the cardiologists' visual interpretation of the angiogram as actually 
performed in the study participants. A quantitative coronary analysis by blinded observers is currently on-
going.  
Our study was designed (but not powered) to assess between-group differences in health outcomes. 
There are too few cardiac events to draw firm conclusions and the prognostic significance of FFR-guided 
management in patients with optimal dual anti-platelet therapy should be further assessed in a larger trial 
with longer term follow-up. 
3.8 Conclusions 
The FAMOUS-NSTEMI trial provides information on the feasibility, safety, and clinical utility of a 
routine physiological approach to guide the management of NSTEMI patients. We have shown that 
compared with angiography-guided standard care, routine FFR measurement is feasible and safe, and FFR 
disclosure resulted in a change in treatment plan in more than one fifth of patients and revascularisation was 
reduced overall. There were no differences in health outcomes and quality of life between the randomised 
groups. In the FFR group, procedure-related MI tended to be reduced but spontaneous MACE during 
follow-up tended to be more common during 12 months follow-up. A large randomised trial is needed to 
definitively assess the cost-effectiveness of an FFR-guided management strategy in invasively managed 
NSTEMI patients. 
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Chapter 5 
 
 
 
 
Assessment of Fractional Flow Reserve in Patients with Recent Non-ST segment Myocardial 
Infarction: A Comparative Study with 3 Tesla Stress Perfusion Cardiac Magnetic Resonance 
Imaging 
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Summary 
 
Background 
 
The use of fractional flow reserve in acute coronary syndromes is controversial. We report the 
findings of a cardiac magnetic resonance (CMR) study to assess the diagnostic accuracy of 
fractional flow reserve compared to 3.0 Tesla stress CMR perfusion in patients with a recent 
acute non-ST segment myocardial infarction (NSTEMI). 
 
Methods 
 
106 patients with NSTEMI who had been referred for early invasive management were included 
from 2 centers. FFR was measured in all major patent epicardial coronary arteries with a visual 
stenosis estimated at ≥30% and if PCI was performed, an FFR assessment was repeated. 
Myocardial perfusion was assessed with stress perfusion CMR at 3.0 Tesla with intravenous 
adenosine (140 µ/kg/min) by trained observers blinded to the FFR results.  
 
Results 
 
Mean age was 56.7±9.8 years.  82.6% were male. Mean time from FFR evaluation to CMR was 
6.1±3.1 days. The mean ± SD left ventricular ejection fraction was 58.2±9.1%. Mean infarct size 
was 5.4±7.1% and mean troponin concentration was 5.2±9.2µg/L. 1696 myocardial segments 
were analyzed and 32 segments were excluded from the analysis due to poor image quality. 
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There were 34 fixed and 160 inducible segmental perfusion defects. There was a negative 
correlation between the number of segments with a perfusion abnormality and FFR (r = -0.77, 
p<0.0001). 
The overall sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) for FFR≤ 0.8 were 91.4%, 92.2%, 76% and 97% respectively. Diagnostic accuracy was 
92%. The PPV and NPV of FFR for flow-limiting coronary artery disease (FFR ≤ 0.8) in 
NSTEMI patients (n=21) who underwent perfusion CMR before invasive angiography were 92% 
and 93%, respectively. ROC analysis indicated that the optimal cut off value of FFR for 
demonstrating reversible ischaemia on CMR was ≤0.805 (AUC 0.94 (0.9-0.99), p<0.0001).  
 
Conclusion 
 
FFR in patients with recent NSTEMI showed high concordance with myocardial perfusion in 
matched territories as revealed by 3.0 Tesla stress perfusion CMR.   
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4.1 Introduction 
 
Fractional flow reserve (FFR) has an established role in guiding percutaneous coronary 
intervention (PCI) in stable coronary artery disease.  In this setting, the use of FFR has been 
associated with improved long-term outcomes and reduced healthcare costs compared with 
angiographic-based strategies(119).  Rates of urgent revascularization are reduced when 
compared with contemporary medical therapy(229). The validity of FFR is predicated on the 
ability to produce maximal hyperemia to achieve a linear relationship between pressure and 
flow(121). Maximal hyperemia may be less readily achieved in patients with recent MI because 
of microvascular dysfunction(128). Evidence on the potential diagnostic accuracy of FFR in 
patients with a recent acute coronary syndrome (ACS) is lacking.   
 
In primary PCI for acute ST-elevation myocardial infarction (STEMI), FFR values are 
influenced and may reflect severe microvascular dysfunction in the territory of reperfused culprit 
artery(235, 236). The natural history of NSTEMI is different with most patients who are 
medically-stabilized presenting without coronary occlusion. In these patients, the 
microcirculation may have recovered and stabilized sufficient vasodilator capacity that FFR may 
be a valid measure of lesion-level flow. Recent clinical studies support the notion that 
contemporary FFR thresholds retain diagnostic accuracy amongst medically stabilized MI 
patients(125, 126, 132). For example, FFR correctly identified inducible ischemia on SPECT in 
57 patients >6 days after MI(118) and in a follow-up study of 124 ACS patients, deferring 
revascularization in lesions with an FFR ≥ 0.75 was safe(237). Based on invasive measurement 
of coronary vasodilator capacity (resistive reserve ratio, RRR) we found that patients with stable 
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angina and NSTEMI have a similar vasodilator reserve (129).  Thus although recent studies are 
informative, more data concerning the validity of FFR in NSTEMI are needed. 
 
We conducted in order to assess the relationships between invasively measured FFR and 
myocardial perfusion with cardiac magnetic resonance at 3.0 Tesla CMR. The purpose of this 
study was to examine the ability of FFR to predict reversible ischaemia when compared to a non-
invasive gold standard in a large cohort of medically stabilized NSTEMI patients.   
 
4.2 Methods 
 
4.2.1 Study Population 
 
106 patients were enrolled between November 2011 and June 2013 from two of the participating 
hospitals in the vicinity of the CMR center. One of the hospitals was a non-academic regional 
hospital and the other was an academic cardiothoracic center The CMR study population 
consisted of patients with recent NSTEMI who had been referred for early invasive management 
guided by coronary angiography (NCT02073422). Exclusion criteria included coronary artery 
bypass graft (CABG) surgery, severe valvular heart disease and standard contraindications for 
CMR. Patients were scheduled for a pharmacological stress perfusion CMR scan at 3.0 Tesla 
following discharge from hospital.   CMR was also performed in a subset of patients who had 
been discharged from hospital for early urgent out-patient coronary angiography/PCI.   
 
The protocol was approved by the regional ethics committee and the study was undertaken in 
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accordance with the Declaration of Helsinki. All of the participants gave written informed 
consent. 
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4.2.2 CMR analysis 
 
Higher field (3.0 Tesla) CMR was adopted as a reference method for assessing myocardial 
perfusion, as well as function and infarction(239). Heart imaging was carried out on a Siemens 
MAGNETOM Verio (Erlangen, Germany) 3.0 Tesla scanner with an 8-element phased array 
cardiac surface coil. The CMR protocol included assessment of left ventricular function using 
Steady State Free Precession (SSFP), myocardial infarction using late gadolinium enhancement 
(LGE), and myocardial perfusion was assessed by first-pass dynamic contrast-enhanced CMR 
(DCE-CMR).  
 
Cine SSFP images with two-fold accelerated parallel imaging (GRAPPA) were acquired in a 
stack of short-axis views of the LV. Imaging parameters were:  repetition time (TR) 3.4 ms, echo 
time (TE) 1.51 ms, flip angle (FA) 50°, typical field of view (FOV) (340 x 286)mm2, matrix 256 
x 216, slice thickness 7 mm, slice gap 3 mm, receiver bandwidth (BW) 977 Hz/px, 25 cardiac 
phases. 
 
For perfusion, DCE-CMR was acquired in basal, mid-ventricular, and apical short axis slices 
during the first pass of 0.05 ml/kg of a 1-molar gadolinium based contrast agent (Gadovist, 
Bayer) injected with a power injector at a flow rate of 4mls/s.  
 
Hyperaemia was achieved with an intravenous infusion of adenosine at 140 µg/kg/min for 3-4 
minutes. All patients had desisted from caffeine for at least 12 hours prior to the scan and had 
otherwise complied with their standard medication. 
 139 
 
DCE-CMR was performed with a fast gradient echo sequence with non-selective saturation 
recovery preparation pulse (TSR = 100ms) and two-fold acceleration (GRAPPA). Perfusion 
sequence readout parameters were: TR/TE/FA = 2.4 ms/1.07 ms/ 12°; FOV (340-400 x 340-400 
mm2); matrix 160 x 120; BW = 651 Hz/px. Slice thickness was 8 mm, with 8 mm gap. 
 
Rest perfusion imaging was acquired using the same DCE-CMR protocol 15 min after the stress 
scan with the administration of 0.05 ml/kg contrast agent (Gadovist, Bayer). 
 
LGE CMR was performed with a T1-weighted segmented gradient-echo phase-sensitive 
inversion-recovery (GRE PSIR) sequence [10], with following parameters: TE/TR/FA = 760 
ms/1.56 ms/20°. The inversion time (TI) was adjusted for optimal suppression of signal from 
normal myocardium (TI~340ms). Typical FOV was (350 x 262)mm2, matrix 256 x 192, slice 
thickness 7 mm, slice gap 2.8 mm, and BW = 465 Hz/px. Images were collected 15-20 minutes 
after the last injection of contrast. 
 
4.2.3 Analysis of stress/rest perfusion CMR: 
 
Stress and rest perfusion CMR images were analyzed side-by-side using dedicated software 
(Argus Dynamic Signal, Siemens, Erlangen, Germany).The stress and rest myocardial perfusion 
scans were viewed simultaneously. The perfusion scans were visually assessed for normal and 
abnormal myocardial hypoperfusion and segments with abnormal perfusion were assigned to 
coronary territories using the American Heart Association coronary arterial 16-segment 
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model(224, 225). In cases of disagreement between observers, a third blinded observer 
adjudicated, and the observers also prospectively evaluated image quality. Two patients were 
excluded due to poor image quality. 
 
A myocardial perfusion abnormalityat rest and/or during pharmacological stress was classified as 
significant according to the presence of reduced perfusion in 2 segments of a 32 segment model 
(16-segment AHA model divided into sub-endocardial and sub-epicardial layers) i.e.:  > 60 
degrees in either the basal or the mid-ventricular slices or  > 90 degrees in the apical slice or any 
transmural defect or two adjacent slices(225). 
 
4.2.4 Invasive Coronary Angiography and Coronary Pressure Wire 
 
All patients received an initial intravenous bolus of 5000 units of unfractionated heparin with an 
additional bolus of heparin as required to maintain an activated clotting time of 250 seconds. All 
patients had been pre-treated with aspirin and clopidogrel. A 6F coronary guiding catheter was 
used routinely and 200 µg of intracoronary nitroglycerin was administered during left and right 
coronary angiography.  A 0.014" coronary pressure-sensing guide wire was calibrated and then 
equalized to the guiding catheter pressure with the guidewire sensor placed in the aorta at the 
ostium of the coronary artery. The wire was then passed beyond the stenosis into the distal third 
of the vessel.  Systemic hyperemia was then established using intravenous adenosine at a dose of 
140mcg/kg/min. Myocardial FFR was taken as the ratio of distal coronary to proximal aortic 
pressure during steady state hyperemia. An FFR≤ 0.8 was used as a measure of stenosis 
significance. An FFR value of 0.5 was given to patients with an occluded or sub-totally occluded 
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vessel(220).  
4.2.5 Safety 
All patients were prospectively evaluated for safety, including in relation to intravenous 
adenosine administration and coronary instrumentation with the diagnostic guidewire. Adverse 
events were recorded by the clinical and research staff in an electronic case report form (e-CRF) 
administered by the Pharmacovigilance Service of the Robertson Centre for Biostatistics, a trials 
unit registered with the National Institute for Health Research (NIHR). 
 
4.2.6 Diagnostic accuracy study methodology 
This analysis was conducted according to Standards for Reporting of Diagnostic Accuracy(240) 
and the study was reported in accordance with established best practice. 
 
4.3 Sample size calculation 
In order to pre-determine the sample size, we estimated that at least 40% of the study participants 
would have an FFR value ≤ 0.80 at the time of the index procedure and approximately 20% of 
the participants would have functionally-significant residual obstructive coronary disease at the 
end of the procedure reflecting incomplete revascularization of non-culprit coronary lesions 
(potentially as part of a staged management plan or lesions that were not amenable to 
revascularization). We therefore estimated that the prevalence of regional perfusion defects 
overall by stress perfusion CMR will be 30%. Theoretically, there should be close to a 1:1 
correspondence with an inducible perfusion abnormality on stress CMR and an FFR ≤ 0.80. 
Assuming a true underlying agreement rate of 90% and only one artery studied per patient, a 
sample size of 104 patients would have approximately 85% power to exclude an agreement rate 
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below 80% based on a one-sided 95% confidence interval. In reality more than one artery could 
be studied on a per-patient basis, hence increasing the power further. 
 
4.4 Results (Table 6 and 7). 
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Table 6 
 
Variable Value 
Male (%) 86(82.6) 
Age ± SD 56.7±9.8 
Diabetes (n/%) 13(12.6) 
Smoker (n/%) 77(73.3) 
Hypertension (n/%) 34(33) 
Hypercholesterolaemia (n/%) 34(33) 
Multivessel Disease (n/%) 55(52.9) 
Previous PCI (n/%) 8(5.1) 
Troponin μg/l (± SD) 5.2±9.5 
BMI (± SD) 29.17±4.7 
GRACE (± SD) 163.6±35 
Syntax Score (± SD) 12.4±7.7 
Approach Score (± SD) 21.8±12.9 
Treatment 
Medical (n) 
PCI (n) 
CABG (n) 
 
27 
74 
3 
 
BMI: Body Mass Index. 
 
Of 251 medically stabilised NSTEMI patients who were randomized in the clinical trial from 
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Golden Jubillee National Hospital and Hairmyres hospital that participated in the CMR study, 
106 (42.2%) were enrolled and had evaluable CMR data.  A total of 1696myocardial segments 
were available for analysis.  32 segments (2 patients) were excluded from the analysis due to 
non-diagnostic image quality so 1664 myocardial segments with evaluable perfusion CMR data 
were finally included.  Of these, 793segments were spatially matched with a coronary artery 
territory in which FFR was measured.  The flow diagram for the CMR sub-study is shown in 
Figure 19. A typical clinical case including the CMR, angiography and FFR observations is 
shown in Figure 20. 
 
Figure 19 
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The demographics and characteristics of the NSTEMI patients are shown in Table 6. The mean 
age of the participants was 56.7±9.8 years and 82.6% male. The mean time from FFR evaluation 
to CMR was 6.1±3.1 days.  The mean time from symptom onset to FFR evaluation was 4.4±2.5 
days. 
 
 
 
Figure 20 – Comparison Between Stress CMR, FFR and coronary angiography. 
 
A total of 21 NSTEMI patients had CMR examinations prior to coronary angiography/PCI and 
83 patients had stress CMR following angiography/PCI (Figure 21). Of these 83 patients, 66 
Perfusion*defect* QCA:*62%*stenosis*LAD*
Ischaemia***FFR*=*0.70*
Anterior*NSTEMI*
Rest* * ******hyperaemia **
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underwent PCI prior to the CMR. Of the 21 patients studied prior to coronary angiography, 8 
patients underwent PCI and 1 patient went on to have CABG. The mean time interval between 
the CMR and FFR for this group was 6.6±3.7days. There were no adverse events related to 
intravenous adenosine infusion during either the invasive procedure for FFR or the stress 
perfusion CMR scan. No adverse events occurred in relation to coronary instrumentation with 
the diagnostic guidewire or with intravenous adenosine for FFR measurement. 
 
 
Figure 21 – Breakdown of Patients Enrolled in the Study 
 
 
 
4.4.1 Coronary Angiography and Physiology  
 
A total of 168coronary arteries were assessed, 96 (57%) in the infarct-related arteries and 
72(43%) in the non-infarct-related arteries. As reported by the interventional cardiologist in the 
104$pa'ents$
PCI$
66"Pa%ents"
Coronary$Angio$
Pre$MRI$
Yes$
No$
No$Yes$
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catheter laboratory, and based on all of the clinical information at the time of the procedure, the 
infarct-related artery was the left anterior descending coronary artery (LAD) in 47 NSTEMI 
patients, the left circumflex (LCx) in 17 patients, and the right coronary artery (RCA) in 18 
patients. In one patient the identity of the culprit artery was unclear.The mean FFR for the 
population was 0.85±0.13. 
 
 
 
4.4.2 CMR Findings (Table 7) 
 
The mean ± SD left ventricular ejection fraction was 58.2±9.1% and the mean infarct size was 
5.4±7.1%. There were 194 segments with a perfusion abnormality including 34 (18%) fixed and 
160 (82%) inducible perfusion defects. The 160 inducible segmental perfusion defects occurred 
in 41 patients. 30 (73%) of these perfusion defects involved the infarct-related artery territory 
and 11 (27%) occurred in the non-infarct artery territory. There were 57 inducible perfusion 
defects (14 vessels) amongst patients imaged prior to and 103 defects (28 vessels) in those 
patients imaged following coronary angiography. There were 40 inducible transmural perfusion 
defects. Five (5%) patients had CMR evidence of perfusion abnormalities in multiple coronary 
artery territories. There was a negative correlation between the number of segments with an 
inducible perfusion defect and FFR (r = -0.77, p<0.0001).   
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Table 7 – MRI and Clinical Variables 
 
 Variable    Value 
LVEF (± SD) 58.2±9.1 
LV Mass (± SD) 70.2±11.4 
EDV (mls) (± SD) 90.4±15.9 
ESV (mls) (± SD) 38.5±13.7 
Infarct Size (± SD) 5.4±7.1 
Infarct Related Artery (n) LAD 47, Diagonal 2, LCx 17, OM 9, Ramus 3, RCA 
18, Unclear 1 
Non-Infarct Related Artery (n) LAD 23, Diagonal 2, LCx 22, Ramus 2, RCA 20, LM 3 
Coronary Stenosis Severity (%)(± SD) 50.3±21.4 
Mean FFR (± SD) 0.85±0.13 
Number of vessels with FFR ≤0.8 41 
Number of with FFR ≤0.75 33 
 
LVEF: Left Ventricular Ejection Fraction, EDV: End Diastolic Volume, ESV: End Systolic Volume 
 
When looking only at the infarct-related culprit artery territory (n =89), there was a moderate 
negative correlation between the number of segments (n=113 segments) with an inducible 
perfusion abnormality on stress CMR and FFR (r=-0.8, p<0.001) When the analysis is restricted 
to coronary arteries with occlusive disease (i.e. arteries with an FFR allocation of 0.5 ascribed for 
severe, flow limiting stenosis/chronic occlusion), the correlation was moderate (r=-0.69, 
p<0.0001, n= 66 arteries, 59 segments). 
 
The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
for FFR≤ 0.8 were 91.4%, 92.2%, 76%, and 97%, respectively. The diagnostic accuracy was 
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92%. The sensitivity, specificity, PPV and NPV for FFR≤ 0.75 was 88.2%, 95%, 83%, and 96%, 
respectively.  
 
ROC analysis indicated that the AUC for FFR predicting an inducible perfusion defect on stress 
CMR was 0.94 (0.90-0.99), p<0.0001 (Figure 22). The optimal cut off value was 0.805 and this 
was associated with a sensitivity of 91.2% and a specificity of 92.2%. Looking specifically at the 
infarct-related culprit artery the AUC was 0.91, p<0.001. The optimal cut off value was again an 
FFR of 0.805 and this was associated with a sensitivity of 86% and a specificity of 95%. 
 
On a per segment analysis, the FFR cut-off value of ≤ 0.8 was associated with an 87.2% 
sensitivity, 91.9% specificity, negative predictive value of 97% and positive predictive value of 
65%.  
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Figure 22 – ROC Curve for FFR vs. Stress Perfusion MRI 
 
 
 
 
4.4.3 CMR before vs. after angiography 
 
NSTEMI patients who were had stress perfusion CMR before invasive angiography (n=21) had 
an altered clinical profile to those patients imaged after PCI/angiography. The mean Grace score 
was lower (GRACE score pre angio 140.0±52.3 vs. 164.2±34.8 [p=0.63]) as was the mean FFR 
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(mean FFR pre-angiography 0.7±0.2 vs. mean FFR post-angiography 0.87±0.13, p=0.004). Other 
clinical characteristics for patients with CMR before vs. after angiography were similar, 
including patient age (57.8±10.6 years vs. 56.4±9.6 years; p=0.6), BMI (30.6±4.6 kg/m2 vs. 
28.7±4.7 kg/m2; p=0.87), time from CMR to FFR assessment (6.1±3.7 days vs. 5.9±3.1days; 
p=0.84) or Syntax score (13.9 vs. Syntax 12.06; p=0.51).  
 
The PPV of FFR for flow-limiting coronary artery disease (FFR ≤ 0.8), compared with stress 
perfusion CMR perfusion before invasive angiography was higher when compared to patients’ 
imaged after invasive management (sensitivity of 92%, specificity of 93.3%, PPV of 92% and a 
NPV 93%), and accuracy was otherwise similar. 
 
4.4.4 Discordance Between FFR and CMR Evaluation of Ischaemia 
 
There was discordance between FFR and CMR involving 63 segments with an almost equal 
distribution between the non-culprit (32 segments) and the culprit (29 segments) territories.  
These involved 21 coronary arterial territories.  However, in 16 territories despite this 
discordance in individual segments, the diagnostic utility of FFR to identify inducible ischaemia 
was preserved.  
 
4.5 Discussion 
 
The most important finding of this study is the high diagnostic accuracyof FFR at established 
thresholds for lesion-level flow limitation when compared against myocardial perfusion revealed 
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by stress perfusion CMR at 3.0 Tesla. We have shown that as a diagnostic test for detecting 
flow-limiting coronary artery disease, the performance of FFRwas excellent with an AUC of 
0.94. Prior to our study, the validity of FFR and its established ischemic thresholds of 0.80 and 
0.75 in patients with a medically stabilized NSTEMI was uncertain. The high prevalence of 
multivessel coronary disease and the impractical use of non-invasive tests in the acute setting 
support the theory that FFR might have potential diagnostic value in this population. Since the 
performance of FFR could rule-out the need for deferral of treatment in order to obtain a non-
invasive stress test to assess the functional significance of bystander coronary disease, FFR has 
potential clinical utility in the context of a single diagnostic and therapeutic procedure in 
NSTEMI patients during urgent ad hoc invasive management. 
 
4.5.1 Use of 3T CMR as Non-Invasive Reference Standard 
 
Comparing FFR with a non invasive gold standard for diagnosing ischaemia is a point of 
contention within the medical literature (241, 242) particularly because FFR was originally 
compared with non-invasive imaging for its own validation. However, with the continued 
improvements in CMR imaging and with a lack of a clear gold standard for non-invasively 
diagnosing ischaemia, CMR was chosen as a reference standard to assess the accuracy of FFR  
 
4.5.2Concerns regarding the use of FFR to guide management in ACS 
 
Culprit Arteries 
In the setting of emergency primary PCI for acute STEMI severe microvascular injury precludes 
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maximal hyperemia such that FFR is not valid as a diagnostic test (235, 236, 243). In the 
NSTEMI setting, the nature of the microvascular injury is typically different since the culprit 
coronary artery remains patent with normal antegrade flow, which is the usual finding during 
invasive angiography13. In some NSTEMI patients, the natural history may involve intermitted 
coronary occlusion (e.g. due to vasopasm, thrombus burden), but typically the occlusion is 
transient. Furthermore, microvascular injury may also be transient such that initial measurements 
of FFR may be artificially elevated but following stabilisation of the coronary microcirculation, 
FFR reflects the true haemodynamic impact of the coronary stenosis. In our study, FFR was 
restricted by protocol to coronary arteries with normal flow, and in the case of CTOs or very 
severely obstructed arteries an FFR value of 0.5 was assigned. Furthermore, in NSTEMI 
patients’ invasive angiography is generally performed on a sub-acute basis usually 24 hours or 
more after initial presentation during which time anti-thrombotic treatments are given. 
Theoretically, maximal coronary vasodilatation that is required to establish the critical linear 
relationship between pressure and flow necessary for the assessment of FFR (79)may still not be 
achieved. The attainment of maximal hyperemia is predicated on preserved microcirculatory 
function, since the distal coronary microcirculation is the major contributor to coronary vascular 
resistance. However, using cardiac positron emission tomography (PET), Uren and colleagues 
provided evidence of impaired microcirculatory function in the infarcted region compared with 
healthy controls up to 6 months following AMI (127).  Thus, in patients with recent MI 
microvascular injury, stunning and oedema may result in a failure to achieve minimal resistance 
and FFR values may be falsely elevated (127). Tamita and colleagues highlighted this by 
demonstrating a higher post-PCI FFR in patients with STEMI compared with patients with stable 
angina despite similar intravascular ultrasound parameters. Patients with TIMI II flow also had a 
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higher FFR compared to those patients with TIMI III flow. Thus in patients with severe 
microvascular dysfunction the assessment of FFR may be unreliable.  
 
We have demonstrated a good correlation between inducible ischaemia demonstrated on a non-
invasive gold standard and FFR in the culprit artery of patients with NSTEMI.  Furthermore we 
have shown excellent test accuracy with an AUC of 0.91, a sensitivity of 86% and specificity of 
95%. Indeed the optimal cut off value for FFR was 0.8. This excellent concordance provides 
further evidence for the validity of FFR measurements in the culprit vessel of patients with 
recent NSTEMI and supports previous findings(125).  
 
Non-Culprit Arteries 
Several studies have clearly demonstrated altered blood flow patterns and impaired vasodilator 
response in territories remote from the culprit vessel (127, 244).  As discussed above this could 
potentially have implications for the assessment of FFR in non-culprit vessels in patients 
presenting with ACS. 
 
4.5.3 FFR thresholds in ACS 
 
In patients with stable CAD, a myocardial FFR≤0.80 is an evidence-based physiological 
threshold indicative of lesion-level ischaemia due to obstructive CAD that may be amenable for 
revascularization (79). The original validation studies that determined the FFR threshold for 
ischemia were all performed in stable patients.  However, there have been several studies that 
have aimed to establish and validate FFR thresholds for ischaemia in patients with ACS. In 48 
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stabilized patients with recent MI, Samady and colleagues compared FFR in the infarct-related 
artery to non-invasive findings using SPECT and myocardial contrast echocardiography (MCE). 
Patients had a mean time to angiography of 3.7 days. 73% of patients presented with STEMI. 
The group demonstrated that an FFR ≤0.75 had 91% sensitivity, 93% specificity and a diagnostic 
accuracy of 92% for detecting reversible ischaemia. They provided an optimal cut off FFR value 
of ≤0.78 for detecting reversible ischaemia using ROC analysis (125). Furthermore, Ebersberger 
and colleagues reported the findings of a similarly designed FFR vs. CMR study at 3.0 Tesla in 
116 patients with stable angina. They demonstrated sensitivity, specificity, positive and negative 
predictive value of 89%, 95%, 87% and 96% respectively (241).  Our data are in accordance 
with these findings and support the diagnostic utility of FFR in patients with NSTEMI in the 
culprit and non-culprit territories at 4 days after MI to identify reversible ischaemia.  
Our findings are similar to those of Samady and colleagues and higher than the threshold 
originally put forward for patients with stable angina (245) and may reflect higher microvascular 
resistance in patients with recent NSTEMI compared with controls in line with recent 
observations by our group (129) 
 
4.5.4 Current Evidence for Benefit of FFR in ACS 
 
The FAME trial also included patients with NSTEMI/Unstable Angina(119, 126). FFR-guided 
revascularization was associated with a similar magnitude of treatment effect over angiography-
guided PCI in patients with recent NSTEMI/UA compared to those with stable angina.  
However, the pooling of patients with unstable angina and NSTEMI, the lack of information on 
the timing of the index infarction or troponin values and risk stratification (e.g. with the GRACE 
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score) supported the case for further studies investigating the relationship between FFR and 
NSTEMI.(126).  
 
Most data relating to FFR in NSTEMI thus far have been retrospective or observational.  Potvin 
et al demonstrated that in 201 unselected patients presenting to the catheter laboratory the use of 
an FFR threshold of ≤0.75 was safe to allow deferral of stenting.  However only 21 % of patients 
had a recent STEMI/NSTEMI and the use of FFR was not randomized or blinded. Thus although 
helpful, these studies were in relatively stable patients and not powered to detect any impact of 
FFR-guided management on health outcomes or to determine the clinical utility of FFR or 
optimal cut-off in patients with ACS. 
 
Lopez-Palop et al have recently published the results of an observational non-randomized cohort 
of 107 NSTEMI patients who had FFR evaluation of non-culprit stenoses(246). They 
demonstrated no difference in outcome between patients who had revascularization deferred on 
the basis of FFR compared with those who underwent angiographically guided revascularization. 
In addition, Ntalianis et al evaluated the assessment of non-culprit stenoses in 26 patients with an 
acute NSTEMI (within 72 hours) and 126 patients with STEMI and showed that FFR values in 
the non-culprit vessel were unchanged when measured again approximately 5 weeks later(247). 
Thus the use of FFR to evaluate non-culprit stenoses has been shown to be reasonably accurate 
and reproducible in different NSTEMI populations, including from this analysis also. 
The results from our study are in accordance with FAME(247) and provide further evidence of 
the validity of FFR in this population. 
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4.5.5 Potential Benefits of FFR guided stenting in patients with ACS 
 
Contemporary guidelines recommend making revascularization decisions for culprit lesions in 
patients with convalescent STEMI and NSTEMI/UA in the same manner as stable angina. This 
strategy appears to improve symptoms and reduce rates of death and non-fatal MI at long-term 
follow-up (23). However, there has been discordance in the literature with some authors 
suggesting a lack of prognostic benefit of revascularization over modern medical therapy in 
NSTEMI (248). Current revascularization guidelines for stable angina recommend the use of 
non-invasive stress testing/FFR for lesions that are angiographically intermediate in severity(1, 
249). However, this strategy, whilst appropriate in stable angina, is problematic in patients with 
NSTEMI not only because stress testing is not recommended but also because FFR has not been 
extensively validated in this population.  Our data provide further evidence of the applicability of 
FFR in patients with recent NSTEMI in both the culprit and non-culprit vessels. 
 
4.5.6 Discordance Between FFR and CMR 
 
We observed discordance between FFR and CMR diagnosis of ischaemia in 63 MRI segments. 
However, this most commonly involved an isolated segment within an already ischaemic 
territory.   As this did not meet the pre-specified CMR definition of ischaemia the diagnostic 
utility of FFR was preserved. Due to the small numbers, we could not define a relationship 
between discordance and timing of MRI/clinical presentation. 
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4.6 Limitations 
A minority of the NSTEMI patients in our study had stress perfusion CMR before invasive 
management whereas the majority had CMR afterwards. This meant that a significant proportion 
of patients had revascularization prior to the CMR.   However, CMR was performed on average 
6 days after invasive management allowing time for microvascular dysfunction related to the PCI 
procedure (performed after FFR) to improve.  Nevertheless, the time-interval between CMR and 
FFR, and PCI-related microvascular injury may be confounding factors for the FFR vs. perfusion 
CMR relationship.  
 
Since many centers perform intervention on NSTEMI patients within 48 hours of presentation, 
the generalizability of our results is limited to patients who present within a similar time frame.  
However, since FFR was performed within 5 days of presentation to hospital and a pre-defined 
inclusion was that the patients must have pain within the last 5 days (or have had their NSTEMI 
in the last 72 hours) our data remain relevant. 
 
We found evidence of a high sensitivity and a specificity of FFR for flow-limiting coronary 
disease, as revealed non-invasively by stress perfusion CMR. Our results are in keeping with 
established data (125, 241) but should be interpreted on the basis that the NSTEMI participants 
had a high pre-test likelihood of coronary artery disease. This fact is also relevant when 
considering the higher PPV of FFR for abnormal myocardial perfusion in patients undergoing 
CMR before invasive angiography and revascularization.  
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Whilst we have demonstrated excellent concordance between FFR and stress CMR, we should 
not expect one-to-one concordance between FFR and myocardial perfusion since fundamentally 
the tests are different. FFR is an invasive guidewire-based pressure-derived index of coronary 
blood flow that can be anatomically specified to individual coronary lesions with a readout 
displayed in real-time on a hemodynamic monitor. Perfusion MRI is non-invasive and provides 
information on myocardial perfusion based on dynamic changes in myocardial contrast kinetics 
and signal intensity in just a few heart beats. In clinical practice the signal changes are assessed 
visually. We have assumed spatial concordance for the coronary artery instrumented for FFR 
measurement and its distribution on the myocardial perfusion scan, but other biological factors 
may affect this relationship including subject-specific variations in coronary anatomy with 
respect to standard angiographic classifications (e.g. Coronary Artery Surgery Score (250) 
(CASS), DUKE Jeopardy (251) Score) and also coronary collateral supply. 
 
 
4.7 Conclusion 
This is the first study to date to examine the diagnostic accuracy of FFR in a reasonably large 
cohort of patients with recent NSTEMI vs. a high fidelity non-invasive reference method. Our 
results indicate that FFR and stress perfusion CMR at 3.0 Tesla were highly concordant and add 
further evidence for the utility of FFR in this population. 
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      Chapter 6 
 
Diagnostic Accuracy of 3.0 Tesla Magnetic Resonance T1 and T2 Mapping and T2W STIR 
Edema Imaging for the Infarct-Related Coronary Artery in NSTEMI 
 
 
 
 
 
 
 
 
 
 
 161 
 
 
 
 
 
 
 162 
Summary 
Background: Patients with recent non-ST elevation MI (NSTEMI) typically have heterogeneous 
infarct characteristics that may be difficult to assess clinically.  
 
Methods and Results: We prospectively studied the diagnostic accuracy of two novel (T1, T2 
mapping) and one established (T2-weighted short tau inversion recovery (STIR)) magnetic 
resonance imaging (MRI) methods for imaging the ischemic area-at-risk and myocardial salvage 
in 73 NSTEMI patients (mean age 57±10 yrs, 78% male) at 3.0 TMRI within 6.5±3.5 days of 
invasive management. The infarct-related territory was identified independently using a 
combination of angiographic, ECG and clinical findings.The presence/extent of infarction was 
assessed with late gadolinium enhancement imaging (Gadovist, 0.1 mmol/kg). Area-at-risk was 
independently assessed with native T1, T2 and T2W-STIR methods. The mean infarct size was 
5.9±8.0% of left ventricular mass. The area-at-risk T1 and T2 times were 1323±68 ms and 57±5 
ms, respectively. The extent of area-at-risk (% of LV mass) estimated with T1 (15.8±10.6%) and 
T2 maps (16.0±11.8%) was similar (p=0.838), and moderately well correlated (r=0.82, p<0.001). 
Mean area-at-risk estimated with T2W-STIR (7.8±11.6%) was lower than that estimated with T1 
(p<0.001) or T2 maps (p<0.001). There were moderate correlations between area-at-risk 
estimated with T1 maps vs. T2W-STIR (r=0.54, p<0.001), and area-at-risk estimated with T2 
maps vs. T2W-STIR (r=0.46, p<0.001). The diagnostic accuracies of T1 and T2 MRI for 
identification of the infarct related artery were similar (p=0.125) and both were superior to T2W-
STIR (p<0.001).  
 
Conclusions: In NSTEMI patients, T1 and T2 MRI mapping have higher diagnostic accuracy 
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than T2W-STIR for delineating acute myocardial injury, implying superior clinical utility. 
 
 
5.1 Introduction 
 
Following acute myocardial infarction cardiac MRI imaging techniques have been shown to 
estimate the ischaemic area at risk (AAR), that is, the myocardial perfusion bed directly affected 
by ischaemia due to the acute occlusion of a coronary artery (35). Furthermore, as a result of 
even transient ischaemia producing differences in the myocardial longitudinal (T1) and 
transverse (T2) relaxation times, newer techniques have shown improved sensitivity in 
identifying the culprit territory (47, 48). Dark-blood fat-suppressed (short tau inversion recovery, 
STIR) T2-weighted MRI methods (T2W STIR) are widely used for clinical and research 
purposes (37, 49, 252, 253). However, T2W STIR is prone to artifacts from motion, blood-tissue 
borders and coil sensitivity issues cause signal loss with depth of field(254, 255) and may lead to 
diagnostic uncertainty. Novel fast T1 and T2 parametric methods for mapping the area at risk 
have been described in patients with STEMI, typically a syndrome associated with large areas at 
risk and large, transmural myocardial injury. In these cohorts, both T1 and T2 mapping 
techniques demonstrated superior accuracy compared with T2W STIR(48, 54) Since edema 
persists for days or weeks after an acute ischaemic injury, STEMI patients have generally been 
studied following revascularisation, a time when potential benefit of identifying the AAR is 
limited. NSTEMI is a condition typified by smaller degrees of myocardial injury and non-
occlusive culprit lesions. Compared with STEMI, the clinical utility of identifying the AAR in 
NSTEMI patients may be enhanced since NSTEMI is a more heterogeneous condition and MRI 
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can be performed prior to a decision to proceed to an invasive management strategy. However, 
data allowing direct comparison of T1/T2 mapping sequences and T2W STIR in NSTEMI, 
particularly at 3.0 Tesla, are lacking.  
 
We performed a prospective study of medically stabilized NSTEMI patients referred for 
coronary angiography to compare the diagnostic accuracy of T1 and T2 mapping compared to 
dark blood edema imaging (T2W STIR) for detection of the infarct-related artery. We also 
compared these MRI methods for estimation of the ischaemic area at risk.   
 
 
5.2 Methods 
 
5.2.1 Patient population 
 
Patients with a diagnosis of Type 1 NSTEMI (25) with at least one cardiac risk factor scheduled 
for early coronary angiography were prospectively recruited. Exclusion criteria represented 
standard contraindications to MRI, including metallic devices and severe kidney disease (an 
estimated glomerular filtration rate <30 ml/min/1.73 m2). The participants in this study had been 
enrolled in a clinical trial (ClinicalTrials.gov identifier:NCT02073422).  All patients provided 
written, informed consent. The local ethics board approved the study. Pharmacological 
management of patients reflected contemporary guidelines including treatment with dual anti 
platelet therapy, an HMGCo-enzyme inhibitor and a beta-blocker (23).  
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5.2.2 MRI Acquisition 
 
MRI was performed on a Siemens MAGNETO Verio (Erlangen, Germany) 3.0 T scanner with 
an 8-element phased-array cardiac surface coil. The MRI protocol included steady state free 
procession (SSFP) cine MRI, T1 and T2 parametric maps, as well as T2W STIR. Cine SSFP 
images with two-fold accelerated parallel imaging (GRAPPA) were acquired in a stack of short-
axis views of the LV. Imaging parameters were:  repetition time (TR) 3.4 ms, echo time (TE) 
1.51 ms, flip angle (FA) 50°, typical field of view (FOV) (340 x 286)mm2, matrix 256 x 216, 
slice thickness 7 mm, slice gap 3 mm, receiver bandwidth (BW) 977 Hz/px, 25 cardiac phases. 
 LGE CMR was performed with a T1-weighted segmented gradient-echo phase-sensitive 
inversion-recovery (GRE PSIR) sequence [10], with following parameters: TE/TR/FA = 760 
ms/1.56 ms/20°. The inversion time (TI) was adjusted for optimal suppression of signal from 
normal myocardium (TI~340ms). Typical FOV was (350 x 262)mm2, matrix 256 x 192, slice 
thickness 7 mm, slice gap 2.8 mm, and BW = 465 Hz/px. Images were collected 10 to 15 
minutes after the administration of 0.1 mmol/kg contrast agent (Gadovist, Bayer).  
 
The ECG-gated single shot modified Look-Locker Inversion Recovery (MOLLI) method was 
used to measure myocardial longitudinal relaxation times (T1)(55, 256). The MOLLI parameters 
included a T1 start of 100 ms, an increment of 80 ms and a trigger delay of 160 ms. The protocol 
included GRAPPA acceleration factor of 2. Following pixel-wise T1 fitting, T1 (ms) was 
displayed on a quantitative colour scaled map. 
 
Myocardial transverse (T2) relaxation times were estimated using a T2 mapping technique that 
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involved a T2 prepared TrueFISP pulse sequence to produce single-shot T2 prepared images, 
each with different T2 preparation times (257). The T2 prepared TrueFISP images were acquired 
at intervals of at least 3 R-R intervals to allow for sufficient magnetisation recovery in between 
acquisitions. Motion correction was enabled to prevent misregistration between images. T2 was 
estimated by pixel-wise fitting assuming a mono-exponential signal decay and a colour scaled 
motion corrected myocardial T2 map was then generated. For both T1 and T2 maps, an 
algorithm for motion correction based on previous work was applied prior to curve fitting (258). 
 
The breath hold black blood triple inversion recovery sequence (T2W STIR) involves a pair of 
selective and non-selective 180 degree inversions pulses to null the blood pool signal followed 
by a third inversion pulse (STIR) to null the fat signal(49).  Surface coil intensity correction was 
routinely performed with pre scan normalisation and slice-related shimming as appropriate. 
Typical imaging parameters were TE/TR/FA =2RR intervals /47ms/180, with 310 Hz/pixel 
bandwidth and turbo factor 15. In-plane spatial resolution was 2.2 x 1.4 mm (with acquisition 
matrix of 151 x 256, GRAPPA = 2), and slice thickness was 6-mm.Short axis left ventricular 
views were sequentially acquired with T1/T2 parametric maps and T2W STIR matched to the 
same slice position. We obtained 3 slices, basal, mid and apical. Sample images are shown in 
Figure 23. 
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Figure 23- Clinical Vignette  - T1 and T2 Maps vs. T2W STIR imaging 
 
MRI findings in a 62 years old male patient with acute NSTEMI (A=T2 Map, B= T2W STIR, 
C= T1 Map, D=Late Gadolinium Enhancement). Inferior subendocardial infarction, as revealed 
by LGE, corresponds with transmural edema revealed with T1 and T2 maps but this is not seen 
with T2W STIR. 
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5.2.3 MRI Image analysis 
 
Anonymised images were analysed in a random order on a Siemens workstation by 2 MRI 
trained cardiologists with > 3 years experience with imaging myocardial edema. An image 
analyst coordinated data management to ensure blinded analysis.  A third MRI trained 
cardiologist as well as an MRI trained technician performed quantitative assessments of infarct 
area and area-at-risk as determined by both T1 and T2 maps. 
 
Two MRI trained cardiologists who were blind to the patients’ clinical presentation reviewed 
Hyperintense zones on T1- and T2-weighted MRI images independently. Each observer assessed 
for the presence/absence of edema in each short axis slice and ascribed it to a segment in 
accordance with the 16-segment model of the American Heart Association.  A third observer 
resolved discordance between cardiologists. Each observer was also asked to assign a culprit 
coronary arterial territory for each patient based on each edema imaging modality. In addition, 
each observer was asked to categorize overall image quality (non-diagnostic, poor, adequate, 
good, or excellent) as well as to comment on the presence/absence of artifacts for each edema 
imaging sequence.  An artifact was was only recorded if there was concordance in 2 out of the 3 
observers. 
 
The jeopardized left ventricular area at risk was defined as the percentage of left ventricular area 
delineated by the hyper intense zone on T1 and T2 images. The signal intensity threshold 
indicating edema was set at 2 standard deviations (SD) above the mean intensity of reference 
ROI placed in remote unaffected myocardium. Myocardial tissue with a signal intensity at least 2 
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SD above the mean signal obtained in the remote non-infarcted myocardium was considered the 
area at risk(44, 66). Myocardial salvage was calculated by subtraction of percent infarct size 
from percent area at risk(44). The extent of infarct scar was delineated as an area of myocardial 
enhancement (cm2) mapped on LGE images, using a signal intensity threshold of >5 standard 
deviations (SD) above remote region, and expressed as a percentage of total LV mass(259, 260). 
MVO was defined as a dark zone present within an area of gadolinium enhancement. Infarct 
regions with evidence of MVO were included within the infarct area, and MVO area was also 
recorded individually as a percentage of total LV mass. 
 
5.2.4 Angiographic Analysis 
 
The attending interventional cardiologist using a combination of clinical history, ECG and 
coronary angiographic findings identified the culprit artery. The Alberta Provincial Project for 
outcome Assessment in Coronary Heart Disease (APPROACH) lesion score was used to provide 
estimates of the AAR(59).  Culprit artery assignment was independently analysed and verified by 
an accredited interventional cardiologist (MMC).   
 
5.2.5 Statistical analyses 
 
Statistical analyses were carried out using IBM SPSS Statistics software, version 21.0 (Armonk, 
USA). Normality was tested with the Shapiro-Wilk test. All results are given in a format of 
mean±SD, unless otherwise stated. Correlations between AAR quantified with T1/T2maps and 
T2W STIR, APPROACH lesion scores were tested by Pearson or Spearman’s methods as 
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appropriate. Comparisons of normally distributed continuous data between T1/T2 maps and 
T2W STIR were undertaken using a Student t test. Between- group comparisons of non-normally 
distributed data were performed with a Mann Whitney test. The level of agreement between 
AAR quantified with T1/T2 maps and T2W STIR was assessed using Bland-Altman plots and 
95% limits of agreement. The 95% limits of agreement were calculated using the mean 
difference between AAR quantified by the two imaging modalities ±2 SD of these differences, 
and contained approximately 95% of all such differences. The McNemar exact test was used to 
compare diagnostic accuracy of the T1, T2 and T2W STIR sequences in identifying the infarct-
related artery, when compared to current gold-standard method of coronary angiography. An 
inter-observer agreement reliability analysis, using the Kappa statistic (κ), was performed to 
determine consistency of infarct-related artery diagnosis among observers. To assess 
reproducibility, quantitative assessment of the area at risk on T1 and T2 maps was assessed by a 
second observer on a subset of 18 patients. The level of agreement between the two observes 
assessing the area at risk on T1 and T2 maps was assessed using Bland Altman plots and 95% 
limits of agreement.  
 
5.3 Results 
 
5.3.1 Patient characteristics (Table 8) 
Between February 2012 and May 2013, we recruited seventy-three NSTEMI patients (mean age 
57±10 years, 78% male) who underwent cardiac MRI within 6.5±3.49 days of invasive 
management. All patients fulfilled the diagnostic criteria for acute NSTEMI and the infarct-
related coronary arteries were identified by clinical criteria including the ECG and coronary 
 171 
angiography. Patient demographics and clinical characteristics are provided in table 8.  The mean 
GRACE score at hospital was 156±37.25.  Overall, 27.4% of patients were imaged prior to, and 
72.6% following coronary angiography. Angiographic characteristics, in particular, the infarct 
related artery assignments are provided in table 8.  Sixty three percent of the study population 
underwent percutaneous coronary intervention. 
 
5.3.2 Cardiac MRI findings 
The cardiac MRI findings are summarized in Tables 9 and 10. Of 26 patients (35.6%)without 
evidence of LGE. 16(61.5%) had evidence of edema.The mean infarct size as a percentage of LV 
volume was 5.9±8.0%. There was no evidence of edema using two out of the three imaging 
methods in 10 (13.6%) patients and MVO was present in 10 patients (14%). The mean left 
ventricular ejection fraction was 57±12%. On average, 3 short axis slices were available for 
native T1, T2 maps and T2 STIR images. 83.3% of patients had either excellent or good image 
quality. No patient was excluded due to poor image quality. 
There were significantly more artifacts with T2 STIR (57.1% images) compared with T1 maps 
(14.4%) and T2 maps (3.7% images), p<0.0001. When comparing the two parametric mapping 
techniques directly, there was significantly more artifacts with T1 maps compared with T2 maps 
(p<0.0001) 
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Table 8 – Baseline Characteristics of Cohort 
Characteristic Value 
 
Age, years 
57±10 
 
Male, n (%) 
57(78) 
 
Body Mass Index, kg/m2 
28.7±4.8 
 
Smoker, n (%) 
52(72.2) 
 
Hypertension, n (%) 
25(34.7) 
 
Hyperlipidaemia, n (%) 
23 (32.4) 
 
Diabetes, n (%) 
9 (12.3) 
 
Previous percutaneous coronary intervention, n (%) 
6 (8.2) 
 
GRACE score 
156±37.25 
 
Troponin, mg/dl 
0.92 (0.2,5.3) 
 
Infarct Related Artery 
 
 
  
Left Anterior Descending, n (%) 33(45) 
Circumflex, n (%) 23(32) 
Right Coronary, n (%) 17(23) 
  
 
Treatment Strategies 
 
 
  
Medical Therapy only, n (%) 
 
21(28.7) 
Coronary Artery Bypass Surgery, n (%) 
 
6(8.2) 
Percutaneous Coronary intervention, n (%) 
 
46(63) 
 
APPROACH Lesion Score, % left Ventricular mass 23.45±12.6 
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Table 9 – MRI Findings 
MRI parameter Value 
 
Left Ventricular dimensions and 
function, mean±SD 
 
 
Left Ventricular ejection fraction, 
% 
57±12 
End-diastolic volume index, 
ml/m2 
93±17 
End-systolic volume index, 
ml/m2 
41±16 
Left Ventricular mass index, g/m2 71±10 
 
Late gadolinium enhancement 
 
 
Patients with evidence of LGE, n 
(%) 
48(66) 
Mean ±SD acute infarct size,% of 
LV mass 
5.9±8.0 
Microvascular Obstruction, n(%) 10(14) 
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Table 10 – Values in Remote and Injured Zones with Different Edema Imaging Modalities 
 Remote Edema P 
T1 time, ms 1152±43 1323±68 <0.001 
T2 time, ms 45±3 57±5 <0.001 
T2W-STIR, 
arbituary units 
90±25 146±55 <0.001 
 
The mean signal intensity (SI) of remote and injured myocardium is shown in Table 10 for each 
of the imaging methods. The measurements from acutely ischemic regions were higher 
compared to remote, unaffected myocardium for each method (T1 maps edema: 1323±68 msec 
vs. no edema 1152±43 msec, P<0.001; T2 map edema: 57±5 msec vs. no edema 45±3 msec, 
P<0.001; T2W STIR edema 146±55 vs. no edema 90±25, P<0.001). 
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Figure 24 and 25: T1 and T2 values (m/sec) in remote territory and in the injury zone (IZ) 
 
Figure 24 
 
Figure 25 
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For area-at-risk estimated by 2 independent observers using T1 mapping there was good 
correlation between observer 1 and observer 2 (r2=99.7%). The 95% limits of agreement were -
1.76 and 1.63 and there was no evidence of bias (0.25). For area at risk estimated by T2 mapping 
between these observers, there was good correlation (r2=98.9%), with 95% limits of agreement 
being -2.98 and 3.36 and no evidence of bias (0.19). 
 
5.3.4 Detection of Acute Edema by T1, T2 maps and T2 STIR. 
Table 11 
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T1 maps more frequently reported evidence of regional myocardial edema (64 [88%] patients) 
when compared with T2 maps (63 [86%] patients), and T2W STIR (42 [58%] patients) (Table 
11). For the comparisons of AAR with these methods, scatterplots of correlations are presented 
in Figure 26. 
 
There was a good correlation between T1 and T2 maps for estimation of AAR (r=0.82, P<0.001; 
T1 vs. T2: 15.8±10.6% of LV mass vs. 16.0±11.8%, P=0.838). The 95% limits of agreement for 
mean AAR estimated with T1 versus T2 maps were -13% and 13% of left ventricular mass with 
a minimal bias (0.2±6.8%). 
 
There were moderate correlations between AAR estimated with T1 maps versus T2W- STIR 
(r=0.54, P<0.001), and AAR estimated with T2 maps versus T2W-STIR (r=0.46, P<0.001). 
Mean AAR estimated with T2W STIR (7.8±11.6% of LV mass) was lower than that estimated 
with T1 (P<0.001) or T2 (P<0.001). The 95% limits of agreement for mean AAR estimated with 
T1 maps versus T2W- STIR and T2 maps versus T2W- STIR were wider with a higher level of 
bias when compared to the comparison for T1 vs. T2 maps (T1 versus T2W STIR -28% and 12% 
of LV mass, with a bias of -8.0±10.6%; and for T2 versus T2 STIR maps -32% and 16%, with a 
bias of -8.1±12.1%). 
 
The average amount of myocardial salvage (%left ventricular myocardial mass) estimated with 
T1 maps (10.1±8.9%) compared with T2 maps (10.5±9.5%, P=0.616) was similar. However, the 
mean myocardial salvage estimated with T2W STIR (4.7±9.7% of left ventricular mass) was 
significantly lower than estimates with T1 (P<0.001) or T2 (P<0.001) maps. 
 178 
Figure 26: Correlation between the area at risk estimated with T1 and T2 mapping and also dark 
blood T2W STIR imaging. 
 
 
 
5.3.5 Diagnostic accuracy of T1, T2 maps and dark blood T2 STIR  
The diagnostic accuracies of each edema imaging for identification of the infarct-related 
coronary artery, as defined by clinical data including the ECG and coronary angiogram are 
shown in table 11. The infarct-related artery was correctly identified more often with T2 maps 
when compared with other edema imaging methods (77% T2 maps, 71% T1 maps, 44% T2W 
STIR). However, when assessing diagnostic accuracy, there was no difference when comparing 
T1 and T2 maps (P=0.125). By contrast, a difference in diagnostic accuracy was shown between 
T1 maps and T2W- STIR (P<0.001), and T2 maps and T2W STIR (P<0.001). For infarct-related 
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artery identification, a high level of inter-observer agreement was found with T1 (κ=0.790, 
P<0.001) and T2 (κ=0.794, P<0.001) maps, while the level of agreement was moderate 
(κ=0.555, P<0.001) with T2W- STIR. Moreover, there was a lower level of discordance between 
observers for individual patients using T1 maps (discordant findings in 13.69%) and T2 maps 
(15.06%) respectively compared to dark blood T2W-STIR (30.14% cases, p<0.001).  
 
5.3.6 Correlation of Area at Risk Estimated by T1 and T2 Weighted MRI Versus 
APPROACH lesion score 
 
The mean APPROACH lesion score was 23.4±12.6 of the left ventricular mass. Cardiac MRI 
estimates of area at risk did not correlate with the APPROACH lesion score. Area at risk: T1 vs. 
APPROACH (r=0.13, p=0.29), T2 vs. APPROACH (r=0.11, p=0.37), T2W STIR vs. 
APPROACH (r=0.08, p=0.49).  
 
5.4 Discussion 
 
The main results of our study are as follows. First, using 3.0 Tesla MRI, native T1 and T2 maps 
have a higher diagnostic accuracy compared to dark blood T2 STIR in detecting the infarct-
related artery in patients with recent NSTEMI. Second, T1 and T2 maps produced highly 
congruent results when estimating the size of AAR and myocardial salvage. This was in contrast 
to dark blood T2 STIR imaging that tended to underestimate AAR and myocardial salvage. 
Third, there was a high level of inter-observer agreement for identification of the infarct-related 
artery with T1 and T2 maps, when compared to dark blood T2 STIR. Finally, artifacts were 
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significantly more prevalent with dark blood imaging when compared with T1 and T2 maps. 
 
The detection of myocardial edema using a dark blood turbo spin-echo technique has been 
shown to facilitate prompt diagnosis of acute coronary syndromes and allow identification of 
both the area at risk and the amount of myocardial salvage post-reperfusion (39, 261, 262). Yet, 
despite great theoretical promise, the clinical reality of using dark blood T2-STIR imaging has 
been far from optimal due to methodological problems inherent with the technique.  The 
limitations include data susceptibility to artifacts from respiratory and cardiac motion, the 
variability in myocardial signal related to surface coil intensity inhomogeneity, and the 
subjectivity of image interpretation (50, 51). Acute infarction alters T2 relaxation times by 
increasing myocardial cell water content (263) and transient ischaemia without infarction can 
also increase T2 time (39, 261, 264). Thus, a more reliable method of assessing the T2 signal 
alteration may increase the clinical utility of T2 edema imaging potentially leading to wider 
adoption. Recently, a non contrast, quantitative T2 mapping sequence using T2 SSFP has been 
proposed and been shown to be more accurate than conventional T2W STIR at predicting AAR 
in animal and human models (45, 54).   
Previous experimental studies have also shown that T1 values increase with increasing 
myocardial water content and thus with ischaemia and infarction (45) By directly quantifying T1 
values for each voxel in the myocardium, a parametric map can be generated representing the T1 
relaxation times of any region of the heart. The most widely adopted T1-mapping sequence is 
based on the Modified Look- Locker Inversion-recovery (MOLLI) technique (55, 265). The use 
of T1 maps has also been shown to be more accurate at predicting edematous myocardium than 
dark blood T2W STIR(58).  However, most of this work concerning the superior precision of T2 
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and T1 maps has been performed in the STEMI population, typically a syndrome associated with 
large degrees of myocardial injury. 
 
5.4.1 Dark Blood Imaging 
Following its development by Simonetti and colleagues Dark blood STIR edema imaging has 
enjoyed widespread use to assess for the presence of myocardial edema(49).  Indeed several 
investigators have shown prognostic information using STIR imaging. For example, in a 
prospective study involving 88 patients with NSTEMI, Raman and colleagues highlighted the 
potential for T2STIR imaging in identifying edematous myocardium and to distinguish patients 
requiring coronary revascularization from those that did not. Moreover, the presence of edema 
was associated with a higher hazard of a cardiovascular event or death within 6 months after a 
non-ST elevation acute coronary syndrome.(37). However, the technical limitations of T2 
weighted dark blood CMR have stimulated other groups to develop methods of edema imaging 
that are both quantitative and accurate. 
 
Ferreira and colleagues investigated the diagnostic performance of dark blood imaging when 
compared to Bright Blood (ACUT2E) imaging as well as a novel T1 mapping method 
(ShMOLLI) in patients with Takotsubo cardiomyopathy and edema syndromes without 
infarction at 1.5 Tesla(58). The group demonstrated superior diagnostic accuracy with T1 
mapping when compared to dark blood and bright blood T2 imaging methods.Verhaert and 
colleagues have also demonstrated superior accuracy of a novel T2 mapping technique when 
compared with dark blood imaging at 1.5 Tesla(54). Amongst 27 patients - only 11 of whom 
presented with NSTEMI, the use of T2 maps was associated with more reliable and improved 
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detection of edema. 
 
NSTEMI is the commonest form of acute coronary syndrome and an important public health 
problem(23), yet information on the diagnostic and clinical utility of edema imaging with MRI in 
STEMI patients is lacking. To date, no study has directly compared T1 and T2 maps with dark 
blood T2W-STIR in NSTEM. Our study has shown, for the first time in a large NSTEMI 
population, that at 3 Tesla, the diagnostic performance of dark blood imaging is inferior to newer 
novel mapping sequences with an underestimation of the AAR as well as myocardial salvage. 
The identification of edema and diagnostic accuracy of dark blood imaging was also limited 
which is important from a clinical perspective. Previous studies comparing dark blood imaging 
with newer T2 or T1 methods have included only small numbers of patients with NSTEMI.  
Overall the mean infarct size in these subpopulations have been moderate; 16.7% of LV mass 
reported by Payne et al (57) and in the study by Verhaert and colleagues the mean peak troponin 
concentration was 50mg/dl (54). In ourNSTEMI population, the mean infarct size was 5.9% and 
troponin value was 0.92mg/dl - a much lower infarct size reflecting less myocardial injury.  The 
poor performance of STIR in this population calls into question the use of dark blood edema 
MRI for imaging NSTEMI patients. This point becomes all the more relevant as the sensitivity of 
the biochemical detection of NSTEMI falls with the adoption of high sensitivity troponin assays. 
The higher sensitivity of T1 and T2 mapping for detecting subtle alterations in signal intensity 
that can occur in NSTEMI patients suggests that these methods may be more useful in clinical 
practice. 
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5.4.2 T1 and T2 Maps in NSTEMI 
 
In-vivo and ex vivo studies have demonstrated that non-contrast T1 and T2 mapping can 
accurately quantify the ischaemic area at risk. STEMI is defined by acute coronary occlusion 
whereas the natural history of NSTEMI is different. In NSTEMI, thrombotic plaque rupture may 
lead to non-occlusive or intermittently lead to transient vessel occlusion. Both of these scenarios 
usually result in smaller degrees of myocardial injury, which may give rise to diagnostic 
uncertainty in clinical practice. 
 
In a canine model of ischaemia and using a microsphere reference standard, Ugander and 
colleagues compared T1 (ShMOLLI) and T2 maps at 1.5 T for defining the area at risk. Both 
imaging modalities demonstrated equivalence with excellent correlation(45). Recently, Dall’ 
Armellina and colleagues assessed T1 with T2 mapping amongst 41 patients presenting with 
myocardial infarction at 3 Tesla (48). 73% of the study cohort presented with STEMI. There was 
a similar diagnostic performance of T1 vs. T2 maps for detecting oedematous injured 
myocardium. In a subgroup analysis performed in only 9 patients with NSTEMI, the authors 
demonstrated a superior diagnostic performance of T1 maps over T2 maps and also less 
variability in T1 compared with T2 maps. In a much larger cohort of NSTEMI patients and using 
a different T1 mapping method, our results indicate that T1 and T2 maps had similar diagnostic 
accuracy for estimating the myocardial area at risk in patients with NSTEMI. In contrast to the 
findings of Dall’Armellina and colleagues although there was no advantage in terms of accuracy, 
there were significantly fewer artifacts with T2 maps compared to T1 maps suggesting an 
advantage for this mapping sequence. Importantly, and despite this lower degree of injury, the 
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utility of T1 and T2 mapping was preserved.  
 
5.4.3 Angiographic Area at Risk   
 
Several studies have clearly demonstrated the accuracy of both T1 and T2 maps in the 
assessment of the angiographic area-at-risk in patients with acute coronary syndromes.  
However, the patient populations have largely consisted of STEMI patients. The APPROACH 
score has been shown to correlate with the myocardium at risk derived through cardiac MRI 
(44), and the magnitude of the correlation increased with the transmural extent of infarction (59). 
Typically, NSTEMI patients have smaller, sub-endocardial infarcts and thus it is not surprising 
to find that the AAR as measured with oedema imaging sequences in our population did not 
correlate with the APPROACH score.  
 
5.4.4 Clinical Application 
Retrospective imaging of the ischaemic area at risk is clinically relevant since the amount of 
salvageable myocardium is a predictor of prognosis and the potential response to therapy(45).  
 
This study demonstrates the greater accuracy of T1 and T2 maps at identifying oedematous 
myocardium when compared with T2W STIR imaging in patients with NSTEMI.  Patients who 
experience a NSTEMI tend to be older, have more concomitant health problems, and multivessel 
coronary disease. Using a more sensitive marker of myocardial injury than dark blood T2W 
STIR in this heterogeneous population may allow for improved risk stratification for patients 
who would benefit from early invasive assessment and accurately identify the culprit territory 
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when faced with a patient who has multivessel coronary disease.  
 
5.5 Study limitations 
The timing of MRI post MI was influenced by the clinical course of the patients (e.g. recurrent 
ischaemia, the timing of invasive angiography etc.). Although, this variation in timing may have 
been introduced some measurement heterogeneity we think the MRI data became more 
representative of real life clinical practice. The participants were also enrolled in a clinical trial 
but the intervention in this trial was not relevant to the MRI study. 
 
From an anatomical perspective, inter-individual variation in coronary artery distribution may 
confound infarct-artery assignment. In NSTEMI, multivessel coronary artery disease is common 
and there may be more than one culprit lesion. Therefore, it could be that an infarct-related artery 
which was missed on angiography was correctly identified with the MRI maps. Because patients 
underwent the cardiac MRI after invasive management with PCI, it is possible that the 
myocardial injury detected with T1, T2 and T2W STIR maps actually originated from the PCI 
treatment rather than the initial MI. However, according to the current Universal Definition of 
Myocardial Infarction(25) none of the participants in this study experienced peri-procedural MI. 
 
5.6 Conclusion 
 
T1 and T2 maps are novel, quantitative imaging methods that have a high diagnostic accuracy in 
detecting infarct-related artery in NSTEMI. They produce congruent results when estimating 
AAR, whereas using T2W STIR imaging yielded less accurate results with more artifact. 
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Findings suggest that T1 and T2 mapping represent a clinically valuable novel imaging method, 
with a particular usefulness in the assessment of reversible myocardial injury and salvaged 
myocardium. Based on our findings, the utility of T2W STIR imaging in the assessment of 
oedema in patients with NSTEMI is limited. 
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     Chapter 7 
 
Safety of Adenosine and Pressure Wires in Patients with Acute Coronary Syndromes 
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Summary 
 
Background: Coronary guidewire-based diagnostic assessments with hyperaemia may cause 
iatrogenic complications. In 2013 the U.S. Food and Drug Administration (FDA) issued a safety 
warning on pharmacological stress testing. We assessed the safety of guidewire-based 
measurement of coronary physiology using intravenous adenosine in patients with an acute 
coronary syndrome. 
Methods and Results: We prospectively enrolled invasively managed STEMI and NSTEMI 
patients in two simultaneously conducted studies in 6 centers. All of the participants underwent a 
diagnostic coronary guidewire study using intravenous adenosine (140 µg/kg/min) infusion for 1 
- 2 minutes. 648 patients (n=298 STEMI patients in 1 hospital; mean time to reperfusion 253 
min; n=350 NSTEMI in 6 hospitals; median time to angiography from index chest pain episode 3 
(2, 5) days) were included between March 2011 to May 2013. Two NSTEMI patients (0.03% 
overall) experienced a coronary dissection related to the guidewire. No guidewire dissections 
occurred in the STEMI patients. The aortic systolic blood pressure was reduced during 
intravenous adenosine administration (systolic BP (rest vs. adenosine): 124.5 (26.0) mmHg vs. 
111.7 (24.7) mmHg, (n=330) [95% CI 12.8 (11.3, 14.3) p<0.001].  Diastolic BP was also 
reduced (67.0 (12.8) mmHg vs. 60.5 (13.2) mmHg (n=330) [95% CI 6.5 (5.6, 7.4) p<0.001]. 
Chest symptoms were reported in the majority (86%) of patient’s symptoms during the 
adenosine infusion. No serious adverse events occurred during infusion of adenosine and all of 
the symptoms resolved after the infusion ceased.  
Conclusion: In this multicenter analysis, guidewire-based measurement of FFR using 
intravenous adenosine was safe in patients following STEMI or NSTEMI. 
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6.1 Introduction 
Coronary guidewire-based sensors can be used in the cardiac catheterization laboratory to 
provide functional information on coronary artery disease severity and microvascular function. 
The myocardial fractional flow reserve (FFR) assesses the physiological significance of a 
coronary stenosis and is expressed as the ratio of maximal blood flow in a stenotic artery to 
maximal flow if theoretically the artery was unobstructed. FFR-guided management is evidence-
based in patients with stable coronary artery disease (DEFER(228), FAME(119), FAME-2(229)) 
and has emerging clinical utility for measurement of non-infarct artery disease in patients with 
recent or acute myocardial infarction (MI)(126). However since FFR measurement involves 
pharmacological hyperaemia and guidewire instrumentation, there are theoretical risks of serious 
adverse events (SAE) including ventricular arrhythmias with intravenous adenosine and coronary 
dissection (both ~0.5% incidence)(230). 
Intravenous adenosine induces hyperaemia through interactions with A2A receptors. However, 
due to the ubiquitous expression of adenosine receptors, adenosine is also associated with 
unwanted off-target side-effects. For example, interaction with bronchial A2B receptors can lead 
to mast cell degranulation and bronchoconstriction(147). Furthermore, activation of cardiac A1 
receptors has a myocardial depressant effect with negative chronotropic and dromotropic 
effects(267). It is these unwanted effects of adenosine that have motivated researchers to find 
other drugs for initiation of hyperaemia or develop non hyperaemic indices of stenosis 
assessment in the catheter laboratory(217, 268). 
Intracoronary adenosine may also be used therapeutically for the treatment of no-reflow in 
STEMI(89), and the role of FFR-guided PCI in STEMI patients with multivessel coronary 
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disease is currently being evaluated in the COMPARE-ACUTE (NCT01399736), COMPLETE 
(NCT01740479) and PRIMULTI (NCT01960933) clinical trials. 
In November 2013 the United States (US) Food and Drug Administration (FDA) issued a safety 
announcement on the risk of myocardial infarction (MI) and death in patients receiving 
Adenoscan (adenosine) for stress testing(269). This announcement followed from reports in the 
FDA Adverse Event Reporting System (FAERS) and medical literature of serious adverse events 
(SAE) from 1995 to 2013, including 6 cases of MI and 27 cases of death following adenosine 
administration (typically within 6 hours) (269).  
We aimed to prospectively assess the safety of guidewire-based measurement of coronary 
physiology using intravenous adenosine amongst patients with acute or recent myocardial 
infarction (MI). Based on our prior experience with intravenous adenosine in this setting (129, 
266), we hypothesised that in accordance with recent literature, intravenous adenosine would be 
safe and well tolerated (270).  
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6.2 Methods 
6.2.1 Study Population 
We simultaneously conducted two prospective studies involving assessments of coronary 
physiology in patients with acute or recent MI. Two hundred and ninety-eight STEMI patients 
were enrolled acutely and had coronary physiology measured invasively in the culprit coronary 
artery with a diagnostic coronary guidewire (PressureWire Certus™, St Jude Medical) during 
primary or rescue PCI. The protocol did not involve FFR measurements in the non-infarct 
arteries. The enrolment period was March 2011 - November 2012. Patients diagnosed with an 
acute STEMI and who were undergoing primary or rescue PCI were eligible to participate. In the 
second study, three hundred and fifty NSTEMI patients were enrolled from. six hospitals in the 
United Kingdom participated (3 academic and 3 non-academic regional hospitals). The patients 
in this study underwent urgent invasive management and had an FFR measurement in one or 
more coronary arteries with at least a single coronary stenosis ≥ 30% severity of the reference 
vessel diameter by visual assessment. The patients with NSTEMI were enrolled during urgent 
care and the median time to invasive angiography was 3 days.  
The exclusion criteria for administration of intravenous adenosine included evidence of 2nd or 3rd 
degree heart block on the ECG, long QT syndrome, cardiogenic shock, or a history of asthma 
concurrently treated with bronchodilators. The exclusion criteria for both studies are provided in 
Tables 12 and 13. The study was approved by the UK National Research Ethics Service and all 
participants provided written informed consent.  
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Table 12 
STEMI Study Exclusion Criteria 
2nd or 3rd degree heart block on ECG 
Long QT syndrome 
Cardiogenic shock  
History of asthma concurrently treated with bronchodilators 
Terminal systemic illness (e.g. cancer limiting survival <12 months) 
Pregnancy 
Inability to provide informed consent 
 
Table 13 
 
NSTEMI Exclusion Criteria 
Contra-indications to intravenous adenosine including 1) A history of asthma concurrently treated with 
bronchodilators; 2) 2nd or 3rd degree heart block on ECG; 3) Long QT syndrome 
A life expectancy < 1 year (e.g. cancer limiting survival <12 months) 
Pregnancy 
Inability to provide informed consent 
Hemodynamic Instability 
MI with persistent ST elevation 
Ineligible for coronary revascularization on clinical grounds 
Plan for non-coronary heart surgery 
Prior CABG 
Angiographic evidence of severe (e.g. diffuse calcification) or mild (< 30% severity) coronary disease 
Intolerance to anti-platelet drugs, 
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6.3 Catheter laboratory management 
The clinical and catheter laboratory management followed contemporary guidelines for STEMI 
and NSTEMI(23).  
 
6.3.1 Measurement of FFR  
Figure 27- Example of Haemodynamic Recording 
 
 
 
 
A hemodynamic recording obtained from a diagnostic pressure- and temperature-sensitive 
guidewire (PressureWire Certus™, St. Jude Medical, Mn.) located in a culprit coronary artery at 
the end of primary PCI. 
The blue arrow represents the thermodilution recordings during resting conditions before 
adenosine administration. The thermodilution curve represents the transit time for the change in 
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temperature detected by the distal guidewire thermistor following intra-coronary bolus injection 
of saline (room temperature) via the guiding catheter. The subsequent yellow arrow represents 
the transit times for thermodilution curves following intra-coronary injections of saline during 
hyperaemia with adenosine (140 µg/kg/min). During hyperaemia, there is evidence of a 
reduction in arterial blood pressure depicted by the yellow arrow, reflecting the typical 
hemodynamic response in the systemic and coronary circulations to intravenous adenosine.  
 
In patients with STEMI, infarct artery coronary physiology (FFR) was measured at the end of the 
primary or rescue PCI (Figure 1). In patients with NSTEMI, FFR was measured at the beginning 
of the diagnostic procedure in all participants. Intravenous adenosine was administered at a rate 
of 140 µg/kg/min via a large peripheral vein for 1 - 2 minutes. (Table 24). 
 
Table 14 – Methods for Making Adenosine Infusion 
Step Action 
1. Remove 40ml from a 100ml bag of IV saline and discard 
2. Draw up 30ml (90mg) of adenosine (3mg/ml either 15x2ml vials or 3x10ml vials) 
3. Add adenosine to the 60 ml IV saline giving a concentration of 1mg/ml 
 
 
The patient's response to adenosine administration was a pre-defined safety outcome. Aortic and 
distal coronary pressures were recorded invasively before and during adenosine administration. 
In addition, patients’ symptoms and heart rate during the adenosine infusion were also 
prospectively documented using a study proforma. All SAEs in study participants were 
prospectively documented by clinical and research staff after the patient was enrolled in the 
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study in line the trial protocol. All adverse events were recorded in the clinical report form 
(CRF). SAEs were notified to the Sponsor of the studies for pharmacovigilance and assessed, 
reported, analysed and managed in accordance with the Medicines for Human Use (Clinical 
Trials) Regulations 2004. 
An SAE was defined as an event that results in death, is life threatening, requires hospitalisation 
or prolongation of existing hospitalisation, results in persistent or significant disability or 
incapacity, or is otherwise considered medically significant by the investigator. 
Major adverse cardiac events (MACE), were defined as the occurrence of death, myocardial 
infarction, or hospitalisation for heart failure(271). In the STEMI study, source data for all of the 
SAE and MACE were assessed by a cardiologist who was independent of the research team. This 
cardiologist was blinded to all of the other clinical data. In the NSTEMI study, source clinical 
data for all SAE of suspected cardiovascular origin and all deaths were reviewed by an 
independent clinical event committee blinded to treatment group assignment (FFR-guided group 
or angiography guided group). The CEC also assessed the angiograms of SAE attributed to 
procedure-related complications. 
6.4 Statistics 
Continuous data with a normal distribution were summarized with the mean ± standard deviation 
(SD). Paired t-tests were used to assess hemodynamic data before and during adenosine 
administration. Significance was defined as a p value < 0.05. The statistical analyses were 
performed using the SPSS statistical software package 14.0 for Windows (SPSS Inc., Chicago, 
IL, USA).  
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6.5 Results  
Baseline characteristics  
648 patients (n=298 patients with STEMI in 1 hospital; n=350 patients with NSTEMI in 6 
hospitals) were included between March 2011 - May 2013. Their clinical characteristics are 
presented in Table 15.  
In the patients with STEMI, evidence of haemodynamic instability on arrival in the cardiac 
catheter laboratory was common. Thirty-three (11.1%) patients had a systolic blood pressure 
(BP) of < 90 mmHg, 20 (7.2%) patients had ventricular fibrillation (VF) or ventricular 
tachycardia (VT) before or during PCI but prior to adenosine administration, and 4 (1.4%) 
patients received intra-aortic balloon pump (IABP) counterpulsation therapy during the PCI. In 
the patients with NSTEMI there were no patients with VF/VT during the procedure and only 1 
(0.3%) patient required IABP. 
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Table 15 – Baseline Clinical Characteristics 
Characteristics*  STEMI patients 
n=298 
NSTEMI patients 
n=350 
Clinical    
Age, years  59.4 62.0 
Male sex, n (%)  216 (72)  260 (74) 
BMI, (kg/m2)  28.7  29 (5) 
History    
Hypertension, n (%)  95 (32) 159 (45)  
Current smoking, n (%)  184 (62) 143 (41) 
Hypercholesterolemia, n (%)  81 (27) 127 (36) 
Diabetes mellitus‡, n (%)  32 (11) 52 (15) 
Previous myocardial infarction, n (%)  20 (7) 46 (13) 
Previous PCI, n (%)  16 (5) 38 (11) 
Presenting characteristics    
Heart rate, bpm  80 (44) 74 (16) 
Systolic blood pressure, mmHg  135 (25) 141 (27) 
Diastolic blood pressure, mmHg  79 (14) 81 (17) 
Time from symptom onset to reperfusion, min  253 - 
Time from index episode of myocardial ischemia to invasive 
angiogram, days 
 - 3 (2, 5) 
Ventricular tachycardia or fibrillation†, n (%)  20 (7) 0 (0) 
Heart failure, Killip class at presentation, n (%) I 212 (71) 308 (88) 
 II 64 (22) 33 (9) 
 III 16 (5) 5 (2) 
 IV 6 (2) 4 (1) 
Coronary angiography    
Reperfusion strategy, n (%)    
Primary PCI   275 (92) - 
Rescue PCI (failed thrombolysis)  23 (8) - 
Adjunctive Therapy During PCI    
Aspirin (%)  297 (99)  348 (99) 
Clopidogrel (600mg) (%)  297 (99) 337 (96) 
Heparin (%)  298 (100) 333 (95) 
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Anti-GP IIb/IIIa (%)  273 (92) 79 (26) 
Number of diseased arteries¥, n (%) 0 0 (0) 10 (3) 
 1 165 (55) 130 (37) 
 2 95 (32) 141 (40) 
 3 38 (13) 60 (17) 
 4 0 (0) 9 (3) 
Culprit artery, n (%) LMS 0 (0) 2 (1) 
 LAD 110 (37) 152 (43) 
 LCX 55 (18) 106 (30) 
 RCA 133 (45) 90 (26) 
TIMI coronary flow grade pre-PCI, n (%) 0/1 214 (72) - 
 2 56  (19) - 
 3 28  (9) - 
TIMI coronary flow grade post-PCI, n (%) 0/1 2 (1) 33 (9) 
 2 14 (5) 27 (8) 
 3 282 (94) 289 (83) 
 
6.5.1 Symptoms and adverse events  
During adenosine infusion, 255 (85.6%) STEMI patients reported symptoms including chest 
discomfort, dyspnoea and facial flushing, all of which resolved immediately after the infusion 
ceased. There were no other symptoms reported. No MACE or atrial or ventricular arrhythmias 
occurred in association with intravenous adenosine administration. There were no SAEs related 
to adenosine.  
In the STEMI cohort, MACE occurred in 3 (1.0%) patients within 24 hours of the PCI. One 
patient experienced an acute stent thrombosis associated with a dissection at the distal end of the 
stent; one patient with severe left ventricular dysfunction experienced ventricular fibrillation 
in the coronary care unit; one patient died suddenly from myocardial rupture that was confirmed 
at autopsy. All of these events occurred in the coronary care unit and none of these events were 
 199 
temporally associated with the adenosine infusion in the catheter laboratory. In the STEMI 
cohort there were no pressure-wire related dissections and no SAE related to arrhythmias. 
In the NSTEMI cohort, no MACE occurred in association with the adenosine infusion. There 
were 2 (0.6%) cases of coronary dissection related to the guidewire. There were 4 cases of in-
hospital adverse events, including 3 (0.9%) cases of contrast nephropathy and 3 (0.9%) cases of 
major bleeding but none related to adenosine infusion. There were no SAE related to 
bradyarrhythmias or tachyarrythmias and FFR was measured in all subjects. 
6.5.2 Haemodynamic changes 
All Patients 
In 330 patients with complete hemodynamic data (n=186 STEMI, n=144 NSTEMI), aortic 
systolic blood pressure was reduced during adenosine administration (systolic BP (rest vs. 
adenosine): 124.5 (26.0) mmHg vs. 111.7 (24.7) mmHg, (n=330) [95% CI 12.8 (11.3, 14.3) 
p<0.001] as was diastolic BP (67.0 (12.8) mmHg vs. 60.5 (13.2) mmHg (n=330) [95% CI 6.5 
(5.6, 7.4) p<0.001]. Heart rate increased to 64.7 (13.0) bpm from 58.3 (12.1) bpm,) [95% CI 6.3 
(5.6, 7.1) p<0.001]. The proximal aortic pressure (Pa) was also reduced during adenosine 
administration (systolic BP (rest vs. adenosine): 119.7 (26.6) mmHg vs. 104.2 (25.0) mmHg, 
(n=351) [95% CI 15.5 (13.9, 17.0) p<0.001] as was the distal coronary pressure (64.7 (14.4) 
mmHg vs. 55.2 (14.4) mmHg [95% CI 9.4 (8.5, 10.4) p<0.001]. 
STEMI  
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Table 16: Blood pressure and heart rate at the start and end of emergency PCI in 298 STEMI 
subjects. 
Parameter  PCI start PCI end Mean Change (CI) P value 
Mean heart rate (SD) bpm 80.1 (44.1) 79.5 (14.5) 0.6 ( -4.3, 5.6) 0.800 
Mean systolic BP (SD) 
mmHg 
135.1 
(24.7) 
121.0 
(21.1)* 
14.0 (11.6, 16.4) <0.001 
Mean diastolic BP (SD) 
mmHg 
79.0 (13.9) 71.9 
(12.9)* 
7.0 (5.6, 8.5) <0.001 
 
Table 17: Coronary (Pd) systolic and diastolic blood pressure recorded in 258 STEMI subjects. 
Blood Pressure (BP) Rest  Adenosine  Mean Change (CI) P value 
Mean systolic (SD) mmHg 114.6 
(22.6) 
98.8 (21.8)* 15.8 (14.1, 17.5)  <0.001 
Mean diastolic (SD) 
mmHg 
65.5 (13.9) 56.1 (14.4)* 9.4 (8.4, 10.3) <0.001 
 
In the STEMI cohort (n=298), non-invasive hemodynamic data were available for all of the 
participants (Table 16). Distal coronary (Pd) artery blood pressure was recorded in 258 STEMI 
subjects (Table 17) and complete intracoronary hemodynamic data before and during adenosine 
infusion were available in 186 STEMI patients. The mean (SD) aortic systolic BP fell from 120.0 
(22.6) mmHg at baseline to 106.5 (21.3) mmHg during adenosine infusion [95% CI 13.5 (11.6, 
15.5) p<0.001]. Aortic diastolic BP was also reduced by adenosine infusion (67.9 (13.5) 
mmHg vs. 61.0 (13.6) mmHg [95% CI 7.0 (5.8, 8.1) p<0.001] whereas heart rate increased from 
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63.2 (12.1) bpm at rest to 69.8 (12.5) bpm [95% CI 6.6 (5.6, 7.6) p<0.001]. Compared to patients 
who did not experience symptoms with adenosine, patients who did experience symptoms had a 
greater rise in heart rate, but BP changes were similar (Table 18). 
 
Table 18: Blood pressure and heart rate of STEMI patients with symptoms recorded (n=186) and 
who reported symptoms vs. no symptoms. 
Parameter Symptoms 
(n=154)  
No 
Symptoms 
(n=32)  
Mean Difference 
(CI) 
P value 
Mean (SD) systolic change, 
mmHg 
-14.2 (13.5) -10.5 (13.5) -3.6 (-8.3, 1.5) 0.167 
Mean (SD) diastolic change, 
mmHg 
-7.2 (7.8) -6.0 (8.4) -1.2 (-4.2, 1.9) 0.451 
Mean (SD) HR change, bpm 7.1 (7.0) 4.0 (6.2)* 3.1 (0.5, 5.7) 0.020 
 
 
NSTEMI 
In the NSTEMI cohort (n=350), complete non-invasive aortic hemodynamic data and distal 
coronary (Pd) hemodynamic recordings were available for 144 and 165 patients respectively. 
The mean (SD) non-invasive aortic systolic BP reduced from 130.3 (28.8) mmHg under resting 
conditions to 118.5 (27.0) mmHg during adenosine infusion [95% CI 11.8 (9.4, 14.2) p<0.001]. 
Aortic diastolic BP was also reduced by adenosine infusion (65.9 (11.9) mmHg vs. 60.0 (12.7) 
mmHg [95% CI 5.9 (4.5, 7.2) p<0.001]. Heart rate increased to 58.1 (11.0) bpm from 52.1 (8.8) 
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bpm (n=144) [95% CI 6.0 (4.8, 7.2) p<0.001] and distal coronary (Pd) pressure was reduced also 
(Table 19).  
 
Table 19. Distal coronary (Pd) artery blood pressure recorded in 165 NSTEMI subjects. 
Abbreviations – Blood Pressure (BP), Standard Deviation (SD) *p<0.001 vs. baseline (paired t-
test) 
 
Blood Pressure (BP) Rest  Adenosine  Mean Change (CI) P value 
Mean systolic (SD) mmHg 125.7 
(28.3) 
110.4 
(26.4)* 
15.3 (13.0, 17.7) <0.001 
Mean diastolic (SD)  
mmHg 
63.7 (14.2) 53.7 (13.7)* 10.0 (8.4, 11.5) <0.001 
 
6.6 Discussion 
 
We report the largest study to date of guidewire-based measurements of FFR in patients with 
acute coronary syndromes. Our study is the first to report information on a pre-specified outcome 
relating to the safety of intravenous adenosine in patients with an acute STEMI or recent 
NSTEMI, who were prospectively enrolled simultaneously in parallel studies.  
The main findings of our multicenter study are that, first, coronary dissection due to the 
guidewire was rare (≤0.03%). Second, brief intravenous adenosine infusion in MI patients for 
diagnostic purposes was commonly associated with symptoms but these symptoms were brief 
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and self-limiting and were not associated with any SAEs; most importantly, the use of adenosine 
was safe and not associated with any SAEs during routine emergency care.  
Only 2 guidewire-related coronary dissections occurred in 698 prospectively enrolled MI 
patients undergoing emergency or urgent invasive management. This result represents evidence 
for the safety of guidewire-based assessments of coronary physiology. Guidewire dissections 
were less common than in previous studies [e.g. RIPCORD (1.5%)](230). We think that the 
timing of the pressure wire study within the procedure partially explains the difference in the 
dissection rates. In the patients with acute STEMI, pressure wire instrumentation in the infarct-
artery post-PCI was not associated with any complications. In the patients with recent NSTEMI, 
the 2-guidewire dissections occurred in diagnostic procedures before stent implantation. In the 
350 NSTEMI participants in this trial, 706 lesions (≥ 30% lumen narrowing) were reported and 
FFR data were obtained in 704 (>99%) of these lesions. On average 2 arteries per patient were 
instrumented with a pressure wire. Despite this, the incidence of guidewire dissections in the 
NSTEMI patients was very low and this experience is evidence of safety in the hands of trained 
cardiologists.  
In our study, predictable symptoms associated with adenosine occurred in the majority of 
patients and can be explained by the pharmacological effects of this naturally occurring 
vasodilator(270). However, since the half life of adenosine is < 10 seconds, these symptoms are 
extremely short-lived(272). Patients who experienced symptoms had a slightly higher increase in 
heart rate. A minority of patients (14%) did not experience symptoms with adenosine infusion. 
This may be explained by the presence of concurrent chest symptoms associated with myocardial 
infarction and also treatment with sedative and opiate therapies. There were no serious adverse 
events associated with intravenous adenosine. None of the patients experienced sustained atrial 
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or ventricular tachyarrhythmia. Overall, the reported symptoms that were observed in these 
cohorts were typical of what might be expected with intravenous adenosine. Based on the 
evidence of safety in this study, we think that when a clinician plans to administer intravenous 
adenosine, the patient should be advised that symptoms are likely but self-limiting and not 
associated with any other consequences. Adverse events, such as atrial and ventricular 
fibrillation, are rare and, in fact, no such events occurred in the 648 MI patients in this analysis. 
Systolic and diastolic blood pressures were reduced with intravenous adenosine consistent with 
an A2A receptor-mediated response. However, a rise in heart rate of >10% or a fall in systolic 
BP >10% occurred in less than half of the STEMI and NSTEMI patients in our study. These 
observations could be explained by the fact that the patients already had tachycardia due to 
STEMI, and they had been treated with vasoactive drugs, which attenuate the systemic reflex 
sympatho-excitation response (e.g. intravenous morphine). It is also possible that there was an 
attenuated sympathetic response due to beta blocker treatment.  
Of the 6 hospitals in the NSTEMI cohort 3 were regional non-academic centers without a track 
record in coronary physiology research. The multicenter design was intended to make the results 
of this trial more representative of routine care, relevant to “real world” practice and novel. 
Potential diagnostic applications are emerging for FFR to inform the acute treatment decisions 
for patients with non-infarct artery disease(131). Intracoronary adenosine is used to treat no-
reflow and FFR-guided PCI in STEMI patients with multivessel coronary disease, is currently 
being evaluated in the COMPARE-ACUTE (NCT01399736), COMPLETE (NCT01740479) and 
PRIMULTI (NCT01960933) trials. 
Adenosine is an established drug for use in pharmacological stress testing. Adenoscan has been 
marketed from 18 May 1995. From this date until 10 April 10 2013 the FAERS database accrued 
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26 reports of myocardial infarction (MI) and 29 deaths with regadenoson and 6 reports of 
myocardial infarction and 27 deaths reported with Adenoscan. There were two case reports of 
MI associated with Lexiscan administration but none with Adenoscan(274, 275) and the 
incidence of cardiovascular adverse events associated with these drugs is similarly 
uncommon(198, 215). In light of these post-marketing reports the FDA recommended to "Avoid 
using these drugs (Lexiscan or Adenoscan) in patients with signs or symptoms of unstable angina 
or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular 
adverse reactions"(269).The FDA warning was directed to office-based administration of 
intravenous adenosine, and this environment contrasts with the cardiac catheterization laboratory 
where medical support is immediately available to treat patients with iatrogenic complications. 
Our results also provide reassurance for the use of intravenous adenosine in the catheter 
laboratory setting. 
In contrast to the FDA recommendations, our findings are supported by the results from similar 
studies in other centers, in which intravenous adenosine has been used in patients with acute 
MI(180, 243, 276). Moreover, a meta-analysis evaluating the safety and efficacy of intracoronary 
adenosine in 460 patients with STEMI undergoing PCI found no difference in the safety 
endpoints of bradycardia, ventricular arrhythmia and chest pain compared with placebo(277). 
Our study is different since the safety of diagnostic guidewire instrumentation and systemic 
administration of adenosine (rather than intracoronary adenosine) were prospectively assessed in 
NSTEMI and STEMI patients. Another study, using a similar protocol for adenosine, 
demonstrated all patients tolerated adenosine infusion with no episodes of clinically significant 
bradycardia(243). In our hands, adenosine was not associated with any SAE when administered 
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to reperfused patients with STEMI at the end of emergency PCI for a short period of time (1-2 
minutes) and the absence of SAE in the NSTEMI patients provides further evidence of safety. 
6.7 Limitations 
Our study has several limitations. First, we do not have information on other hyperaemic drugs, 
such as regadenoson. Second, although safety assessments were performed and recorded in all of 
the patients at the time of the procedure, symptom reporting was incomplete. The available 
results confirm that symptoms typically occur with intravenous adenosine. Lastly pressure wire 
studies were restricted to the infarct-related artery rather than the non-infarct artery in the STEMI 
cohort study. Nonetheless, we provide comprehensive hemodynamic data and information on 
symptoms from prospective evaluations in individual patients who were enrolled in studies that 
had been designed with an open approach to enrolment of ‘all-comers’. We think our 
observations are representative of ‘real-world’ clinical practice.  
6.8 Conclusion 
Guidewire-based measurement of coronary physiology involving intravenous adenosine infusion 
was safe during emergency or urgent PCI for STEMI and NSTEMI. The symptoms related to 
adenosine were predictable, self-limiting and not associated with adverse events.  
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Future Directions	  
 
This thesis has examined a variety of invasive and non-invasive methods for evaluating patients 
with acute coronary syndromes.  However, there are many emerging techniques that are being 
evaluated at the time of writing this thesis that may also assist in the assement of patients with 
NSTEMI. 
 
The Instantaneous Wave Free Ratio (iFR)   
 
The instantaneous wave free ratio is a novel method of assessing coronary stenoses in patients 
undergoing coronary angiography.  It is an adenosine free index and assumes that at a specific 
point in diastole there exists a period of minimal resistance.  This is known as a ‘wave free 
period’.(278)  In theory, as resistance is minimised there is no need to use adenosine to achieve  
hyperaemia thus avoiding potentially unwanted pharmacological effects. Presently, there is a 
paucity of outcome data with this technique and in particular in patients with ACS.  However, its 
potential to assist with revascularisation decisions amongst patients with NSTEMI will be an 
exciting area of future research.   
 
Optical Coherence Tomography (OCT)  
 
Optical coherence tomography is an optical analogue of ultrasound using light rather than sound 
to produce an image. As distinct from sound, it has a ten times higher resolution (15 microns) 
meaning that highly detailed imaging can be achieved. For many years, OCT has been 
implemented in the characterisation of the retina.  However, it was not until 1996 that OCT was 
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used in coronary arteries to characterise plaque. Unlike traditional intracoronary imaging 
techniques, OCT has a ten-fold higher resolution thereby providing a more definitive anatomical 
assessment within the vessel. This advantage has seen OCT successfully applied to the 
assessment of atherosclerotic plaque, stent apposition and coverage(279).   
 
The best histological precursor for a ruptured plaque, which is the cause of 80% of MI, is the so-
called thin fibrous cap atheroma (TCFA). The in-vivo visualization of a thin fibrous cap cannot 
be appreciated by coronary angiography and similarly, is also poorly detected by Intravascular 
Ultrasound. With its excellent spatial resolution, OCT is ideally placed to identify vulnerable plaque that 
could result in ACS.	  Recent studies have demonstrated clinical benefit in pacifying these “hot” 
atherosclerotic plaques which were once thought to remain dormant.(87, 280) The use of OCT to 
identify  and then treat these ‘hot plaques’ is currently under investigation in clinical trials and 
represents an innovative and exciting area of ongoing research in patients with ACS. 	  
CT Coronary Angiography. 
 
A number of CT-based coronary plaque characteristics of a “vulnerable plaque” associated with 
culprit lesions for future ACS have been identified in retrospective observational studies 
Non Calcified Plaque, spotty calcification, higher mean plaque volume and positive remodelling 
are all features associated with a high positive and  high negative predictive value for future 
ACS. Furthermore, it has been proposed that the presence of a ring-like attenuation in a CT 
angiographic cross section may be a surrogate marker of TCFAs(281).   
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The use of these high risk plaque features together with novel techniques that assess functional 
significance such as CT-FFR and stress perfusion CT offer an exciting opportunity in future 
noninvasive ACS research. 
 Conclusion	  
In conclusion we have shown that the use of fractional flow reserve (FFR) is feasible amongst 
patients with NSTEMI and has clinical utility. The increase in prescription of medical therapy in 
the FFR guided arm was an important landmark for the study as was the demonstration of 
discordance between the interpretation of the angiogram and FFR. However, as this was a pilot 
study it will not be a practice changing trial.  The increase in late events in the FFR guided arm is 
also of interest.  Due to the lack of power of the study any inferences regarding the use of FFR in 
NSTEMI cannot be made.  Rather, this study provides valuable data to inform a larger, 
multinational trial that has sufficient power to answer the important question regarding the use of 
FFR in NSTEMI. 
 
Another important finding of this study was concerning the validity of FFR thresholds for 
ischaemia in NSTEMI.  This is a controversial area of interventional cardiology that we have 
successfully answered.  We have clearly shown that amongst patients with NSTEMI, the current 
threshold of FFR (≤0.8) was diagnostic of inducible perfusion defects when compared to a non-
invasive gold standard (Stress perfusion CMR) with a high level of accuracy. This provides more 
evidence in support of using FFR routinely amongst patients with NSTEMI. 
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We have also shown that traditional oedema imaging techniques (dark blood T2W) are inferior 
to newer, novel mapping methods (T1 and T2) for the estimation of the area at risk and 
myocardial salvage.  This has important implications for the use of such techniques amongst 
patients with NSTEMI.  Myocardial salvage is an increasingly important end point in many 
clinical trials.  Since dark blood imaging failed to detect oedema and underestimated salvage in a 
significant proportion of patients, when compared to both T1 and T2 maps, its use as an oedema 
imaging method in NSTEMI should be questioned. 
 
Finally, we have confirmed the safety of using adenosine in patients with ACS in a large cohort 
of both STEMI and NSTEMI. This has important implications in light of the recent FDA 
announcement. 
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